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ABSTRACT 
Essential hypertension is a complex multifactorial condition with a known genetic 
component. Several lines of evidence suggest a contributory role of adrenal cortex 
function to the heritable component of hypertension. 
In the human adrenal cortex, the enzymes 11 P-hydroxylase and aldosterone synthase are 
responsible for the final stages in the synthesis of cortisol and aldosterone respectively. 
The gene encoding 11 P-hydroxylase ( CYP 11 B 1) lies in tandem with the gene encoding 
aldosterone synthase ( CYP 11 B2) on chromosome 8. The two genes are highly 
homologous with the main differences being in their regulatory regions, as ACTH 
primarily regulates CYP 11 B 1 whereas CYP 11 B2 is under the control of angiotensin II 
and potassium. 
Variation within these genes has been implicated in certain fonns of hypertension. 
Mutations in CYP 11 B 1 and CYP 11 B2 account for the biochemical and haemodynamic 
abnormalities in the Dahl salt-sensitive rat. In humans, mutations in CYP 11B2 and/or 
CYP 11B1 lead to the rare clinical syndromes of glucocorticoid-suppressible 
hyperaldosteronism and 11 P-hydroxylase deficiency that are associated with 
mineralocorticoid hypertension. For these reasons, previous studies have examined 
whether polymorphisms associated with CYP 11 B2 are involved in hypertension. 
Several studies have reported that variation within the 5'UTR (-344 CIT) and intron 2 
(intron conversion (IC)) are associated with increased aldosterone levels and increased 
blood pressure. However, these findings have not always been confirmed and the -344 
CIT variation seems to have no influence on aldosterone biosynthesis in vitro. 
Paradoxically, it is more closely associated with markers of an impaired 11 P-
hydroxylase activity, which draws attention to the homologous gene CYP 11B1. The 
studies reported in this thesis aimed to identify the pattern of variation across the 
CYP 11 B1/CYP 11 B2 locus in order to determine the genetic variation responsible for the 
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observed impaired 11 ~-hydroxylation and its link with aldosterone levels and 
hypertension. 
In Chapter 3, an attempt was made to identify polymorphisms in CYP 11 B1 that 
associate with hypertension and a raised aldosterone-to-renin ratio (ARR) and therefore 
might contribute to the genetic component of these phenotypes. No polymorphism was 
identified that could account for either phenotype. However, eight novel missense 
mutations were identified out of 160 subjects screened, indicating a high sequence 
variation. These were identified in exons 2 and 3 of the CYP 11 B 1 gene and alter the 
encoded amino acids; R43Q, L83S, H125R, P135S, Fl39L, L158P, L186V and T196A. 
These variants were recreated in vitro to examine their effects on enzyme function. 
Enzyme activity was assessed by conversion of 11-deoxycortisol (S) to cortisol (F) and 
11-deoxycorticosterone (DOC) to corticosterone (B). 
The mutants L158P and L83S almost abolished enzyme function whilst R43Q, F139L 
and P135S and T196A enzymes resulted in product levels that were approximately 30% 
to 50% that of wildtype levels. The mutant enzymes H125R and L186V resulted in 
substrate-specific alterations in enzyme function. H125R decreased conversion of S to 
F and L 186V increased S conversion. Neither had an effect on the conversion of DOC 
to B. An attempt was made to assign these residues to locations within the protein 
molecule using homology-modelling techniques. This confirmed that none of the 
mutations are located within the putative active site. The importance of these affected 
residues, remote from the active site, to enzyme function, will inform subsequent 
studies of structure/function relationships. 
The study in Chapter 4 aimed to analyze the pattern of variation across the 
CYP 11B2/B1 locus in detail. This confirmed that the overall sequence variation across 
the CYP 11 B locus is high and that there is tight linkage disequilibrium across the entire 
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region with only 4 common haplotypes accounting for 68% of chromosomes in the data 
set. The detailed sequencing identified several candidate polymorphisms that could 
account for the observed phenotypes, including increased aldosterone levels and 
inefficient 11 ~-hydroxylase function, previously associated with the -344 CIT 
polymorphisms in CYP 11B2. The polymorphisms identified within the coding regions 
of the two genes were either synonomous (CYP IIB2 Ser169Ser and Arg374Arg, 
CYP llBI Leu75Leu and Asp82Asp) or are known to have no affect on activity 
(CYP IIB2 Lysl73Arg). The majority of variants were identified in the introns and 
3'UTR ofCYP11B2 and CYPllBI and their functional effects remain to be determined. 
Of particular interest, due to their potential to alter gene transcription, was the 
identification of2 in the 5' regulatory region of CYPllBI (-1889 G/T and -1859 A/G) 
and 7 within the 5' regulatory region of CYP II B2. 
In Chapter 5, the frequency and phenotypic associations of the newly identified 
CYPllBI 5'UTR polymorphisms -1889 G/T and -1859 A/G were investigated in a 
hypertensive population. The frequencies were found to be -1889 G-0.53, T- 0.47; -
1859 A-0.5, G-0.5. Interestingly, the -1889 G/T and -1859 A/G polymorphisms were 
found to associate with an impaired 11 ~-hydroxylase efficiency in a hypertensive 
population. The THS/total F ratio (index of liB-hydroxylase activity) was significantly 
higher in -1889 TT homozygotes than in GG homozygotes (p = 0.025). A similar 
pattern was seen with the -1859 SNP, with GG homozygotes tending to have a higher 
ratio than AA homozygotes (p = 0.056). 
These steroid data were supported by the results from Chapter 6 that examined the 
effects of these polymorphisms in vitro using luciferase reporter gene constructs 
transfected into Yl mouse adrenal cells. There was no significant effect on basal 
expression levels. However, the construct containing the -1889 T and the -1859 G 
alleles had a significantly reduced response to stimulation with either 1 )..lM ACTH (p < 
4 
0.001) or lOJ.!M Forskolin (p = 0.036) when compared to the contrasting allele 
combination. 
Evidence of a slightly reduced 11 P-hydroxylase efficiency is a consistent finding in 
subjects with essential hypertension when compared to normotensive controls. 
However, preliminary investigation of the -1889 G/T and -1859 A/G polymorphisms in 
a hypertensive case-control population failed to show any association with hypertension 
(Chapter 5). 
In summary, these studies have confirmed that the CYP11B2 and CYPllBI genes 
contain a high frequency of genetic variation. Many of the variants identified in 
CYP llBI have been shown to alter activity significantly. There is strong evidence to 
suggest that the impaired 11 P-hydroxylase efficiency previously associated with the -
344 CIT and IC variants in CYP11B2 is due to linkage with the -1889 G/T and -1859 
AIG polymorphisms upstream of CYP 11 B I. However, the causative link with 
hypertension and a raised ARR remains to be determined. 
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3~HSD 
11~-HSD 
17-0H-P 
17-0H-PREG 
18-0H-B 
AC 
ACE 
ACTH 
ACTH-R 
A'dione 
AlP 
Aldo 
AME 
Angi 
Angii 
AP-I 
ARR 
AT1 or 2 
ATF-1 
ATP 
B 
BAH 
BMI 
BSA 
c 
Ca2+ 
[Ca2+]i 
CaMK 
lipoid CAH 
cAMP 
CBP 
eDNA 
CHIF 
cr 
CMOIIII 
DEFINITIONS 
Gene encoding 3~-hydroxysteroid dehydrogenase 
11~-Hydroxysteroid dehydrogenase 
1 7-H ydroxypro gesterone 
17-Hydroxypregnenolone 
18-Hydroxycorticosterone 
Adenylyl ( adenylate) cyclase 
Angiotensin converting enzyme 
Adrenocorticotropin 
ACTH receptor 
Androstenedione 
Aldosterone induced protein 
Aldosterone 
Apparent mineralocorticoid excess 
Angiotensin I 
Angiotensin II 
Activator protein 1 
Aldosterone-renin ratio 
Angiotensin II receptor 1 or 2 
Activating transcription factor 1 
Adenosine triphosphate 
Corticosterone 
Bilateral adrenal hyperplasia 
Body mass index 
Bovine serum albumin 
Cholesterol 
Calcium ions 
Intracellular free calcium concentration 
Ca2+ -calmodulin-dependent protein kinase 
Congenital adrenal lipoid hyperplasia 
3 ', 5 '-Cyclic adenosine monophosphate 
CREB binding protein 
Complementary deoxyribonucleic acid 
Corticosteroid hormone induced factor 
Chloride ions 
Corticosterone methyl oxidase type I or II 
18 
CNS 
COUP-TF 
CRE 
CREB 
CRH 
CYPIIAI 
CYPllBI 
CYPIIB2 
CYP17 
CYP21 
CYP450 
DAG 
DBD 
DBI 
DHEA 
DNA 
DMEM 
DNA 
DOC 
DOCA 
DMSO 
EDTA 
EMSA 
E 
ENaC 
EtOH 
F 
FAD 
FMN 
G protein 
GR 
GRE 
GSH 
GTP 
HDL 
HPA 
Central nervous system 
Chicken ovalbumin upstream promoter-transcription factor 
cAMP-response element 
cAMP-responsive element binding protein 
Corticotrophin-releasing hormone 
Gene encoding side-chain cleavage enzyme 
Gene encoding 11 P-hydroxylase 
Gene encoding aldosterone synthase 
Gene encoding 17-hydroxylase 
Gene encoding 21-Hydroxylase 
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CHAPTER! 
The Role of Corticosteroids in Essential 
Hypertension 
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1.1 Essential Hypertension 
Essential hypertension or hypertension of unknown cause accounts for more than 
90% of cases of hypertension (Oparil et a! 2003). It is a major clinical problem 
affecting over 25% of the adult population worldwide (Kearney et a! 2005). For 
diagnostic purposes hypertension is defined as resting blood pressure levels 
repeatedly above 140/90mm Hg in adults. This is more common in men than in 
women and also in people aged over 65 than in younger people. Blood pressure is a 
quantitative trait showing a continuous distribution within the population. Therefore 
there is no logical sharp boundary between 'normal' and 'abnormal' values. 
Essential hypertension can be defined as the blood pressure value associated with an 
inceased risk of cardiovascular disease. At this elevated level of blood pressure, the 
risk of myocardial infarction, stroke and heart failure is greatly increased (Mosterd et 
a! 1999) and the higher the blood pressure, the worse the disease. Cardiovascular 
diseases are responsible for approximately a third of all deaths (Kearney et a! 2005) 
and so adequate control of blood pressure within the population is a very important 
goal both clinically and economically. The current understanding of essential 
hypertension is that it is a complex condition resulting from the interaction of 
multiple genetic and environmental factors. However, the identity of the genes that 
predispose to hypertension remains largely unknown. A better understanding of the 
contributing genetic factors would provide sites for targeted pharmacotherapy. 
In the following sections of this review, I wish to explore the evidence for a 
contributory role of adrenal cortex function to the heritable component of 
hypertension. I shall discuss briefly the general factors predisposing to hypertension 
including the evidence for a general genetic component. The structure of the adrenal 
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gland and the biosynthestic pathways for the synthesis of its principal corticosteroid 
hormones, cortisol and aldosterone will be described. The major effects of these 
hormones and their mechanisms of action will be explained with particular attention 
to the ways in which they influence blood pressure. A description of clinical 
syndromes of corticosteroid deficiency or excess highlights their importance in blood 
pressure regulation. However, to address the main aim of this review which is to 
evaluate the contribution of adrenocortical function to the heritable component of 
hypertension requires a detailed look at the molecular genetics of aldosterone and 
cortisol synthesis. In particular, focusing on gene and enzyme structure and 
regulation of expression. The strong evidence from both animal models and rare 
monogenic forms of human hypertension, that modification of these genes affect 
blood pressure and cardiovascular function is presented. Finally there is evidence to 
suggest that similar genetic variation is associated with the increasingly common 
syndrome of essential hypertension. 
From this review I will present the hypothesis that genetic variation within the genes 
responsible for aldosterone and cortisol synthesis act not only independently to 
increase risk but also interact in a previously unsuspected way. This will form the 
basis of my experimental work. 
1.2 Environmental Risk Factors 
Evidence suggests that hypertension results from an interaction between genetic and 
environmental risk factors and that this accounts for the high prevalence of essential 
hypertension in industrialized countries (Kornitzer et al 1999). The main modifiable 
risk factors are: high salt intake, alcohol consumption, obesity and low physical 
activity. It seems likely that changes in these risk factors have made an important 
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contribution to the rapid rise in the frequency of hypertension over recent years. The 
evidence for the contribution of each of the main risk factors is reviewed briefly 
below. 
1.2.1 Salt Intake 
The link between salt intake and blood pressure seems predictable from the 
relationship between salt and vascular volume homeostasis. In 1972, Dahl found a 
correlation between urinary salt excretion and prevalence of hypertension in humans 
(Dahl 1972). This association was confirmed by the large international 
epidemiological study, INTERSALT, which revealed an association, in 52 
populations, between sodium excretion and the increase in blood pressure with age. 
Sodium excretion and systolic blood pressure were also found to be related after 
adjustment for age, gender, body mass index (BMI), alcohol and potassium intake 
(Stamler et al 1989). Several meta-analyses of randomized clinical trials have 
confirmed that decreasing salt consumption reduces blood pressure. One meta-
analysis comparing randomised clinical trials of hypertensive subjects with those of 
normotensive subjects concluded that salt reduction resulted in a significant decrease 
in blood pressure in hypertensive individuals and a small non-significant fall in 
normotensives (Kornitzer et a/1999). However, dietary sodium intake does not raise 
blood pressure in everyone, and distinction has been made between 'salt sensitive' 
and 'salt resistant' individuals. This phenotype is also observed in animal models of 
hypertension such as the Dahl salt sensitive hypertensive rat (Cicila et a/1993) (see 
section 1.15.1.1). 
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1.2.2 Potassium Intake 
The INTERSAL T study also showed that potassium has a significant inverse 
relationship with blood pressure in individuals after correction for confounding 
factors. Therefore, the sodium/potassium ratio is significantly positively related to 
blood pressure (Stamler et al 1989). This inverse relationship of potassium to blood 
pressure was confirmed in the Multiple Risk Factor Intervention trial (Stamler et al 
1997). In an interventional study it was demonstrated that a diet of foods with high 
potassium content such as fruit and vegetables significantly reduced blood pressure 
compared with a normal diet (Appel et a/1997). 
1.2.3 Alcohol Consumption 
The affect of alcohol intake on blood pressure depends on age and gender (Kornitzer 
et al 1999). Long-term high alcohol consumption increases blood pressure but the 
precise nature of the relationship varies between studies. The INTERSAL T study 
found an association between high alcohol intake (2: 300 ml/week) and the 
prevalence of hypertension after adjusting for age, sex, BMI and urinary Na+ and K+ 
excretion (Stamler et al 1989). In a study of male subjects, alcohol intake could 
explain between 7 and 11% of the occurrence of hypertension (MacMahon 1987). 
Reducing alcohol intake has a favourable affect on both systolic and diastolic blood 
pressure in hypertensive subjects (Puddey et a/1987). 
1.2.4 Obesity 
Many population studies have found a significant association between BMI and 
blood pressure (Kornitzer et al 1999). The INTERSAL T study found this to be an 
independent effect (Stamler et al 1989). Other studies have shown a favourable 
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effect on blood pressure of reduction of calorie intake or body weight in hypertensive 
subjects (Kornitzer et al 1999). 
1.2.5 Other Factors 
Many other environmental factors can potentially affect a person's blood pressure. 
For example, a sedentary lifestyle, smoking and stress have all been associated with 
hypertension although the extent of their contribution is not always clear (Kornitzer 
et a/1999; Odermatt 2004). In particular the contribution of stress to hypertension is 
unclear as it is hard to define or quantify stress and there is a high degree of 
variability between individuals. 
1.3 Evidence for a Genetic Component 
Heritability is defined as the total phenotypic variance in a trait that is due to additive 
genetic effects. Although environmental factors are known to play an important role 
in the pathogenesis of essential hypertension, evidence from family and 
epidemiological studies suggests that 30-60% of blood pressure variation within a 
population is genetic (Ward 1990). 
1.3.1 Family Studies 
Population studies such as the one conducted in Tecumseh, Michigan, demonstrate 
that there is a greater similarity of blood pressure within families than between 
families (Longini, Jr. et a/1984). This is not simply due to a shared environment as 
there is a significant correlation of blood pressure between first-degree relatives but 
not between spouses who have been sharing the same environment for 1 0 years or 
more (Havlik et al 1979; Miall et al 1967). This is confirmed in adoption studies 
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where there is a significant correlation of blood pressure between parents and natural 
children or between natural siblings but not between these and adopted children 
living in the same household (Biron et al1976). The correlation of blood pressure is 
higher between monozygotic than dizygotic twins, strongly suggesting that a 
proportion of the population variation of blood pressure is genetically determined 
(Feinleib et al 1977). The genetic contribution can be quantified using the sibling to 
risk ratio (lambda-S). This compares the prevalence of hypertension in sibships to 
the prevalence in the general population. A lambda-S > 2 is believed to indicate a 
significant genetic component. The lambda-S for hypertension is roughly 3.5 (Jones 
1999). 
1.4 Identifying the Genes Involved 
Having established that essential hypertension is a complex quantitative trait with a 
strong genetic component, there are several methods to determine which genes (or 
quantitative trait loci (QTL) contribute to blood pressure). The two main methods 
for identifying the genes involved are genome wide scans and candidate gene studies. 
For human subjects, investigations are conducted either as family studies consisting 
of affected members (usually sibling pairs) or as association studies where groups of 
hypertensive and normotensive subjects are compared. 
A genome wide scan uses random genetic markers spread over the entire genome to 
identify a QTL that associates with blood pressure. This method allows the detection 
of novel susceptibility genes that a candidate gene approach would miss. However, 
an identified QTL will typically consist of a large chromosomal region containing 
100-300 genes and further, more stringent linkage mapping must be performed to 
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reduce the locus and focus on fewer relevant genes. Each of these genes must then 
be examined for variants. 
The candidate gene approach is based on a prior knowledge of the pathophysiology 
of hypertension, which will suggest potential causative genes. There are several lines 
of evidence suggesting a contributory role of adrenal corticosteroids in essential 
hypertension and therefore that the genes encoding the enzymes for their 
biosynthesis may be key candidates. 
1.5 Structure of the Adrenal Gland 
The adrenal glands are paired pyramidal-shaped organs situated above each kidney. 
Each comprises an inner medulla and a surrounding cortex (see figure 1.1). The 
cortex is divided into 3 layers: zona glomerulosa, zona fasciculata and the zona 
reticularis. These 3 zones are histologically and enzymatically distinct with the 
steroid hormones produced by each of the zones being dependent on which enzymes 
are present in the cells of that zone. 
Capsule -1:: 
Capsule----...,.": 
Ad enal cortex 
Adrenal medulla { 
} 
] - zona glamerulosa 
Zona fascicular.a 
}-z,,," '"''"'" 
}Adrenal medulla 
Figure 1.1. Cross section of the adrenal gland showing the distinct layers of the 
adrenal cortex 
(Taken from the McGraw-Hill online learning center; Ch20 Endocrine System 
http://highered. mcgraw-hill. com) 
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1.6 Corticosteroids 
Corticosteroids are hormones produced by the adrenal cortex that are essential for 
life. The adrenal corticosteroids secreted by the cortex are divided into two main 
groups: the mineralocorticoids and the glucocorticoids. The mineralocorticoid 
aldosterone is synthesised in the zona glomerulosa and affects water and electrolyte 
homeostasis. The glucocorticoids, cortisol in man and corticosterone in the rat, are 
synthesised in the zona fasciculata and control carbohydrate, fat and protein 
metabolism as well as contributing to the control of the immune response. The zona 
reticularis is the site of sex steroid synthesis (mainly the androgen precursors 
dehydroepiandrosterone (DHEA) and androstendione (A'dione)). 
Corticosteroids are a group of C21 steroids characterized by a double bond at C-4, a 
C-21 hydroxyl group and an oxo group at C-20. A hydroxyl group or an oxo group 
may or may not be present at C-11. The presence or absence of a hydroxyl group at 
C-17 differentiates the 17 -oxygenated corticosteroids, such as cortisol or 11-
deoxycortisol (S) from the 17-deoxycorticosteroids such as 11-deoxycorticosterone 
(DOC), corticosterone (B) and aldosterone. The chemical and common names for 
some of the adrenal steroids are listed in table 1.1 and the structure of the more 
important ones are shown in figure 1.2. It is possible to relate these structural 
features to their biological activities. For example the presence of hydroxyl groups 
at C-17 and C-11 enhances glucocorticoid activity so that cortisol is the most active, 
whereas absence of a C-17 hydroxyl group results in mineralocorticoid activity eg 
DOC. Aldosterone contains a hydroxyl group at C-11 but is unique in that it 
contains an aldehyde group on C-18. The close proximity of these groups results in 
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hemi-acetyl formation, reducing the influence of the C-11 hydroxyl group and hence 
decreasing glucocorticoid activity. 
All of the adrenal steroids are synthesised from a common substrate, cholesterol, by a 
series of enzymatic conversions performed by two types of enzyme: cytochrome 
P450 and hydroxysteroid dehydrogenase enzymes. 
Common name Abbreviation Systematic name 
cholesterol c cholest-5-en-3 ~-ol 
pregnenolone PREG 3 ~-hydroxypregn-5 -ene-20-one 
progesterone p pregn-4-ene-3 ,20-dione 
17-hydroxypregenolone 17-0H-PREG 3 ~, 17a-dihydroxypregn-5-ene-20-one 
17-hydroxyprogesterone 17-0H-P 17a-hydroxypregn-4-ene-3,20-dione 
dehydroepiandrosterone DHEA 3 ~-hydroxyandrost-5-ene-17 -one 
androstenedione A'dione androst-4-ene-3,17-dione 
11-deoxycortiso I s 17a,21-dihydroxypregn-4-ene-3,20-dione 
cortisol F 11 ~' 17a,21-trihydroxypregn-4-ene-3,20-dione 
cortisone E 17a,21-dihydroxypregn-4-ene-3, 11 ,20-trione 
11-deoxycorticosterone DOC 21-hydroxypregn-4-ene-3 ,20-dione 
corticosterone B 11 ~,21-dihydroxypregn-4-ene-3 ,20-dione 
IS-hydroxycorticosterone 18-0H-B 11 ~, 18,21-trihydroxypregn-4-ene-3,20-dione 
aldosterone AI do 11 ~,21-dihydroxypregn-4-ene-3 ,20-dione-18-al 
Table 1.1. Common and systematic names and abbreviations of some important 
adrenal steroids 
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Cholesterol 
CH20H 
11-Deoxycorticosterone 
(DOC) 
Aldosterone 
(Aido) 
CH 20H 
0 
11-Deoxycortisol 
(S) 
IS-hydroxycorticosterone 
CH20H 
OH 
(F) 
Figure 1.2. Steroid structures and common names 
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1. 7 Cytochrome P450 Enzymes 
Cytochrome P450 (CYP450) enzymes form a large superfamily present in all life 
forms that catalyze the mono-oxygenation (hydroxylation) of a diverse range of 
substrates. A total of nearly 4000 CYP450 genes have now been identified. Their 
main functions in humans are xenobiotic metabolism within the liver and steroid 
synthesis within the endocrine glands such as the gonads and the adrenal cortex. 
Five CYP450s are involved in the synthesis of steroids in humans. 
CYP450 enzymes are mixed function oxygenases that catalyze the incorporation of 
one oxygen atom from an oxygen molecule into the substrate and reducing the other 
to water. All these enzymes possess a covalently bound haem prosthetic group to 
manipulate oxygen and electrons. They are dependant on molecular oxygen (02) and 
electrons donated by NADPH in the following stoichiometry: 
R-H + NADPH + H+ + 02 ---7 R-OH = NADP+ +H20 
Each of the steroid hydroxylation reactions involves a two-electron reduction of one 
molecule of oxygen with concomitant oxygenation of various substrates. The 
CYP450 enzymes, which are divided into 2 biochemical classes, mitochondrial and 
microsomal, are the terminal components of an electron transport system. The type I 
enzymes (side chain cleavage (P450scc), liP-hydroxylase (P450u~) and aldosterone 
synthase (P450aldo)) are part of a system located on the inner mitochondrial 
membrane, comprising NADPH, adrenodoxin reductase (a FAD-containing 
flavoprotein) and the iron sulphur protein (2Fe-2S) adrenodoxin (see figure 1.3). 
Two high-energy electrons are transferred from NADPH to the FAD of adrenodoxin 
reductase. Adrenodoxin accepts electrons from adrenodoxin reductase one at a time 
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and transfers them to the haem iron of the cytochrome P450 enzyme, which is bound 
to the inner mitochondrial membrane (Bernhardt et al 1998). Type II enzymes (21-
hydroxylase (P450c21) and 17-hydroxylase (P450c17)) are located within the 
endoplasmic reticulum and rely on a single NADPH-specific P450 oxidoreductase 
for the transfer of electrons (see figure 1.3). In some cases, this transfer may be 
assisted by cytochrome b5. 
Mitochondrial 
2 e- DONOR 
NADPH+W 
NADP• 
Microsomal 
2 e- DONOR 
NADPH +W 
Figure 1.3. Electron transport chains of mitochondrial and microsomal P450 
monooxygenases. 
Electrons are transferred from NADPH through NADPH-adrenodoxin reductase 
(ADR) and adrenodoxin (ADX) to mitochondrial P450 or through P450 
oxidoreductase to microsomal P450 to exhibit the monooxygenase activity. 
RH and ROH indicate the substrate and the product, respectively. 
(Adaptedfi·om Kominami et al 1984) 
The CYP450 reaction involves cyclic oxidation/reduction of the P450-containing 
haem iron in conjunction with substrate binding and oxygen activation. The cycle is 
initiated by substrate binding which induces a conformational change that activates 
the CYP450 from its resting state to form a high-spin ferric (Fe3+) complex on the 
haem iron. This substrate-bound complex has a much greater +ve reduction 
potential. The subsequent reduction of the haem iron by two electrons enables 
oxygen binding, the breaking of the 0-0 bond within molecular oxygen and the 
transfer of one oxygen atom to the substrate to yield the oxidised product. 
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Many CYP450s can bind more than one structurally distinct substrate due to their 
ability to undergo conformational changes, making them an exception to the classic 
'lock and key' concept of enzyme function. 
Evidence suggests that adrenodoxin does not form a static ternary complex with 
adrenodoxin reductase and CYP450 but that it functions as a mobile electron shuttle. 
Each of these associations is dependent on ionic interactions between complementary 
charged residues. Site-directed mutagenesis studies have shown that CYP450s 
interact with adrenodoxin at specific amino acid residues and that changes in the 
primary sequence of the CYP450 or adrenodoxin can alter the interaction. Factors 
affecting this interaction, the amount of adrenodoxin or its electron transfer 
properties can affect the level or pattern of adrenal steroid biosynthesis (Beckert & 
Bernhardt 1997). The electron transfer proteins are not specific to individual 
CYP450s. Therefore, adrenodoxin is able to interact with P450scc as well as P450 1 1 ~ 
and P450aldo· Competition for electrons from the adrenodoxin, among the P450 
enzymes can also alter the pattern of product yields. 
1.8 Corticosteroidogenesis 
The sequence of reactions which converts cholesterol to corticosteroids in the human 
adrenal cortex are illustrated in figure 1.4. For steroidogenesis to occur, cholesterol 
must first be delivered to the mitochondrion. 
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Figure 1.4. Major pathways of corticosteroid biosynthesis in human adrenal 
cortex. 
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1.8.1 Cholesterol Uptake 
The first stage in the biosynthesis of all adrenal steroids is the cleavage of 
cholesterols side chain by the cytochrome P450 side chain cleavage enzyme 
(P450scc), encoded by CYPllAI, to produce pregnenolone (see figure 1.4). The 
rate-limiting step of adrenal steroidogenesis is the uptake of cholesterol, which is 
hydrophobic, across the aqueous intermembrane space of the mitochondrion to the 
inner mitochondrial membrane where P450scc is located (Black et al 1994) (see 
figure 1.5). 
Tropic 
Hormone 
Plasma membrane 
Ca+ 
0~ 
~ 
cholesterol 
G) ---+~ Free cholesterol 
Lipid droplet ! 
1------1 De novo synthesis 
Figure 1.5. Activation of steroid hormone production 
(Adapted from Stocco & Clark 1996) 
17-0H 
preg 
The main supply of cholesterol to adrenal cells in man is from the circulation in the 
form oflow-density lipoprotein cholesterol (Gwynne & Strauss 1982) whereas in rats 
the main source is from high-density lipoproteins (Gwynne & Mahaffee 1989). The 
cholesterol can then be stored within the cell in lipid droplet stores as cholesterol 
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esters. A low level of de novo synthesis of cholesterol from acetate also occurs 
within the adrenal cortex (Borkowski et al 1967). Upon stimulation, these 
intracellular cholesterol-containing vesicles are transported to the mitochondria along 
the cytoskeleton fibres of the cells. Free cholesterol is then transported across the 
intermembrane space to the inner mitochondrial membrane by mechanisms still not 
well understood. Several putative regulatory proteins have been identified; sterol 
carrier protein-2 (SCP-2) (Vahouny et al 1985), steroidogenesis activator protein 
(SAP) (Frustaci et al 1989; Pedersen & Brownie 1983), the mitochondrial 
benzodiazepine receptor (PBR) and its endogenous ligand diazepam-binding 
inhibitor (DBI) (Papadopoulos 1993) and the steroidogenic acute regulatory (StAR) 
protein which has been the most widely studied and has the most compelling 
evidence for this role (Clark et al1994). This is considered in more detail below. 
1.8.2 Steroidogenic acute regulatory (StAR) protein 
StAR is synthesised as a 37-kDa cytosolic precursor with an N-terminal 
mitochondrial-signalling sequence, which upon hormonal stimulation can be 
imported and modified by the mitochondria to a mature 30-kDa form (Epstein & 
Orme-Johnson 1991 ). Several studies have shown that the synthesis of the 30-kDa 
protein correlates with the synthesis of steroids (Epstein & Orme-J ohnson 1991; 
Krueger & Orme-Johnson 1983). In vitro studies have demonstrated that 
transfection of either MA-10 murine Leydig tumour cells or COS-1 cells with the 
eDNA of the StAR precursor protein increases the conversion of cholesterol to 
pregnenelone (Clark et al1994; Sugawara et al1995). 
Perhaps the most compelling evidence for the role of StAR in steroidogenesis came 
when several nonsense mutations within its gene were identified as causing the 
38 
disorder, congenital lipoid adrenal hyperplasia (lipoid CAH) (Lin et al 1995). Lipoid 
CAH is a lethal, inherited disorder characterized by severely impaired steroid 
hormone biosynthesis and enlarged adrenal glands containing high levels of 
cholesterol and cholesterol esters due to the impaired delivery of cholesterol to 
P450scc. Targeted disruption of the StAR gene to produce knock-out mice results in 
a similar phenotype to that of congenital adrenal hyperplasia (Caron et al 1997; 
Hasegawa et al2000). 
The mechanism by which StAR regulates cholesterol transfer to the inner 
mitochondria remains unclear. It was thought that during the import of StAR into the 
mitochondria, contact sites form between the outer and inner membrane allowing 
cholesterol import (Stocco & Clark 1996). However, studies using recombinant 
StAR proteins lacking the mitochondrial import sequence have biological activity 
equivalent to wildtype StAR, demonstrating that mitochondrial import is not 
essential for activity (Arakane et al 1998; Bose et al 2002). Moreover, 
adrenocortical mitochondria have characteristically tubular cristae, which may not 
form such contact sites. 
1.8.3 Cholesterol side-chain cleavage enzyme (P450scc) 
This first step in the synthesis of all steroids is the cleavage of the side-chain of 
cholesterol by the cholesterol side-chain cleavage enzyme (P450scc). It is located on 
the inner mitochondrial membrane and catalyzes the conversion of C27 cholesterol to 
C21 pregnenolone by 3 separate reactions: 20a-hydroxylation, 22a-hydroxylation 
and a C20-22 bond scission. The location of this enzyme highlighted the 
mitochondria as an important site for cholesterol delivery. The CYP IIAI gene 
located on chromosome 15 encodes for P450scc. 
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1.8.4 3f3Hydroxysteroid dehydrogenase (3/3-HSD) 
The product of side chain cleavage of cholesterol, pregnenolone, exits the 
mitochondria and is converted within the cytoplasm by the enzyme 3~-HSD to form 
progesterone. 3~-HSD also converts 17-hydroxypregnenolone, which is formed 
from pregnenolone by CYP 17 (see section 1.8.5), to 17-hydroxyprogesterone, and 
dehydroepiandrosterone (DHEA) to androstenedione. 3~-HSD is a member of the 
microsomal short chain dehydrogenase family and the only non-P450 enzyme in the 
pathway. Two isoenzymes have been identified in the human (3~-HSD1 and 2). The 
isoforms are encoded by separate genes that lie in tandem on chromosome 1, 3 J3-
HSD1 and 3j3-HSD 2 respectively (Berube et a/1989; Lachance et a/1991). It is the 
3~-HSD2 isoform that is found in the adrenals and gonads (Lachance et a/1991). 
1.8.5 17a-Hydroxylase(P450c17) 
Progesterone and pregnenolone are both 'hydroxylated' by the enzyme 17a-
hydroxylase (P450c17), which is encoded by the CYP 17 gene on chromosome 10, to 
produce 170H-progesterone and 170H-pregnenolone respectively (Sparkes et al 
1991 ). This 17 a-hydroxylation step is essential for glucocorticoid, androgen and 
oestrogen synthesis. 170H-Progesterone and 170H-pregnenolone are converted by a 
17,20 lyase reaction catalyzed by the same enzyme to form the adrenal androgens, 
androstenedione and dehydroepiandrosterone (DHEA) respectively. The zona 
glomerulosa, where pregnenolone is converted to produce the mineralocorticoid 
aldosterone, does not express P450c17. Therefore, P450c17 is important in 
determining the zone specific nature of adrenal steroid synthesis. 
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1.8.6 21-Hydroxylase (P450c21) 
The enzyme 2I-hydroxylase (P450c2I) 1s encoded by the CYP2I gene on 
chromosome 6 (White et ali9S6). P450c2I performs 2I-hydroxylations to produce 
II-deoxycorticosterone (DOC) or II-deoxycortisol (S) from either progesterone 
(zona glomerulosa) or 17-0H progesterone (zona fasciculata) respectively. P450c2I 
is expressed in all three zones of the adrenal cortex (Shinzawa et ali9SS). 
1.8. 7 Aldosterone Synthase (P450atdo) 
The final steps in the synthesis of mineralocorticoids (aldosterone) and 
glucocorticoids (cortisol) were originally thought to be performed by a single 
enzyme encoded by a single gene locus (Miller I9S7). This is indeed the case of the 
bovine, porcine and frog enzyme(Nonaka et al I99I; Ogishima et al I9S9). 
However in man, rat and mouse the final stages are performed by two distinct 
enzymes. The three terminal stages in the synthesis of aldosterone (II-
hydroxylation, IS-hydroxylation and dehydration) are all carried out by the enzyme 
aldosterone synthase (P450atct0 ), which is encoded by the CYP II B2 gene on 
chromosome S (Curnow et al I99I; Kawamoto et al I992; Momet et al I9S9). 
P450atdo is expressed exclusively in the zona glomerulosa of the adrenal cortex where 
it performs the following reactions: 
I. II ~-hydroxylation of DOC to form corticosterone 
2. IS-hydroxylation of B, producing IS-hydroxycorticosterone (lS-OHB) 
3. IS-oxidation of IS-OHB, resulting in aldosterone 
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In vitro studies have demonstrated that DOC is the preferred substrate ofP450aldo and 
that it remains bound to the active site throughout these reactions with B and 18-
0HB only being released as by-products (Denner et al 1995). 
1.8.8 11/3-hydroxylase (P45011p) 
The final stage in the synthesis of cortisol (or corticosterone in the rat) is an 11-
hydroxylation by the enzyme 11 P-hydroxylase (P450ll 13) encoded by the CYP 11 Bl 
gene on chromosome 8 (or 7 in the rat) (Momet et al 1989). This converts 11-
deoxycortisol to cortisol within the mitochondria and is specific to the zona 
fasciculata-reticularis (Ogishima et al 1992). P450lll3 can also convert DOC to 
corticosterone (B) highlighting the functional similarity with aldosterone synthase. 
P450 11 13 can also perform 18- and 19- hydroxylations of DOC, resulting in 18-
0HDOC (18-hydroxy-11-deoxycorticosterone) and 19-0HDOC (19-hydroxy-11-
deoxycorticosterone ), respectively as well as the conversion of corticosterone, to 18-
0HB (18-hydroxycorticosterone) (Okamoto & Nonaka 1992). 
1.9 Effects of Corticosteroids 
Corticosteroids are involved in a wide range of physiological systems. Some vital 
functions of glucocorticoids include the regulation of carbohydrate, protein and lipid 
metabolism, inflammatory, immunogenic and stress responses and the maintenance 
of blood pressure and cardiovascular function. Mineralocorticoids are essential for 
the control of electrolyte and water balance. Two homologous corticosteroid 
receptors have been identified, the mineralocorticoid receptor (MR) (Arriza et al 
1987) and the glucocorticoid receptor (GR) (Hollenberg et al 1985). The MR and 
GR receptors both belong to the thyroid/steroid hormone receptor superfamily of 
42 
transcription factors and share 94% ammo acid conservation within their central 
DNA binding domain (DBD) and approximately 57% within their C-terminalligand-
binding domain (Arriza et a/1987). Of particular interest here are the ways in which 
corticosteroids influence blood pressure. 
1.9.1 Mineralocorticoid Effects 
The term 'mineralocorticoid' is derived from the first recognized and the 
physiologically most important action of aldosterone, to regulate transport of 
electrolytes across epithelial surfaces. The main site of action is the kidney but the 
salivary glands and the colon also respond (Orth et a! 1992). Recent work has 
suggested that aldosterone also exerts rapid non-genomic effects via membrane 
aldosterone receptors that are distinct from its effects on gene transcription (see 
section 1.9.1.5). 
1.9 .1.1 Epithelial actions of aldosterone 
Aldosterone exerts its classic genomic effects on epithelia by binding to the MR 
within the cytosol. MR has high affinity for aldosterone, corticosterone and cortisol 
but is specifically activated by aldosterone in aldosterone target tissues due to the 
inactivation of the glucocorticoids by the enzyme 11 ~-hydroxysteroid dehydrogenase 
type 2 (11 ~-HSD2) (see section 1.9.3). In the absence of ligand, MR is maintained in 
an inactive state by association with a complex of chaperone proteins including 
hsp90. Upon ligand-binding, these proteins dissociate revealing nuclear localization 
signals and allowing translocation of the ligand-receptor complex to the nucleus (see 
figure 1.6). There it acts as a transcription factor by binding to a nuclear hormone 
response element (HRE) (with the consensus sequence AGAACAnnnTGTTCT) in 
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the 5'UTR of aldosterone-responsive genes. This results in activation or repression 
of expression of specific target genes. Hormone-receptor complexes bind to DNA as 
dimers. More recently it has been demonstrated that activated steroid receptors can 
also affect transcription independent of DNA binding by direct protein-protein 
interactions with other factors (Karin 1998; Reichardt et a/1998) (see section 1.9.2). 
Corticosteroid 
nucleus 
J1 Cytoplasmic 
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Figure 1.6. Ligand mediated activation of the corticosteroid receptor (MR or 
GR). (Adaptedfrom Weige/1996) 
In the absence of hormone, each receptor (R) monomer is associated with a heat-
shock protein complex (HSP). Binding of steroid causes a conformational change 
resulting in dissociation of the heat -shock complex and allowing dimerization of the 
receptor and DNA binding to a hormone response element (HRE) to alter 
transcription of target genes. 
The net effect of aldosterone within epithelia is to increase the reabsorption ofNa+ 
ions at the expense of K+ and H+ ions (White 1994) (see figure 1. 7). The principal 
sites of aldosterone action within the kidney are the luminal cells of the distal 
convoluted tubule and the collecting duct as reflected by the high expression levels 
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of MR at these sites. Aldosterone-responsive epithelia have high electrical resistance 
and regulated permeability to water and electrolytes. Sodium reabsorption at the 
apical membrane is facilitated by an electrochemical gradient and mediated by the 
amiloride-sensitive epithelial sodium channel (ENaC). The ENaC is the rate-limiting 
step and major determinant of renal sodium reabsorption (Horisberger 1998). Sodium 
transport out of the cell is by means of active transport across the basolateral 
membrane mediated by the sodium-potassium ATPase (Na+-K+-ATPase). This 
drives the entry of sodium coupled to the excretion of potassium via the luminal K+ 
channel. Sodium reabsorption is accompanied by an influx of water. In addition to 
these main targets, other potential mediators of aldosterone action are the luminal 
Na+1H+-exchanger (NHE3) in the colon and the luminal thiazide-sensitive Na+/cr 
cotransporter in the distal renal tubule (Cho et al 1998; Kim et al 1998). The 
principal mechanism of aldosterone-induced electrolyte transport appears to involve 
an increased activity of ENaC, the limiting step in the transport process. Evidence 
suggests that aldosterone regulates ENaC activity by increasing the number of 
channels at the apical membrane and/or by increasing their open-probability (Garty 
& Palmer 1997; Verrey 1999). The resulting gene products are thought to mediate 
these effects and are termed aldosterone-induced protein(s) (AlP). 
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Figure 1. 7. The classical genomic action of aldosterone on epithelial tissue. 
HRE - hormone response element 
(Adaptedfrom Connell & Davies 2005) 
1.9 .1.2 Aldosterone-Induced Proteins 
AlP's may exert effects on the apical membrane, the basolateral Na+-K+-ATPase 
pump and/or cellular energy production to produce an increase in sodium 
reabsorption with a concomitant potassium and hydrogen ion excretion. Several 
putative AlP's have been identified. 
Sgkl 
The serum- and glucocorticoid-regulated kinase 1 (sgkl) was one of the first 
identified and perhaps is the best characterized of the AlPs. Aldosterone increases 
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expressiOn of sgkl in the kidney and the distal colon in vitro and in vivo. 
Coexpression studies of sgkl with the ENaC in Xenopus larvis oocytes demonstrate 
strong activation of the ENaC-mediated Na+ transport by sgkl; it also appears to 
activate the Na+1K+-ATPase and Na+/K+/Cr cotransporter (Henke et a/2002; Naray-
Fejes-Toth et al 1999; Shigaev et al 2000). There is some evidence that sgkl may 
phosphorylate the ENaC a-subunit to alter channel activity or that it can regulate the 
gene expression of the subunits but the precise mechanism of action of sgkl remains 
unclear (Boyd & Naray-Fejes-Toth 2005; Diakov & Korbmacher 2004). However, 
sgkl modulates the activity of the ENaC regulator protein Nedd4-2 (neuronal 
precursor cell-expressed, developmentally down regulated protein 4-2). The 
importance of this protein in the regulation of ENaC is highlighted by the pathology 
of Liddle's syndrome. Nedd4-2 is a ubiquitin-protein ligase that regulates the 
degradation rate of ENaC. Sgkl kinase interacts with Nedd4-2 and modulates its 
activity by phosphorylation to reduce its binding to ENaC (De bonneville et al 2001; 
Synder et al 2002). This results in a reduced ubiquitination of ENaC, with a 
subsequent increase in channel density and stability at the apical membrane and an 
increased capacity for sodium reabsorption. The sgk1-knockout mouse has 
symptoms of pseuedohypoaldosteronism, similar to that of the MR knockout (Berger 
et al 1998; Wulff et al 2002). However, the phenotype in the MR knockout is much 
more severe, suggesting there are other essential targets of MR action. 
Corticosteroid hormone-induced factor (CHIF) 
Corticosteroid hormone-induced factor (CHIF) belongs to the FXYD family of small 
transmembrane proteins that regulate the activity of ion channels and transport 
proteins. The y-subunit of Na + IK+ -ATPase also belongs to this family and shares 
47 
>50% sequence homology with CHIF (Geering et al 2003). CHIF is expressed 
within the kidney and distal colon on the basolateral epithelial membranes. In the 
distal colon, aldosterone, dexamethasone, Na+ restriction and K+ loading have all 
been shown to increase the expression of CHIF (Brennan & Fuller 1999; Capurro et 
al 1996). Na + restriction increases CHIF protein levels in the kidney and the colon 
(Shi et al 2001). The precise physiological function of CHIF is unknown, but it is 
associated with the Na+1K+-ATPase in renal tissue and modulates its tranport 
properties by enhancing the affinity of the Na+/K+-ATPase for Na+ (Beguin et al 
2001). This may at least partly explain the increase in Na+/K+-ATPase activity in 
response to aldosterone. 
Kirsten Ras GTP-binding protein-2A (Ki-RasA) 
Ki-RasA is a small monomeric GTP-binding protein that appears to play an 
important role in mediating aldosterone action in renal epithelia. Aldosterone 
increases Ki-RasA expression and protein levels during the early phase of action, 
with increases as early as 30 minutes after aldosterone administration. There is some 
controversy surrounding the importance of Ki-RasA to aldosterone action as the 
levels of Ki-Ras or its induction by aldosterone appears to be very small (or absent) 
in some of aldosterone's target epithelia. Evidence suggests that Ki-RasA increases 
the open probability of the ENaC channel but decreases the number of channels. The 
mechanisms for these apparently conflicting actions remain unclear (Spindler & 
Verrey 1999; Stockand 2002; Stockand & Meszaros 2003). 
PI3K 
The enzyme, phosphatidylinositide 3-kinase (PI3K), phosphorylates inositol 
phospholipids to produce the second messengers, 3-phosphorylated inositides, which 
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mediate diverse cellular signalling functions. PI3K is not an AlP but aldosterone 
increases its activity, perhaps through induction of Ki-RasA. Inhibition of PI3K 
affects both the early and late phases of aldosterone action, with a decrease in Na + 
transport even in the presence of sustained aldosterone levels. PI3K also appears to 
be important for the sodium transport changes mediated by insulin and vasopressin, 
indicating a point of convergence for the signalling pathways of these hormones to 
interact and regulate ENaC and Na+1K+-ATPase. (Blazer-Yost et al1999; Stockand 
2002). 
1.9 .1.3 Nonepithelial aldosterone action 
As well as the principal site of aldosterone action on epithelial cells surfaces, MR 
have also been identified in a number of nonepithelial cells including vascular 
smooth muscle and endothelial cells (Christ et al1995; Takeda et al1996), neurones 
and support cells (Qin et al 2003), circulating lymphocytes (Wehling et al 1990), 
cardiomyocytes (Stockand & Meszaros 2003; Wang et al 2002) and cardiac 
fibroblasts (Stockand & Meszaros 2003). It is now accepted that aldosterone has 
physiological and pathophysiological effects in nonepithelial tissues, especially in 
the central nervous system (CNS) and cardiovascular system. Of particular interest 
to this study are the effects on the cardiovascular system. 
1.9.1.4 Cardiovascular effects of aldosterone 
Within the cardiovascular system, aldosterone is thought to exert effects on both the 
vasculature and the heart, causing vascular inflammation and damage as well as 
cardiac hypertrophy and fibrosis, by pathways independent of its effects on blood 
pressure. However, all these changes may themselves contribute to an altered blood 
pressure regulation. 
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Aldosterone effects on the vasculature 
In the vascular system, aldosterone promotes smooth muscle hypertrophy and 
endothelial dysfunction. Activation of MR in vascular smooth muscle cells increases 
the contractile response to adrenergic stimulation and impairs the vasodilatory 
response to acetylcholine (Farquharson & Struthers 2002; Jazayeri & Meyer, III 
1989; Komel et al 1988; Taddei et al 1993). Aldosterone also stimulates an increase 
in the Ang II receptor (ATl) density in cardiovascular tissues, which may also 
modulate vascular tone (Robert et all999). Aldosterone decreases the availability of 
the vasodilator nitric oxide (NO) and enhances vascular and systemic oxidative 
stress. These effects are thought to contribute to the vascular alterations observed in 
the spontaneously hypertensive rat (Sanz-Rosa et al 2005). In patients with heart 
failure spironolactone, a non-specific MR antagonist (which also acts on androgen 
receptors), greatly increases NO bioactivity, with a concomitant improvement in 
endothelial function (Farquharson & Struthers 2000). Excess aldosterone is also 
thought to cause vascular remodelling through collagen deposition in the blood 
vessels with a resulting decrease in compliance. In support of this, there is evidence 
to suggest that aldosterone levels are inversely related to arterial compliance in 
essential hypertension (Blacher et al1997). 
Aldosterone effects on the heart 
Aldosterone promotes cardiac hypertrophy as well as perivascular and interstitial 
fibrosis (Brilla et al 1990). Hypertension is known to cause cardiac hypertrophy and 
fibrosis through hemodynamic changes, but the aldosterone-induced hypertrophy and 
fibrosis, although dependent on salt status, have been shown to occur independently 
of blood pressure. In support of this, patients with primary aldosteronism are more 
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likely to have left ventricular hypertrophy (L VH) or stroke than in age and sex 
matched subjects with essential hypertension of similar severity (Rossi et al 1997; 
Tanabe et a/1997). 
The importance of MR activation m promoting cardiovascular injury has been 
recently further highlighted by several clinical trials, including The Randomized 
Aldactone Evaluation Study (RALES) (Pitt et a! 1999) and the Eplerenone Post-
Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) 
(Pitt et al 2003). Addition of low doses of MR antagonist to standard therapy 
reduced cardiac moribidity and mortality in heart failure patients and in patients after 
an acute myocardial infarction. This effect was independent of blood pressure 
reduction or fluid loss, suggesting that antagonism of the non-classical actions of 
aldosterone at non-epithelial sites, such as the heart and vasculature, may be 
responsible for the beneficial effects. A substudy of RALES demonstrated that 
markers of collagen synthesis, which associate with cardiac fibrosis, correlated with 
disease severity and increased risk. Low doses of spironolactone decreased the 
levels of collagen, with an associated decrease in risk. This supports a role for 
aldosterone and cardiac fibrosis in the pathology of heart failure (Zannad et a/2000). 
The mechanisms of these aldosterone-induced effects is unclear but are thought to 
involve the regulation of collagen deposition in cardiac tissue (Brilla et al 1990). In 
the presence of a high sodium intake, aldosterone exerts a direct pro-fibrotic action 
by stimulating the accumulation of fibrillar type 1 collagen in the myocardium with 
associated hypertension and L VH (Brilla & Weber 1992). 
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Oxidative stress and perivascular inflammation appear to be indirect mediators of 
aldosterone-induced fibrosis. After several weeks, aldosterone/salt treatment of rats 
induces coronary inflammation, characterized by macrophage, monocyte and 
fibroblast inflitration of the perivascular space and increases in mRNA for pro-
inflammatory mediators and cytokines (Farquharson & Struthers 2002; Rocha & 
Funder 2002). This inflammatory response appears to be necessary for the 
accumulation of fibrillar collagen and fibrous tissue within the heart. 
Aldosterone also increases the expressiOn of NADPH oxidase, which in tum 
catalyses the formation of the superoxide anion. The superoxide anion reacts with 
NO to form peroxynitrite, reducing NO bioavailability with a resulting 
proinflammatory and fibrogenic phenotype. All these responses can be blocked by 
MR antagonists or antioxidant agents such as N-acetylcysteine, suggesting that 
oxidative stress is at least partly responsible for the pro-inflammatory phenotype 
induced by aldosterone (Rocha & Funder 2002; Sun et al2002). 
A role for the classic MR in mediating these cardiac effects is suggested as most of 
the observed phenotypes take several weeks to develop and the antagonist 
spironolactone is able to prevent aldosterone-induced fibrosis (Brilla et al 1993). It 
has recently been demonstrated that the vascular inflammation and cardiac fibrosis 
stimulated in rats by 4 weeks of DOC treatment, can be completely reversed by the 
eplerenone but not mineralocorticoid withdrawal alone (Young & Funder 2004). 
MRs have been detected in all four chambers of the heart, within cardiac myocytes, 
endocardium, VSMC and endothelial cells (Pearce & Funder 1987). However, 
whether the MR protector 11 ~HSD2 is expressed here remains controversial. If 
expression occurs, it may only be at low levels and within specific cell types ( eg. 
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VSMC) (Funder 2005). This implies that within the heart, MR is essentially a high 
affinity GR due to the much higher circulating levels of cortisol. This effect would 
be further enhanced if lll3HSD 1 (converting cortisone to cortisol) is expressed. It 
has been identified in vitro in cardiac fibroblasts (Sheppard & Autelitano 2002). It 
has been suggested that local production of aldosterone in the heart could generate 
high local intracardiac levels, enabling MR activation by aldosterone but the lack of 
cardiac remodelling in adrenalectomized rats suggests this is unlikely (Rocha & 
Funder 2002). However, co-infusion with corticosterone antagonizes the actions of 
aldosterone in the heart, preventing a rise in blood pressure and cardiac fibrosis. 
Glucocorticoids may have a protective role within the heart (Young & Funder 1996). 
1.9 .1.5 Non-genomic actions of aldosterone 
In addition to the classic genomic mechanism of aldosterone action, there is also 
increasing evidence that aldosterone can also exert rapid, non-genomic effects that 
involve the activation of second messenger pathways (Wehling et a! 1992; Wehling 
1995). The genomic effects mediated through the MR involve steroid-receptor 
regulation of gene expression and involve a latent period of 1-2 hours. These 
genomic effects can be blocked by inhibitors of transcription (actinomycin D) or 
translation (cycloheximide) as well as by MR antagonists such as spironolactone. 
Several recent studies have reported rapid effects that occur within 15 minutes. 
These are believed to be independent of gene transcription and translation as they are 
not blocked by actinomycin D or cycloheximide (Falkenstein et a/2000; Harvey et al 
2001). These rapid effects have been predominantly demonstrated outwith the 
kidney in cells such as vascular smooth muscle cells (Christ et a! 1995) skeletal 
muscle cells (Passaquin et a! 1998) and myocardial cells (Barbato et a! 2002). A 
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rapid (within 4 minutes) vasoconstrictor response to a modest infusion of aldosterone 
has been recently demonstrated in vivo (Romagni et al 2003). Whether these effects 
are mediated through the classic MR or a novel non-genomic receptor remains 
controversial. Wehling et al demonstrated a rapid response (1-2mins) to aldosterone 
on the Na + IH+ -exchanger and inositoltrisphosphate generation in human lymphocytes 
and vascular smooth muscle cells. This effect was not mediated by cortisol and was 
not blocked by the MR antagonist spironolactone, supporting the existence of a 
distinct, novel receptor (Wehling 1995). A similar pattern was observed in kidney 
cells where aldosterone induced a rapid rise in cytosolic calcium that could not be 
blocked by the classic MR antagonists (Gekle et al 1997). This rapid response of 
calcium to aldosterone can also be induced in MR knockout mice, further supporting 
the possibility of distinct receptors for rapid signalling (Haseroth et al 1999). 
However, in vascular tissue the rapid nongenomic effect of aldosterone on 
intracellular Ca2+ levels, the Na + IH+ exchanger and vasoconstriction are blocked by 
the MR antagonist eplerenone, suggesting a role for the classic MR (Michea et al 
2005). In rat smooth muscle cells, the rapid, aldosterone-mediated sodium efflux, 
which is not blocked by actinomycin, also appears to be MR-dependent. However, 
the recent identification of membrane bound G-protein-coupled receptors for 
progesterone and oestrogen supports the possibility that a similar receptor exists for 
aldosterone. A candidate aldosterone membrane receptor of 50kDa was isolated 
from human lymphocytes using binding assays but the complete structural 
characteristics are yet to be determined (Eisen et a/1994). 
These nongenomic effects of aldosterone (Wehling et al 1998) have been linked to 
the development of increased systemic vascular resistance and so could contribute to 
hypertension and cardiovascular disease (Armanini et al 1991 ). 
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1.9.2 Glucocorticoid Effects 
Cortisol has a wide range of effects throughout many tissues (brain, heart, blood 
vessels and kidney) (Sapolsky et al 2006) as indicated by the almost ubiquitous 
expression of its receptor (GR) (Ballard et al 1974). Glucocorticoids are known to 
acutely increase blood pressure and long-term administration has been shown to 
induce hypertension in humans (Whitworth et al 2000). The precise mechanisms by 
which cortisol regulates blood pressure are complex and not fully understood but 
appear to involve several actions on the vasculature and kidney. Cortisol 
administration results in an increased pressor responsiveness of the vasculature to 
catecholamines and to a lesser extent Ang II (Whitworth 1994). This may at least 
partly occur through upregulation of the receptors for these vasoconstrictors, 
including AT1A. There is also increasing evidence that cortisol inhibits the response 
of the vasodilator, nitric oxide, by inhibiting the enzyme nitric oxide synthase (NOS), 
by preventing transport of the precursor arginine or by inhibiting the synthesis of the 
NOS cofactor, tetrahydrobiopterin (Mitchell & Webb 2002; Whitworth et al2000). 
Cortisol also has indirect effects on the kidney by stimulating angiotensinogen 
(AGT) expression in the liver via two glucocorticoid response elements (GRE's) 
(one full and one half), on the AGT gene. The resulting increase in AGT 
concentration affects intravascular RAS activity, resulting in Ang II-dependent 
changes in blood pressure (Braiser & Li 1996). Another possibility is that cortisol 
activates the MR within the kidney to promote sodium and water retention. Indeed, 
kinetic properties of the enzyme 11 ~HSD2 (the MR protector, see section 1.9.3) 
suggest that even high normal physiological cortisol concentrations could saturate 
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this enzyme (Ferrari 2003). Therefore, cortisol is able to modulate blood pressure by 
altering both intravascular volume and vascular resistance. 
The cytosolic GR receptor is homologous to and functions in a similar way to MR 
(Gustafsson et al 1987). However, GR has moderate affinity for cortisol and 
corticosterone with low affinity for aldosterone and DOC. Ligand binding induces 
GR to dissociate from the complex of heat shock proteins that maintain it in a stable 
state and to form homodimers. This dimerization is thought to occur prior to DNA 
binding. The GRJsteroid dimer complex binds to specific regions within target genes 
called glucocorticoid-responsive elements (GRE) with the consensus palindromic 
DNA sequence 5'-GGTACAnnnTGTTCT-3'. There is also evidence that GR can 
form heterodimers with other transacting factors including MR. The interaction of 
GR with GRE inititates or represses transcription with the help of various coactivator 
or corepressor proteins. There is also evidence that GR can exert its effects on gene 
transcription independent of DNA binding through protein-protein interactions with 
other factors (Beato & Sanchez-Pacheco 1996; Karin 1998; Reichardt et al 1998; 
Stocklin 1996). The following molecular mechanisms of glucocorticoid/receptor 
action on gene transcription have been observed (see figure 1.8): 
1. Trans-activation - Steroid/GR complex binds GRE and increases expression of 
target genes (Strahle et al 1987). 
2. Trans-modulation- Steroid/GR complex binds composite GREs comprised of half 
GRE and a half binding site for another transcription factor ( eg. AP-1) - alter 
transcription of other TF' s (Diamond et al1990; Pearce & Yamamoto 1993). 
3. Trans-repression - Steroid/GR complex binds negative GRE sequences (nGRE) 
and repression of transcription of target genes (Beato et al1989). 
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4. Transcription synergy - Protein-protein interaction with factors such as Stat-5 
(Stocklin 1996). 
5. Transcription repression - Protein-protein interaction with factors such as AP-1, 
CREB or NF -KB (De Bosscher et al2003). 
Trans-activation Protein-protein synergy 
~ + ~g SlatS) + 
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Figure 1.8. Mechanisms of transcriptional regulation by the glucocorticoid 
receptor 
TF = transcription factor 
(Adapted from Karin 1998; Reichardt & Schutz 1998) 
As mentioned previously, the GR is almost ubiquitously expressed compared to the 
relatively selective expression of MR. Due to the high degree of homology between 
MR and GR, it is perhaps not surprising that there is some overlap of ligand binding. 
In particular, the MR has been shown to have the same affinity for aldosterone, 
corticosterone and cortisol in vitro (Krozowski & Funder 1983). In combination 
with the much higher circulating levels of cortisol (1 00 - 1000 fold) compared to 
aldosterone within the body, a mechanism is clearly required to ensure the specific 
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activation of MR by aldosterone. This mechanism is described in the following 
section. 
1.9.3 llfi-hydroxysteroid Dehydrogenases 
The enzyme 11 ~-hydroxysteroid dehydrogenase type 2 (11 ~-HSD2) confers 
specificity on the MR by inactivating cortisol (Edwards et al 1988; Funder et al 
1988) (see figure 1.9). This NAD-dependent enzyme is coexpressed with MR in 
aldosterone target tissues (kidney, colon and salivary glands) and converts cortisol 
into the inactive 11-keto metabolite, cortisone. Disruption of this enzyme-protective 
system, due to mutations in the 11 ~-HSD2 gene, results in the syndrome of apparent 
mineralocorticoid excess (AME) in which cortisol is free to act like a 
mineralocorticoid and activate MR (Mune et al 1995) (see section 1.15.2.2). 
Another distinct 11~-HSD isoenzyme (11~-HSD1) is expressed mainly in the liver 
and visceral adipose tissue, as well as the brain, gonads, muscle, lung and other GR-
expressing tissues (Moisan et al 1990; Monder & White 1993; Walker et al 1992) 
(see figure 1.9). This isoform requires NADP(H) which is supplied by hexose-6-
phosphate dehydrogenase (H6PDH). 11~-HSD1 can function bidirectionally 
(Monder & White 1993) but has been shown in vivo to act as an 11-oxo-reductase, 
particularly in hepatocytes and adipocytes, thereby enhancing GR-dependant 
functions at these sites including gluconeogenesis and adipocyte differentiation 
(Seckl & Walker 2001). Therefore, inhibition of 11~-HSD1 is a potential target for 
treatment of disorders that might be ameliorated by local reduction of glucocorticoid 
action, such as type 11 diabetes and obesity. 
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Figure 1.9. Schematic role of 11~-HSD isozymes and their main sites of action 
(Adapted from Arlt & Stewart 2005) 
The 11 ~-HSD enzymes function to provide tissue-specific mineralocorticoid and 
glucocorticoid effects in the appropriate tissues throughout the body. 
1.9.4 Extra-adrenal Corticosteroid Production 
Within the vasculature and the brain, all the enzymes required for the de novo 
synthesis of corticosteroids from cholesterol have been identified (Davies & 
MacKenzie 2003). Therefore, locally produced aldosterone could act in an 
autocrine/paracrine manner to exert the non-classical effects mentioned previously. 
However, the level of transcription to mRNA suggests that local steroid production is 
small in comparison with adrenal production and so whether extra-adrenal 
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corticosteroids are of any physiological significance remams unclear. However 
intracerebroventricular (icv) infusion of aldosterone, at doses far too low to have an 
effect when administered subcutaneously, significantly increases blood pressure 
(Gomez-Sanchez 1986). Therefore small local amounts can have an effect. Local 
concentration, proximity to target cells and, possibly, tissue-specific control 
mechanisms may all be determining factors. In theory, local aldosterone production 
in the heart would provide an important therapeutic target for cardiovascular disease, 
especially considering the suggestion that aldosterone synthase expression is 
increased in heart failure (Yoshimura et al 2002). However, research into local 
aldosterone production within the heart has yielded contradictory results (Davies & 
MacKenzie 2003; Funder 2004; Gomez-Sanchez et al 2004; Silvestre et al 1999; 
Silvestre et al 1998; Young et al 2001). There have been reports of a high relative 
aldosterone concentration in perfused hearts or homogenates (Silvestre et al 1999; 
Silvestre et al 1998) and yet recent work using a highly sensitive and specific, 
quantitative RT-PCR method failed to detect CYP JJB2 expression in several rat 
models of cardiovascular pathology or in isolated cardiac myocytes treated with 
angiotensin II and ACTH (Y e et al 2005). It is at least possible that the high relative 
aldosterone concentrations within the heart are due to sequestration of the hormone 
from the bloodstream or to slower degradation rather than local synthesis. In favour 
of this, the levels of aldosterone detected in the heart appear to reflect normal 
circulating plasma levels (Gomez-Sanchez et al2004). 
1.10 Abnormal Corticosteroid Production 
Abnormalities in corticosteroid production highlight their importance in influencing 
blood pressure. At a gross level, corticosteroid excess as occurs in Cushing's 
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syndrome (cortisol excess) or primary aldosteronism (aldosterone excess) are often 
associated with hypertension whilst Addison's disease (the deficiency of adrenal 
steroids) is invariably associated with hypotension (White 1994; White & Speiser 
1994). 
1.1 0.1 Cortisol Excess 
Cushings disease is the result of excess cortisol production due to pituitary adenomas 
that secrete excess amounts of ACTH. A similar phenotype or syndrome can occur 
as the result of ectopic ACTH production or adrenal cortisol secreting tumours. The 
syndrome IS characterized by truncal obesity, glucose intolerance and 
hyperglycaemia, osteoporosis, hyperlipidaemia and hypertension. Hypertension 
occurs in 70 - 80% of cases. The increased cortisol levels cause saturation of the 
enzyme 11 ~HSD2, resulting in cortisol activation of the MR by the kidney. 
Evidence of impaired 11 ~HSD2 in patients with Cushings, is demonstrated by the 
ratio of urinary cortisol:cortisone metabolites (Stewart et al1995; Ulick et al1992a). 
A similar finding has also been reported in EH (Soro et al 1995). However, in 
subjects with cortisol-induced hypertension, treatment with spironolactone to block 
the sodium and water retention, have failed to reduce the induced rise in blood 
pressure suggesting other mechanisms are involved (see section 1.9.2) 
Excess glucocorticoids, either endogenous (Cushings syndrome) or exogenous 
(glucocorticoid therapy), can result in hypertension. With cortisol-induced 
hypertension, the risk of cardiovascular morbidity and mortality is high with an 
increased incidence of left ventricular hypertrophy compared to other forms of 
hypertension. The hypertension is associated with an increased cardiac output, 
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increased renal vascular resistance, increased sodium/water retention and an 
increased vascular responsiveness. 
1.1 0.2 Aldosterone Excess 
Aldosterone excess can occur from rare genetic causes (such as Glucocorticoid 
suppressible hyperaldosteronism) or primary aldosteronism (PA). PA can be defined 
as excessive production of aldosterone independent of its normal regulator, Ang II, 
which is produced by renin (Gordon et al 1994a). This relationship is described in 
detail in section 1.12.2. Briefly, autonomous excess of aldosterone will suppress 
renin levels so that the aldosterone-to-renin ratio (ARR) is elevated. PA is 
characterized by increased extracellular fluid volume, hypokalaemia, alkalosis and 
hypertension as a result of the marked sodium and water retention. Jerome Conn 
first described the symptoms in 1954 as a syndrome related to the hypersecretion of 
aldosterone by an adrenal adenoma, now known as Conn's syndrome (Conn & Louis 
1956). For many years this was thought to be the primary cause ofPA, but recent 
studies suggest that bilateral adrenal hyperplasia (idiopathic hyperaldosteronism) 
may be a more common cause of P A than previously realised (Lim et al 2002a; 
Montori & Young, Jr. 2002). 
1.1 0.2.1 ARR as a screening tool for P A 
Until recently, PA has always been considered to be a rare cause of secondary 
hypertension, accounting for less than 1% of cases. However, recent use of the ARR 
as a reliable marker of inappropriate aldosterone activity has led to an increased 
frequency of the diagnosis of P A among hypertensive patients. Generally an ARR 
>750 (when aldosterone is expressed in pmol/L and renin as renin activity in 
62 
ng/ml/hour) is accepted as higher than the normal range. A number of independent 
studies worldwide, including Scotland (Lim et al1999b; Lim et al 2002a), Australia 
(Gordon et al1994b), South East Asia (Loh et al2000) and South America (Fardella 
et al 2000), demonstrate the prevalence of P A using a high ARR as a marker to be 
between 5 to 15% in unselected individuals with hypertension, with a much higher 
proportion of bilateral adrenal hyperplasia (BAH) (Mulatero et al 2004). In most of 
these studies, less than half of the identified patients were hypokalemic, the previous 
prerequisite for diagnosis of mineralocorticoid hypertension. The idea that a 
normokalemic form of P A may account for as many as 20% of patients with essential 
hypertension was first suggested by Conn in 1965 but has largely been forgotten until 
now (Conn et al1965). 
The ARR measurement itself is not conclusive and further confirmatory tests such as 
fludrocortisone suppression test or salt loading are required to demonstrate 
inappropriate regulation of aldosterone levels. Much of the controversy surrounding 
the use of the ARR as a diagnostic tool for P A is due to the plasma renin activity 
dominating the ratio. In many cases, the elevated ratio is due to low renin levels and 
aldosterone levels are often within the 'normal' range and so would not be 
traditionally diagnosed as P A. It is unclear how these subjects differ from the 
previously well-defined subgroup of low renin essential hypertension, which is also 
characterized by aldosterone levels that are inappropriately high for the prevailing 
renin level. Padfield et al proposed some years ago that patients with P A due to 
BAH are no different to the subgroup of low renin essential hypertension (Padfield et 
al 1981 ). Indeed the presence of adrenal nodules with or without hyperplasia that is 
characteristic of BAH can also occur in essential hypertension, low renin 
hypertension or even in normotensive subjects (Kaplan 1967) suggesting there may 
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be substantial overlap between the groups. There is also histological evidence 
demonstrating that subjects with aldosterone-producing adenomas often have 
hyperplasia within the rest of the adrenal, suggesting that solitary adenomas arise on 
the background of an already abnormal gland (Neville & MacKay 1972). Therefore, 
with the new diagnostic criteria, P A may be considered a subtype of hypertension 
with dysregulated renin-angiotensin-aldosterone dynamics that may show 
progression from hypertension with a raised ARR to BAH and finally to classical P A 
with truly autonomous aldosterone secretion. 
There is still much controversy surrounding the use of the ARR as a screening tool 
for P A and the classification of hypertensive patients. However, the use of the ARR 
has lead to an increase in the diagnosis of aldosterone-secreting adenomas, many 
cases of which can be cured completely by surgery. Also, whatever the classification 
of subjects with a high ARR as BAH, PA or low renin essential hypertension, 
although the aldosterone levels may not be particularly elevated, they are still 
innappropriate for the prevailing levels of renin and Ang II. This highlights a role for 
altered aldosterone production or control as a key phenotype in essential 
hypertension. In support of this is the observation that patients with a raised ARR 
respond particularly well to treatment with selective MR antagonists such as 
spironolactone (Lim et al1999a). 
It is clear from the clinical syndromes of Cushing's disease and P A that abnormalities 
in corticosteroid production can be associated with hypertension. However, to 
further explore the contribution of corticosteroids to the genetic component of 
essential hypertension, a review of the molecular genetics of aldosterone and cortisol 
synthesis is required. 
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1.11 The CYPJJBJ and CYPJJB2 Genes 
As mentioned previously, in man the three terminal stages in the synthesis of 
aldosterone (lip-hydroxylation, IS-hydroxylation and 18-oxidation) from DOC are 
all catalyzed by aldosterone synthase (encoded by CYP II B2). Cortisol is also 
synthesized by liP-hydroxylation, in this case of li-deoxycortisol, and catalyzed by 
the enzyme Up-hydroxylase (encoded by CYP 1J B 1). In other species such as 
bovine, pig and bullfrog, there is only a single CYP II B I gene for the synthesis of 
cortisol and aldosterone (Nonaka et a/1995). 
CYP IJB2 and CYP JJBI are situated approximately 40 kilobases apart, on 
chromosome 8 in man. They are both approximately 6.5kb long from the start of 
transcription to the polyadenylation site and contain 9 exons and 8 introns (see figure 
1.10). They are 95% homologous in their coding regions with the main differences 
in their sequences being in their 5'UTR regions that are responsible for the 
differences in their transcriptional regulation and zonal distribution (Chua et a/1987; 
Momet et a/1989; Zhang & Miller 1996). 
S'UTR 
-8Kb 3'UTR 
Figure 1.10. Schematic diagram ofthe exonic-intronic arrangement of the 
CYPJJBJ!B2 genes 
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1.12 Regulation of CYPJJBJ and CYPJJB2 Expression 
Adrenal steroidogenesis is under both acute and chronic regulation by tropic 
hormones. The acute response occurs within minutes and involves the mobilization 
of cholesterol from intracellular stores to the mitochondrial membrane (see section 
1.8.1) in response to ACTH, Angiotensin II, K+ and their respective intracellular 
messenger pathways (see following sections) (Clark et al1995b; Clark et al1995a). 
Of particular interest to this review is the chronic response that takes several hours 
and involves the transcription of the genes encoding the steroidogenic enzymes. 
1.12.1 ACTH 
Corticotrophin releasing hormone (CRH) release is controlled by input from 'higher' 
centres that respond to physiological and psychological stressors (see figure 1.11). 
CRH is released from the hypothalamus and passes into the hypophyseal portal 
circulation to stimulate the release of ACTH from the corticotroph cells of the 
anterior pituitary. ACTH activates its receptor on adrenal cells to stimulate 
steroidogenesis and mcrease glucocorticoid (cortisol) synthesis. Glucocorticoid 
synthesis is controlled by classical endocrine feedback loops whereby cortisol 
inhibits secretion of CRH from the hypothalamus and ACTH from the pituitary. 
ACTH IS synthesised as part of a large presursor molecule pro-
opiomelanocorticotrophin (POMC), which also contains the other peptides 
melanocyte stimulating hormone (MSH) and ~-endorphin. 
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Figure 1.11. Hypothalamic pituitary axis regulation of cortisol secretion 
ACTH itself is a 39 amino acid peptide; the first 24 of which are conserved in all 
species and the first 18 confer its biological activity (Smith & Funder 1988). Normal 
ACTH release from the anterior pituitary is pulsatile and follows a diurnal rhythm 
with the highest levels occurring first thing in the morning and the lowest at night 
(Veldhuis et al1990). ACTH exerts its effects by binding to its receptor (ACTH-R), 
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a G-protein coupled receptor, which is a member ofthe melanocortin receptor family 
(Mountjoy et al 1992). After binding to its receptor, ACTH activates adenylate 
cyclase, resulting in an increased intracellular cAMP concentration and activation of 
protein kinase A (PKA) (Buckley & Ramachandran 1981; Sala et al 1979) (see 
figure 1.12). ACTH plays an essential role in regulating CYP IIBI gene expression 
(Sewer & Waterman 2003). Each of the ACTH-responsive genes contain unique 
cAMP-response sequences (CRS) within their 5' regulatory regions that bind a 
variety of transcription factors, including homeodomain proteins, SP family, CREB 
and SF-I (Waterman & Bischof 1996). ACTH stimulates CYP IIBI transcription via 
cAMP and the orphan nuclear receptor, SF-1. The cAMP-mediated increase in 
steroidogenic gene transcription takes hours and is inhibited by the protein synthesis 
inhibitor, cycloheximide. This suggests that synthesis of a common, unknown protein 
factor(s) is required. Several other cAMP-independent intracellular signalling 
pathways appear to be induced by ACTH, including protein kinase C (PKC) (Arola 
et al 1994), calcium influx via calcium channels (Yamazaki et al 1998) and the 
lipooxygenase pathway (Yamazaki et al1996). 
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Figure 1.12. Intracellular mechanisms of Ang II, K + and ACTH influencing 
gene expression (Adaptedfrom Cooke 1999; Rossier 1997) 
ACTH has a modest effect on the secretion of aldosterone but the physiological 
relevence is unclear. ACTH acutely stimulates aldosterone secretion (probably 
through activation of StAR protein production but in the long-term, has an inhibitory 
effect on CYP 11 B2 gene expression and aldosterone levels. (Aguilera et al 1996; 
Mitani et al 1996). It is not completely clear how ACTH inhibits expression of 
CYP 11B2. Cyclic AMP (cAMP), the second messenger for ACTH, desensitizes 
adrenocortical cells to Ang II by causing a reduction in the expression of Ang II 
receptors (Bird et al 1994; Yoshida et al 1991). ACTH may also decrease 
aldosterone production by stimulating the expression of CYP 11 B 1 and CYP 17, 
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resulting in a removal of precursors from the aldosterone pathway and using them to 
synthesize cortisol. ACTH receptors are present in both the zona glomerulosa and 
fasciculata. Under normal circulating ACTH levels, the glomerulosa maintains 
CYP II B2 expression by at least two mechanisms. Firstly, Ang II will inhibit ACTH-
stimulated cAMP production in glomerulosa but not fasciculata cells (Begeot et al 
1988; Hausdorff et a/1987). Secondly, the glomerulosa expresses a type of adenylyl 
cyclase that is inhibited by increasing intracellular Ca2+, the second messenger for 
both Ang II and K+ (Shen et al1997). 
Long-term ACTH exposure stimulates adrenal growth both in vitro and in vivo 
through promoting hypervascularization as well as cellular hypertrophy and 
hyperplasia (Arola et al 1993; Bomstein et al 1992; Bomstein & Chrousos 1999; 
Vinson 2003). This results in an increase in the number of cells with the potential for 
steroidogenesis (Arola et al 1993; Dallman et al 1980). ACTH appears to 
specifically induce the proliferation of zona fasciculata cells whilst recruiting and 
transforming glomerulosa cells into fasciculata-like cells (Aguilera et al 1981; Arola 
et al 1993; Mazzocchi et al1986) 
1.12.2 Angiotensin II and Potassium 
Ang II and circulating potassium concentration are the most influential regulators of 
aldosterone secretion. They act through common intracellular signalling pathways to 
increase transcription of CYP II B2 in the zona glomerulosa. 
Ang II is an octapeptide hormone generated by the renin-angiotensin-system (RAS) 
(see figure 1.13). The rate-limiting step in the RAS is the secretion of the protease 
renin from the kidney, which is controlled through a negative feedback loop. Renin 
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is released from the juxtaglomerular cells in the renal tubule in response to a 
decrease in renal perfusion pressure and filtrate sodium content and an increased 
sympathetic tone. It converts angiotensinogen, which is constitutively secreted by 
the liver, into angiotensin I (Ang I). Ang I, which has no apparent activity, is then 
converted by angiotensin-converting-enzyme (ACE) into Ang II, the active 
component of the RAS. Ang II causes an elevation in blood pressure by directly 
constricting blood vessels, increasing sympathetic nerve activity, increasing 
myocardial contractility, enhancing renal salt and water retention both directly and 
indirectly through stimulating aldosterone release from the adrenal (Carpenter et al 
1961; Gavras et a/1976). The resulting increase in Na+ and water retention as well 
as blood pressure inhibit renin release. Ang II also has a proliferative effect on 
tissues, inducing cardiac and vascular hypertrophy, partly through the stimulation of 
growth factors and cytokines (McConnaughey et al 1999). Ang II has been shown to 
activate NADPH oxidase, resulting in increased production of the superoxide anion 
(·02-), which can react with nitric oxide (NO) to produce the harmful oxidant 
peroxynitrite (ONOO-). This may contribute to the vasoconstrictive response to Ang 
II by decreasing the availability of the vasodilator NO (Rajagopalan et al 1996). 
There are two main receptors for Ang II, AT1 and AT2. AT1 occurs as two subtypes 
AT1A and AT1B (Kambayashi et al 1993; Mukoyama et al 1993). Most of the 
known biological actions of Ang II are mediated through AT1, in particular AT1A, 
except for the control of aldosterone secretion from the adrenal cortex, which appears 
to be mediated by ATlB (Gigante et al 1997). The AT1 receptor is a G-protein-
coupled receptor (GPCR) that exhibits zonal distribution within the adrenal cortex. 
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Ang II is thought to stimulate aldosterone synthesis through various intracellular 
signalling pathways including the src family of tyrosine kinases (Sirianni et al2001) 
and the 12-lipoxygenase (12-LO) pathway (Gu et al 2003). However, the best-
characterized pathway is the activation of phopholipase C (see figure 1.12). Once 
activated, phospholipase C hydrolyses phosphatidyl inositol 4,5-biphosphate (PIP2) 
to 1,4,5 inositoltriphosphate (IP3) and diacylglycerol (DAG) resulting in release of 
Ca2+ from intracellular stores and activation of protein kinase C (PKC) respectively. 
At the same time, the membrane's potassium permeability decreases resulting in 
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depolarization of the cell and stimulation of voltage-gated calcium channels, causing 
entry of extracellular calcium (Ca2+). The increased intracellular Ca2+ concentration 
activates calmodulin and regulates CYP 11 B2 transcription through various 
calmodulin-dependent kinases (Condon et al 2002). PKC has no apparent effect on 
CYP 11 B2 transcript levels but does inhibit expression of CYP 17 (Bird et al 1996), 
perhaps contributing to the zonation of the adrenal cortex. 
The RAS is very sensitive to changes in circulating potassium levels. The level of 
potassium affects renin secretion as well as having a direct effect on the adrenal 
cortex to increase aldosterone secretion. Potassium (like Ang II) stimulates 
aldosterone secretion by increasing expression of CYP 11 B2 through an increase in 
intracellular Ca2+ and activation of calmodulin kinases. Potassium signalling is 
mediated through membrane depolarization, leading to an influx of calcium through 
T and L-type channels (see figure 1.12). K+ and partially Ang II stimulation of 
CYP 11 B2 mRNA can be blocked by calcium channel blockers such as nifedipine. 
1.13 Transcriptional regulation of the CYPJJB Genes 
As mentioned previously, chronic regulation of steroidogenesis involves 
transcription of the genes encoding the necessary steroidogenic enzymes. This is 
mediated by alteration of trans-acting factors that bind to the cis-regulatory elements 
within the 5' regulatory regions of the target genes. 
Investigation of the 5' regulatory regions of the bovine CYP 11 B gene revealed six 
cis-acting elements (Ad1-6) (Kirita et al 1990) (see figure 1.14). Deletion and 
mutation analysis confirmed that Adl and a region containing Ad3 and Ad4 were 
essential for the ACTH/cAMP-induced expression of the gene (Hashimoto et al 
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1992; Kirita et al 1990; Takayama et al 1994). These sites are highly conserved 
within the CYP JIB genes of all species studied so far, including hCYP IIBI (Wang 
et al2000) and hCYP IIB2 (Clyne et al1997), with the exception of the rat CYP IIBI 
gene (Rainey 1999). 
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Figure 1.14. Schematic diagram of the bovine CYPJJB promoter with the 
cis-elements (Adl to Ad6) that are conserved among all the CYPJJB genes 
(Morohashi et al 1993) 
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The Ad1 element closely resembles a consensus cAMP regulatory element (CRE) 
site. CRE's play an essential role in cAMP-dependent gene expression of a wide 
variety of genes. Proteins, such as the CRE-binding protein (CREB) (Montminy & 
Bilezikjian 1987) and the highly related activating transcription factors (A TF) (Hai et 
al 1989; Hurst et al 1990), bind to CRE sites to initiate transcription. CREB binds to 
DNA as a dimer (Yamamoto et al 1988) and has a conserved region of leucine 
residues (leucine zipper) at its C terminus that enables dimerization and sequence-
specific DNA binding (Dwarki et al 1990; Yun et al 1990). CREB binds to DNA 
through a domain of basic residues near the leucine zipper. These regions are 
characteristic of the bZIP family of transcription factors and are highly conserved 
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between CREB and ATF1 (Rehfuss et a/1991). CREB functions as a component of 
a variety of signalling pathways, particularly PKA (Montminy 1997), but also 
mitogen-activated protein kinases (MAPKs) (Xing et a/1996) and CaMKs (Sheng et 
a/1991; Sun et a/1994). All these pathways mediate CREB-induced transcription 
by phosphorylating CREB at residue serine 133 (Ser133) (Gonzalez et al 1989). 
Mutation of this Ser133 residue abolishes the transcriptional response to cAMP in 
vitro (Gonzalez et al 1989). The phosphorylated Ser133 binds another protein 
referred to as the CREB-binding protein (CBP) (Chrivia et al 1993). Co-expression 
of CBP in vitro increases the stimulus-induced CREB transcription of CRE reporter 
gene constructs (Kwok et a/1994). CBP is a 265-kDa nuclear protein, which binds to 
phosphorylated CREB and allows recruitment and stabilization of the RNA 
polymerase II transcription complex on the promoter of CREB target genes 
(Nakajima et a/1997; Shikama et a/2000). CBP is also able to alter the chromatin 
structure, making the DNA template more accessible to the transcriptional machinery 
due to its histone acetyltransferase (HAT) activity and ability to recruit other proteins 
with similar functions (Bannister & Kouzarides 1996; Ogrysko et a/1996). 
1.13.2 AD4 (SF-1) 
The Ad4 site (CCAAGGTC) is also found to be important in the regulation of the 
bovine CYP II B gene. This Ad4 site or homologous sequences have been identified 
in the regulatory regions of all other steroid P450 genes (CYPJJAI, CYP2I, CYPI7, 
CYPJJBI, CYPJJB2, CYPI9) (Morohashi et al 1992), suggesting an important 
functional role in steroidogenesis. An AD4-binding protein (AD4BP) has been 
identified and cloned from bovine adrenal cortex nuclear extract (Morohashi et al 
1992). AD4BP is a homolog of the steroidogenic factor 1 (SF-1) identified in the 
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mouse (Ikeda et al 1993; La1a et al 1992). SF-1 is an orphan member, with an 
unknown or possibly non-existent physiological ligand, of the nuclear hormone 
receptor superfamily, with potential phosphorylation sites for cAMP-dependent 
kinases, CaMK or PKC, suggesting a role for SF -1 in cAMP-dependent transcription. 
SF-1 is a 53kDa protein comsisting of a zinc finger domain and ligand 
binding/dimerization domain. These functional domains are conserved between 
species (human, bovine, rat and mouse) supporting the existence of a ligand. The 
oxysterols (25-, 26- or 27 -hydroxycholesterol) enhance SF -1-dependent 
transcriptional activity in vitro, suggesting that SF-1 is a ligand-activated receptor 
(Christenson et al 1998; Lala et al 1997). However, this is a controversial finding 
(Mellon & Bair 1998) and needs further clarification. 
SF -1 is expressed exclusively in steroidogenic tissues and the brain. Important 
information about the role ofSF-1 came from the development ofthe SF-1 knock-out 
mouse (Luo et al 1994). These mice survive the in utero stage of development but 
all die within 8 days of birth due to adrenocortical insufficiency. They lack adrenal 
glands or gonads. Therefore SF -1 plays an essential role in the development and 
function of the primary steroidogenic tissues. Naturally occuring SF-1 mutants have 
also been identified in patients with primary adrenal failure (Ozisik et al 2002). In 
males, these mutations are also characterized by complete sex reversal. Within the 
adrenal, SF -1 has been found to play a key role in the transcriptional regulation of 
most of the steroid hydroxylase genes (CYPllAI, CYP21, CYPllBI, CYP17 and 
CYP 19) as well as 3 fJHSD and StAR. SF -1 regulation of transcription is mediated by 
interaction with various co-activator proteins, including steroid receptor coactivator I 
(SRCI) (Ito et a/1998), glucocorticoid receptor interacting protein (GRIPI) (Hammer 
et a! 1999) and CBP /p300 (Monte et a! 1998) and also through repressors such as 
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DAXl that inhibits SF -!-mediated steroidogenesis (Babu et a! 2002; Ito et a/1997). 
SF-1 is homologous to the Drosophila fushi tarazu factor 1 (FTZ-Fl) (Lala et al 
1992), indicating conservation of the gene between vertebrates and invertebrates, 
again emphasizing the importance of its role in development. 
1.13.3 Transcriptional Regulation ofCYP11B2 
Determination of the important cis-elements within the upstream regulatory region of 
CYP 11 B2 (20 17bp) has been carried out using transient transfection of reporter gene 
constructs in both mouse (Yl) and human (H295R) adrenocortical tumour cell lines. 
These CYP 11B2-reporter gene studies confirm that Ang II, K+, Ca2+ channel agonists 
and cAMP analogues upregulate gene expression (Clyne et al 1996; Clyne et al 
1997). Deletion analysis of this construct has revealed that 3 functionally important 
cis elements are required for basal expression and response to Ca2+ and cAMP. 
These are a near consensus CRE at -71/-64 (Adl) and an element at -129/-114 (Ad5) 
which are homologous to sites previously identified in the bovine CYP JIB gene, Ad1 
and Ad5 respectively, and also a NBRE-1 site at -766/-759 (Bassett et al 2004b; 
Clyne et a/1997) (see figure 1.15). 
CYP1182 
-766/-759 -344/-336 
NBRE-1 Ad4 
-129/-114 
COUP/SF1 
NGFIB/NURR1 
Ad5 
-71/-64 
Ad1 
(CRE) 
Figure 1.15. Schematic diagram of the transcription factor binding sites in the 
hCYPJJB2 5'UTR (Bassett et al2004b). 
77 
The CRE at -71/-64 (TGACGTGA) is common to both human (h)CYP11B2 and 
(h)CYP 11B1, and is also present in other species such as the rat, mouse and hamster 
as well as the bovine CYP 11 B gene (Rainey 1999). The CRE can be regulated by 
both PKA and CaMK mechanisms (Bassett et al 2000; Condon et al 2002). Studies 
of CYP 11 B2 CRE binding by electrophoretic mobility shift assay (EMSA) revealed 
that it binds members of the CREB and ATF (ATF1 and ATF2) families (Bassett et 
al 2000). As mentioned previously, these proteins bind to the CRE following 
activation by phosphorylation. One possibility is that this phosphorylation is 
mediated, at least partly, by CaMK I or IV that are induced by Ang II or K + 
stimulation (Bassett et al2004b ). CaMK I and IV have been shown to phosphorylate 
CREB and ATF-1, increasing the expression of target genes (Matthews et al 1994; 
Ueda et al 1999). Mutations of the CRE site decreased basal reporter gene activity 
by approximately 50% as well as dramatically reducing the response to Ca2+ and 
cAMP stimulation (Clyne et al 1997). However, further deletion studies produced 
further decreases in transcription suggesting that further sites are neccessary to 
account for maximal CYP 11 B2 expression. 
Electrophoretic mobility shift assay (EMSA) analysis ofthe -129/-114 (Ad5) element 
(CTCCAGCCTTGACCTT) has shown that it binds several nuclear proteins, 
including SF-1 and another orphan nuclear receptor, chicken ovalbumin upstream 
promoter transcription factor (COUP-TF) (Clyne et al 1997). On the bovine CYP 17 
and the mouse CYP21 gene, COUP-TF and SF-1 bind competitively to a common 
site (Lund & Bakke 1995; Rice et al1991). It is not clear at present whether they act 
competitively or synergistically on the human CYP 11 B2 gene. Deletion of this site 
decreases basal activity by approximately 80% and also reduces the maximal 
response to Ca2+ and cAMP stimulation (Clyne et al1997). 
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The transcription factors NGFIB (nerve growth factor-induced clone B) and NURRl 
(NUR-related factor 1) are members of the NGFIB family of orphan nuclear 
receptors that bind to a consensus sequence NBRE (AAAGGTCA) (Giguere 1999) 
(Davis et al 1991; Wilson et al 1991 ). These factors can also bind to the Ad5 
element (on the non-coding strand) as well as a novel NBRE-1 site at -766/-759 
(Bassett et al2004a). Both these transcription factors increase CYP IIB2 expression 
when co-tansfected in human adrenal H295R cells (Bassett et al 2004a). They are 
both expressed in the zona glomerulosa and their mRNA levels can be upregulated 
by Ang II or K+ stimulation. There is also evidence of upregulated expression of 
NURRl mRNA that correlates very well with that of CYP II B2 in subjects with 
aldosterone producing adenomas (Lu et al 2004). Mutation of the NBRE-1 site 
decreases basal expression as well as the response to Ang II and K+ (Bassett et al 
2004a). There are subtle differences in the function ofNGFIB and NURRl and there 
is evidence to suggest that NURRl plays a more specific role in the regulation of 
CYP II B2 (Bassett et al 2004a). Therefore the CRE, Ad5 and NBRE-1 sites interact 
to regulate basal transcription as well as the response to each signalling pathway 
(cAMP or Ca2+). 
The Ad4 or SF -1 site identified in the bovine gene has now been identified in all the 
steroid P450s based on sequence alignments, including at position -351/-343 
(AGGTCC) of CYP IIB2. Although this site binds strongly to SF-1, deletion studies 
suggest it is not essential for basal or stimulus-induced expression of CYP II B2 
(Bassett et al 2002). In fact co-expression of CYP II B2 reporter gene constructs with 
SF -1 has a negative effect on gene transcription, making the regulation of CYP II B2 
different to the other steroidogenic genes, StAR, CYPllA, CYP II BI and CYP 17 that 
are all induced by SF-1. The effects of both NGFIB and NURRl on CYP11B2 
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expression can be inhibited by SF -1 supporting a negative effect of SF -1 (Bassett et 
al2004a). 
1.13.4 Transcriptional Regulation ofCYPJJBJ 
Reporter gene studies and deletion analysis of the regulatory regions of CYP II BI 
showed that two cis-elements (Adl and Ad4) are required for basal and 
ACTH/cAMP induction of CYP 11BI transcription (Wang et al 2000). The Adl 
element at position -71/-64 (TGACGTGA) is a near-consensus CRE also required for 
the regulation of CYP 11 B2 expression. In contrast to CYP 11 B2, the expression of 
CYP 11BI is also dependant on the Ad4 or SF-I binding site (Wang et al2000) (see 
figure 1.16). 
CYP1181 
-766/-759 
Ptx1/Ptx1 
Binding element 
-242/-234 
Ad4 
-120/-112 -71/-64 
AdS Ad1 
(CRE) 
Figure 1.16. Schematic diagram of the transcription factor binding sites in the 
hCYPJJB2 S'UTR (Wang et al2000; Wang et al2001). 
Liver receptor homologue-! (LRH-1) is another member of the orphan nuclear 
receptor superfamily that has been shown to stimulate CYP 11BI reporter gene 
expression (Wang et al 2001). LRH-1 is closely related to SF-I and produces a 
similar stimulatory effect on CYP 11BI expression. LRH-1 is mainly expressed in 
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the liver, intestine, colon and pancreas (Nitta et al 1999) but low levels have been 
identified in steroidogenic tissues including adrenal tissue as well as in H295R cells 
(Sirianni et al 2002; Wang et al 2001). Further analysis revealed that it exerts its 
positive regulatory effect on CYP 11 B I by binding to the same cis-element as SF -1 
(Ad4). Whether LRH-1 acts independently or in parallel with SF-1 is yet to be 
determined. 
A similar effect has been observed with the homeodomain-containing transcription 
factor pituitary homeobox 1 (Ptx1/Ptx1) (Hiroi et al2003). This factor interacts with 
SF-1 to mediate pituitary development. Ptx1/Ptx1 has recently been found to be 
expressed within the adrenal gland and to stimulate CYP IIBI expression to a similar 
level as SF-1 after transfection in Y1 cells. Co-expression with SF-1 does not 
produce a synergistic effect, suggesting independent mechanisms (Hiroi et al 2003). 
The effect of Ptx1/Ptx1 is mediated through the hCYPJJBI Ptx1/Ptx1 binding 
element at position -377/372. Mutation of this element decreases the response to 
Ptx1/Ptx1 but has no effect on basal levels of expression. 
These studies highlight specific cis-elements that could account for the different 
transcriptional regulation of CYPJJBI and CYPJJB2. Neither the Ad5 or NBRE-1 
elements required for CYP II B2 regulation are present in CYP II B I whereas the 
-377/372 Ptx1/Ptx1 site appears to be specific to CYPJJBI. Also SF-1, which is 
important for basal and stimulated levels of CYP JJBI expression, actually has a 
negative effect on CYP II B2 expression suggesting a possible mechanism for the 
zonal expression of these isozymes within the adrenal cortex. 
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As well as being homologous at the nucleotide level, aldosterone synthase (P450a1cto) 
and 11 ~-hydroxylase (P450n~) are also homologous at the protein level, with only a 
few amino acids accounting for their differences in structure. The following sections 
will describe some of the features of cytochrome P450 enzymes highlighting some of 
the similarities and differences between P450aldo and P450n~-
1.14 Cytochrome P450 Protein Structure 
The P450aldo and P450n~ proteins both consist of 503 amino acids, including a 24-
residue N-terminal mitochondrial targeting sequence. Their apparent molecular 
masses are 48.5 and 50 kDa respectively (Ogishima et al1991). At the protein level, 
the two enzymes are 93% homologous with only 37 amino acids that differ between 
them (Kawamoto et al 1992; Momet et al 1989) to account for their different 
functions. Although the precise 3-dimensional structures of mammalian P450aldo and 
P450n~ are yet to be determined, some information can be deduced from the known 
structures of other cytochrome P450 enzymes. 
1.14.1 Bacterial/Microsomal P450 homologues 
To date, no structure of a mitochondrial cytochrome P450 has been experimentally 
determined. The tertiary structures of several bacterial P450s have been well 
studied, including P450cam (CYP101), P450BM3 (CYP102) and P450terp 
(CYP 1 08). More recently the structures of three mammalian microsomal P450s, 
CYP2C5 (Williams et al 2000), CYP2C8 (Schoch et al 2004) and CYP2C9 
(Williams et al 2003) were also resolved. Studies of bacterial homologues suggest 
that P-450 enzymes consist of a number of helices (A-L) (Ravichandran et a/1993). 
The haem in cytochrome P-450 enzymes is located between helices I and L. 
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1.14.2 Regions of Conservation 
Although the sequence homology among the P450s is limited to 10-30% (Hasemann 
et al 1995) (Denisov et al 2005), they all appear to have a similar tertiary structure 
with a conserved structural core (Peterson & Graham 1998). This comprises a four-
helix bundle of helices D, E, I and L, as well as regions of helices J and K and the 
structurally conserved ~-sheets 1 and 2. CYP450 enzymes contain haem prosthetic 
groups and use iron-oxo intermediates for oxidative reactions (see section 1. 7). The 
inner helices form a 'pocket' around the haem, enabling substrate binding and 
activation. This haem-binding domain is a region of conserved non-polar residues 
that establish a hydrophobic environment surrounding the haem that is important in 
maintaining its full redox potential. It consists of the B'-C loop, the central I helix, 
the L-helix and the cys pocket (Hasemann et al 1995). The cys pocket is the ~ bulge 
region that surrounds the cysteine residue that is absolutely conserved in all P450 
enzymes. This conserved cysteine residue forms the proximal or fifth ligand to the 
haem iron and is responsible for the characteristic name; the ferrous-CO complex 
gives 450nm Soret absorbance (Denisov et al 2005). The structurally conserved sets 
of~ sheets form the hydrophobic substrate access channel. All of the P450 structures 
also have highly conserved coil, termed the meander, of approximately 20 amino 
acids that runs between the K' helix and the cys pocket. It interacts with the ERR 
triad (Glu(439)-Arg(442)-Arg/His/Asp(498)) located within the K helix forming a set 
of salt bridges that are thought to be important in stabilizing the core structure. 
Disruption ofthis motif results in a loss of haem binding (Hasemann et al1995). 
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1.14.3 Regions of Variability 
The regions of the highest sequence variability among the CYP450s are thought to be 
important for substrate recognition or redox partner association. These variable 
regions tend to form theN terminal part of the protein and include helices A, B, B', F 
and G and their interconnecting loops. Gotoh determined several regions thought to 
be important for substrate binding through analysis of the known structure of 
P450cam and sequence alignment with members of the mammalian CYP2 family. 
He called these regions substrate recognition sites (SRS) 1-6 (Gotoh 1992). 
SRS Secondary structure Residues 
SRS-1 B' helix and B '-C loop 103-106 
SRS-2 C terminus of helix F 209-216 
SRS-3 N terminus of helix G 248-255 
SRS-4 N terminus of helix I 302-320 
SRS-5 ~sheet 3 (p3) 375-385 
SRS-6 ~sheet 5 (~5) 485-493 
The positioning of these SRSs is supported by the identification of residues essential 
for CYP2 substrate recognition that map to the identified sites (Gotoh 1992). 
1.14.4 Homology Modelling 
Homology modelling of aldosterone synthase (P450aldo) and 11 ~-hydroxylase 
(P450 11 ~) using the known structures of the bacterial enzymes P450BY-3 (CYP 102) 
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and P450terp ( CYP 1 08) produced models with a very similar overall structure but 
with differences in the position of the haem (see figure 1.17). The positions of the 
various a-helices and ~-sheets within these models are shown in table 1.2. (Belkina 
et al200I). 
Figure 1.17. Superposition of the homology models of P450u~ (black) and 
P450atdo (grey). The positions of each of the a-helices are marked. While the 
overall structure is similar the position of the haem differs between the two proteins. 
(Taken from Lisurek & Bernhardt 2004) 
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Name I P450us I P450aldo Name 1 P450us I P450aldo 
A-helix 30-44 30-40 F-helix 223-237 224-243 
A1-helix 46-50 46-50 G-helix 247-282 249-281 
~1-1 55-59 55-57 H-helix 289-296 290-296 
~1-2 64-67 65-67 !-helix 301-331 301-331 
B-helix 70-75 71-76 J-helix 334-354 334-351 
B'-helix 94-102 94-102 K-helix 364-376 365-376 
B3-helix 115-118 115-118 ~1-3 401-405 401-408 
C-helix 127-140 127-140 ~1-4 383-386 380-386 
C'-helix 145-150 145-150 ~2-1 389-392 389-393 
D-helix 158-175 157-175 ~2-2 395-398 395-398 
E'-helix 185-192 185-192 K'-helix 406-410 406-416 
E-helix 196-206 195-204 L-helix 450-468 451-466 
D3-helix 209-214 207-213 
Table 1.2. Secondary structures of the P45011 ~ and P450atdo 3D homology 
models (Belkina et al 2001) 
Following targeting to the mitochondrion, P450atdo and P450ll~ bind to the inner 
membrane through interactions that are not yet well defined. However, from the 
homology models, there appear to be hydrophobic patches on the protein surfaces, 
that encompass helices A and A'. These are thought to be involved in protein-
membrane interactions. 
The I helix, the largest helix running through the centre of the molecule, contains 
many hydrophobic amino acids and forms the major part of the putative active site, 
essential for substrate binding and specificity (Belkina et al 2001 ). Excluding the 
mitochondrial targeting peptide, only 29 amino acids differ between aldosterone 
synthase and 11 ~-hydroxylase out of a total of 4 79. Several of these distinguishing 
amino acids are located within the I, helix including amino acids at positions 301, 
302 and 320. Replacing these amino acids within P450atdo with the corresponding 
P450ll~ equivalents (L301P, E302D, A320V) individually, enhances the 11~-
hydroxylation activity of P450atdo by approximately 2 fold. When all 3 mutations are 
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present as a triple mutant, there is a synergistic effect with an increase in 11 ~­
hydroxylase activity to 85% of wildtype P4501 1 ~ and a suppression of aldosterone 
synthase activity to 10% of wildtype P450aldo (Bortner & Bernhardt 1996). In the 
opposite scenario, exchanging amino acids within P450 11 ~ for the P450aldo 
equivalents to produce the mutants Val320Ala, Ser288Gly and Asn335Asp (either 
alone or in combination) confers aldosterone synthase activity to P450 11 ~ with no 
apparent affect on its 11 ~-hydroxylase function (Bortner & Bernhardt 1996; Curnow 
et al1997; Mulatero et al1998). Therefore, the differences in amino acid sequence 
within the I helix may largely explain the differences in specificity of the two 
enzymes. 
The I helix within P450aldo or P450 11 ~ is encoded by residues from exon 5 and exon 6 
of the genes. Studies on the monogenic hypertensive disorder, glucocorticoid 
suppressible hyperaldosteronism (GSH) support an essential role of this protein 
region for enzyme function (see section 1.5.2.1). GSH is the result of a chimeric 
gene consisting of the 5' region of CYP II B I attached to part of CYP II B2, resulting 
in the synthesis of aldosterone synthase being under the control of ACTH. However, 
if the cross-over point between the genes is after codon 302 (half way through ex on 
5), aldosterone synthase activity is undetectable, suggesting that regions upstream of 
this are indeed essential for enzyme function (Pascoe et al1992a). 
Homology modelling has suggested that the main difference between P450aldo and 
P450 11 ~ is the orientation of the haem. This affects the way in which the haem 
interacts with the side chains of adjacent amino acids. In P45011 f3, the haem interacts 
with Arg448 and Arg384 whereas in P450alcto, the haem forms two interactions with 
Arg448. Mutations in both Arg448 and Arg384 have been identified as the cause of 
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congenital adrenal hyperplasia (11 ~-hydroxylase deficiency) (see section 1.15.2.3) 
with all known mutations completely abolishing enzyme activity (Curnow et al1993; 
Geley et al1996; Nakagawa et al1995; White et al1991), supporting a key role for 
these amino acids in haem stabilization. Due to these differences in haem 
interactions, the active site of P450II~ is predicted to be larger than that of P450aldo 
(Belkina et al 2001). This would seem appropriate as the main substrate for 
P450u~ (S) is larger than that for P450aldo due to the presence of an extra 17a-
hydroxy group. 
Other studies clearly demonstrate that residues relatively remote from the known 
active site of P450aldo or P450u~ can also markedly alter enzyme function. Their 
location provides further insights into the function of cytochrome P450 enzymes. 
Fisher et al (2000) showed that substituting the aldosterone-specific residue D147, 
that is distant from the active centres, for the 11 ~-hydroxylase equivalent (E 14 7) and 
vice versa, significantly alters activity (Fisher et al 2000). 
1.15 Evidence for a Role of the CYPJJB locus in Essential 
Hypertension. 
As early as 1956, functional abnormalities of the adrenal cortex were suggested as a 
cause of essential hypertension (Genest et al 1956) and adrenal cortex hyperplasia 
has been found to be a feature of many hypertensive patients at post-mortem 
(Komiya et al 1991 ). Although no single causative defect in corticosteroid 
biosynthesis has been identified, evidence from animal models and monogenic forms 
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of hypertension demonstrate that modification of the CYP 11 B I and CYP 11 B2 genes 
can affect blood pressure and cardiovascular function and may therefore help to 
identify possible mechanisms contributing to essential hypertension. 
1.15.1 Animal Models of Hypertension 
Animal models have proved extremely useful in studying the heritable component of 
essential hypertension. The complexity of interpreting data from human subjects is 
greatly reduced by using inbred strains, which decreases the genetic heterogeneity, 
and also environmental influences can be completely controlled. Several rat models 
of genetic hypertension have been developed (Rapp 2000). Genetic crosses between 
hypertensive and control strains enable the identificaton of the individual genetic 
causes of hypertension. 
1.15 .1.1 Dahl salt sensitive rat 
In 1962, Dahl selectively bred rats according to the level of blood pressure achieved 
on a high salt (NaCl) diet. Two strains of rat were selected. In one strain, blood 
pressure is salt sensitive (ss) and rats become severely hypertensive upon salt 
loading. In the other, blood pressure is salt resistant (sr). Biochemical analysis 
revealed differences in corticosteroid metabolism. In the rat, the principal 
glucocorticoid is corticosterone, which is synthesised from DOC by 11 ~­
hydroxylase. 11 ~-hydroxylase is also able to catalyze IS-hydroxylation and an 
alternative end product is 18-hydroxydeoxycorticosterone (18-0H DOC), which may 
have weak mineralocorticoid activity. The ratio of corticosterone to 18-0H-DOC 
varies and may be due to variations in 11 ~-hydroxylase structure and function. In 
the ss strain adrenal cortex, there is a proportionally greater synthesis of 18-0H DOC 
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relative to corticosterone (Rapp & Dahl 1972). Investigating the CYP 11 BI gene, 
which encodes for 11 ~-hydroxylase as a possible candidate gene, revealed 
polymorphisms which associate with 18-0H DOC levels as well as with blood 
pressure. The 11 ~-hydroxylase in the sr strain has 5 mutations in exons 2, 6, 7 and 8 
(Cicila et a/1993). A combination of two ofthese, V381L and I384L, causes a loss 
of 11 ~-hydroxylase function in vitro and is thought to be the explanation of why the 
sr animals synthesise less 18-0H-DOC (Matsukawa et al 1993; Nonaka et al 1998). 
A chromosome 7 congenic strain of Dahl rats confirms that this region contains a 
QTL for blood pressure, with the CYP II B I gene being the likely candidate (Cicila et 
a/1997). Mutations have also been identified in CYPJJB2 ofthe Dahl rat (Cover et 
al 1995). However, these appear to cause a decrease in aldosterone synthase activity 
in the ss animal and so their contribution to the hypertensive phenotype is unclear. 
The Dahl rat is an excellent example of how genetic differences, in this case resulting 
in altered corticosteroid production, can lead to hypertension. It is also a good model 
of how environmental factors (salt) and genetic factors can interact to produce a 
hypertensive phenotype. 
1.15.2 Mendelian Hypertensive Conditions 
Several genes have been identified that cause Mendelian forms of hypertension in 
man. These disorders are caused by single gene defects that result in severe, early 
onset hypertension. Although rare, these mutations, which all result in altered renal 
salt reabsorption, give insight into possible molecular pathways involved in the 
pathogenesis of hypertension (Lifton et a/2001). Of particular interest to this review 
are those involving variation at the CYP II B locus. 
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1.15.2.1 Glucocorticoid suppressible hyperaldosteronism CGSH) 
Glucocorticoid suppressible hyperaldosteronism (GSH) is an autosomal dominant 
condition characterized by elevated aldosterone levels despite suppressed plasma 
renin together with hypertension and hypokalaemia (Rich et al1992; Sutherland et al 
1966). The aldosterone levels follow a circadian rhythm identical to that of ACTH 
and can be treated successfully with a synthetic glucocorticoid (dexamethasone) that 
inhibits ACTH production from the pituitary gland. GSH is caused by a chimeric 
gene that forms when the 11 P-hydroxylase ( CYP 11 B I) and the aldosterone synthase 
(CYP JJB2) genes become misaligned during meiosis and crossing over occurs 
(Lifton et al 1992). The chimera has a 5' end containing the promoter region of the 
CYPJJBI gene and exons 1-3 joined to exons 5-9 of CYPJJB2. This results in the 
gene expression and enzymatic activity of aldosterone synthase being controlled by 
ACTH instead of Ang II and which therefore does not respond to Na + status. Ectopic 
secretion of aldosterone from the adrenal fasciculata increases salt and water 
reabsorption and raises blood pressure. Substitution of more than the first 3 exons of 
CYP II B I results in an inactive chimeric gene suggesting residues after ex on 3 are 
crucial to aldosterone synthase activity. 
1.15 .2.2 Apparent Mineralocorticoid Excess CAME) 
Apparent mineralocorticoid excess (AME) is an autosomal recessive trait 
characterized by early onset hypertension with hypokalemia and metabolic alkalosis, 
suppressed renin and very low circulation levels of aldosterone. Despite the low 
levels of aldosterone, hypertension in these subjects responds to mineralocorticoid 
receptor blockade. Genetic analysis of affected families revealed an association 
between the disease and loss of function mutations in the gene for 11 P-
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hydroxysteroid dehydrogenase type II (ll~HSD2) (Murre et al 1995). In normal 
subjects, circulating cortisol levels are up to 1000 fold greater than circulating 
aldosterone levels. Cortisol has a similar affinity for the MR as aldosterone but is 
prevented from binding under normal circumstances by the enzyme 11 ~HSD2 which 
converts it to the inactive steroid, cortisone (Funder et al 1988; Stewart et al 1987) 
(see section 1.9.3). When ll~HSD2 is inactivated, cortisol is free to activate MR 
resulting in hypertension. 
1.15 .2.3 11 ()-hydroxylase deficiency 
Congenital adrenal hyperplasia is the generic name given to a group of inherited 
disorders resulting from mutations in the enzymes involved in corticosteroidogenesis 
(see section 1.8). 11 ~-hydroxylase deficiency is the second most common cause of 
congenital adrenal hyperplasia, accounting for 5-8% of cases in the general 
population (White et al 1992) with a higher frequency in an Israeli population of 
Moroccan Jewish origin (Rosier et al 1992). It is an autosomal recessive condition 
resulting from inactivating mutations in the CYP II B I gene, which causes adrenal 
hyperplasia due to the increased drive of ACTH attempting to maintain normal 
circulating cortisol levels. The result is low-renin hypertension and hypokalemia due 
to the accumulation of the precursor DOC, which has mineralocorticoid properties. 
The circulating levels of DOC are normally too low to activate the MR but in this 
condition result in mineralocorticoid excess. The accumulating precursor steroids are 
shunted into pathways of androgen biosynthesis, causing female virilization. and 
postnatal hyperandrogenism in both sexes (White & Speiser 1994). 
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Mutations causing II j3-hydroxylase deficiency 
The disruptive mutations are distributed across the entire gene but with a slightly 
higher frequency in exons 2, 6, and 8. There also appear to be mutational 'hot spots' 
in codons 318, 384 and 448 (see table 1.3). Several mutations disrupt the reading 
frame of the coding sequence, resulting in the biosynthesis of a truncated non-
functional protein. These include nonsense mutations; W116X, K174X, W247X, 
Q338X, Q356X or frameshift mutations, delC32, 2bp insertion at codon 394, 28bp 
deletion or a 5bp insertion in exon 2 (see table 1.3). The complete loss of enzymatic 
activity is usually explained by mutations, which result in the haem-binding or 
substrate-binding domains being incomplete or absent. Many of the missense 
mutations in exons 2, 5, 6, 7 and 8 have also been shown to abolish 11 ~-hydroxylase 
activity completely after transfection in cell culture; V129M, T318M, A331 V, 
E371G, R374Q, R384Q, V441G and R448C (Curnow et al1993; Geley et al1996). 
In vitro analysis of mutations Pro42S, Asn133His and Thr319Met showed that they 
partially reduced 11~-hydroxylase activity to 15-37% of the wildtype activity 
(Joehrer et al 1997). These mutations were identified in subjects with a non-classic 
or mild form of 11 ~-hydroxylase deficiency. It is characterized by milder androgen 
excess with slightly elevated blood pressure in some cases. The symptoms of 
advanced bone age, accelerated growth, acne and menstrual cycle abnormalities may 
develop during childhood or at puberty. A similar non-classic form of 21-
hydroxylase deficiency also exists, and in fact occurs more frequently than the 
classic form (Merke & Bornstein 2005). Therefore it is likely there are more cases of 
non-classic 11 ~-hydroxylase deficiency that have not been identified due to the 
relatively mild signs and symptoms of androgen excess. 
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Merke et al identified three novel mutations causing 11 ~-hydroxylase deficiency, a 
nonsense mutation at codon 19, a novel missense mutation in codon 318 
(Thr318Arg) and a G to A substitution at the first base pair of intron 5 (318+ 1 A-G) 
within the splice site (Merke et al 1998). These mutations suggest that splice site 
variants may be important causative mechanisms of 11 ~-hydroxylase deficiency and 
also identify codon 318 as an additional mutational 'hot spot'. Merke et al (1998) 
also identified two apparent polymorphisms within the CYP II B I gene of healthy 
control subjects. These turned out to be gene conversions events in exon 1 (R43Q) 
and exon 7 (A386V) whereby the 11 ~-hydroxylase-specific residue had been 
replaced with the corresponding aldosterone synthase-specific residue. The 
frequency of these or similar gene conversion events within the general population is 
unknown. 
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Mutation Ex on Putative 3D Effect in vitro Reference 
location 
Gln19STOP 1 N terminus Truncated protein Merke et al (1998) 
delC32 1 A-helix Complete loss of activity Curnow et al (1993) 
Pro42Ser 1 A-helix 15% t activity Joehrer et al (1997) 
del28bp 2 B'-B3 loop Truncated protein Skinner et al (1996) 
(S105-Ll13) 
Trp116Cys 2 B-C loop 97% t activity Krone et al (2005) 
Trp116STOP 2 B-C loop Complete loss of activity Naiki et al (1993) 
Ins 5bp 121 2 C-helix Truncated protein Skinner et al (1994) 
Val129Met 2 C-helix Complete loss of activity Geley et al (1996) 
Asn133His 3 C-helix 17% t activity Joehrer et al (1997) 
Lys174STOP 3 D-helix Truncated protein Curnow et al (I 993) 
Trp247STOP 4 G-helix Truncated protein Geley et al (1996) 
Gly267Arg 5 G-helix May alter splicing Skinner et al (1996) 
Leu299Pro 5 Start of I helix 99% t activity Krone et al (2005) 
Thr318Met 5 !-helix Complete loss of activity Curnow et al (1993) 
Thr318Arg 5 !-helix Undetermined Merke et al (1998) 
318+1G-A 5+1 - Altered splicing Merke et al (1998) 
Thr319Met 6 !-helix 37% t activity J oehrer et al (1997) 
Ala331Val 6 !-helix Complete loss of activity Geley et al (1996) 
Gln338STOP 6 J-helix Truncated Protein Curnow et al (1993) 
Val348Ala 6 J-helix Undetermined Skinner et al (1994) 
Gln356STOP 6 BetweenJ-K Truncated Protein Curnow et al (1993) 
helix 
Glu371Gly 6 K-helix Complete loss of activity Geley et al (1996) 
Arg374Gln 6 K-helix Complete loss of activity Curnow et al (1993) 
Arg384Gln 7 Haem side chain Complete loss of activity Curnow et al (1993) 
Arg384Gly 7 Haem side chain Undetermined Nakagawa et al (1995) 
Ins2bp394 7 ~1-4 Truncated Protein Helmberg et al (1992) 
Arg427His 8 Meander May affect haem binding Skinner et al (1994) 
delF438 8 Meander Complete loss of activity Krone et al (2005) 
Val441Glu 8 Meander Complete loss of activity Curnow et al (1993) 
Arg448Cys 8 Haem side chain Complete loss of activity Geley et al (1996) 
Arg448His 8 Haem side chain Complete loss of activity White et al (1991) 
Ins3bp464 8 L-helix Complete loss of activity Geley et al ( 1996) 
Table 1.3. Mutations in CYPJJBJ causing 11~-hydroxylase deficiency 
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The reason for the disruptive effects of many of these missense mutations can be 
hypothesised from their putative 3D locations. As mentioned previously, in P450 11 ~ 
the haem interacts with Arg448 and Arg384 and mutations at these sites completely 
abolish enzyme activity (Curnow et a/1993; Geley et a/1996; Nakagawa et a/1995; 
White et a/1991 ). The residue T318 lies within the I -helix or putative active site and 
is completely conserved in all CYP450s. It is thought to be essential for binding of 
molecular oxygen and/or proton transfer, which are essential for enzyme activity 
(Curnow et a/1993; Merke et a/1998). Amino acid residues E371 and R374 within 
the K helix form part of the ERR-triad and so mutations at these sites would be 
expected to cause enzyme destabilization (Hasemann et al 1995). Residue P42 
within the A helix is conserved in all CYP II B isoenzymes and thought to be 
essential for proper orientation of the enzyme in the mitochondrial membrane 
(Joehrer et al 1997). Amino acid N133, also conserved in the CYP liB family, lies 
within a region that may form part of the substrate access channel (Joehrer et al 
1997). Within this region, there is also a cluster of glycines (G123, G128, G134), 
which are conserved between P459ll~ and P450aldo, and are involved in the flexibility 
of the B-C loop. The B-C loop is thought to be important for substrate recognition as 
it contains the proposed SRS-1 (Gotoh 1992) (see section 1.14). Mutations within 
this region, such as W116, would be expected to affect substrate binding (Krone et al 
2005). Residue L229 is located very close to the !-helix/active site. The introduction 
of a proline, which is a large cyclic residue, at this site may alter the position of the 
helix relative to the haem, disrupting enzyme function (Krone et al 2005). Other 
residues such as V129 and A331, although their exact role is unknown, they are 
conserved between the CYP II B isoenzymes and so can be indirectly assumed to be 
functionally important. 
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Although the frequency of lip-hydroxylase deficiency within the general population 
is very rare, it draws attention to the CYP llBllocus as a possible candidate that may 
contribute to hypertension. Also, the more recent identification of mutations causing 
a milder non-classic lip-hydroxylase deficiency highlights the possibility of the 
existence of mutations that cause very subtle differences in enzyme activity that may 
be more difficult to recognise by phenotypic analysis. 
1.15.3 Mendelian Hypotensive Conditions 
As well as the hypertensive conditions, there are also several Mendelian forms of 
hypotension resulting from loss-of-function mutations in 9 different genes that 
impair renal sodium reabsorption (Lifton 2001). These include the genes encoding 
aldosterone synthase (Pascoe at al 1992), 21-hydroxylase (Amor et al 1988), the 
mineralocorticoid receptor (Geller et al 1998) and the subunits of the ENaC (Chang 
et al1996). 
1.15.3.1 Aldosterone synthase deficiency 
Aldosterone synthase deficiency usually presents m newborn infants as a life 
threatening electrolyte imbalance. It is characterised by salt wasting and 
hyperkalemia with elevated plasma renin activity and decreased aldosterone levels, 
resulting in dehydration, vomiting and failure to thrive. There are two types of 
aldosterone synthase deficiency, previously thought to be two separate enzyme 
deficiencies and referred to as corticosterone methyl oxidase type I (CMOI) and type 
II (CMOII) (Ulick 1976). However, the realization that aldosterone synthase is 
responsible for all 3 of the final stages of aldosterone synthesis (lip-hydroxylation, 
IS-hydroxylation and 18-oxidation) (see section 1.8.7) indicates that both types must 
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be caused by mutations m the CYP II B2 (aldosterone synthase) gene. Type I 
deficiency appears to disrupt IS-hydroxylation as indicated by low to normal 
secretion of IS-hydroxycorticosterone and little or no aldosterone production. Type 
II affects IS-oxidation resulting in low or normal aldosterone levels at the expense of 
increased secretion of its immediate precursor, IS-hydroxycorticosterone (Ulick et al 
I992b). The largest numbers of Type II cases identified have been Iranian Jews, born 
from consanguineous parents, but the disease has also been documented throughout 
Europe and North America. 
Mutations causing aldosterone synthase deficiency 
Aldosterone synthase deficiency is a rare autosomal recessive condition arising from 
mutations within the CYP II B2 gene. Like II P-hydroxylase deficiency the causative 
mutations are spread throughout the entire gene, in this case CYP II B2, but with a 
tendency to cluster in exon 3 (see tables 1.4a and b). However, the number of 
mutations reported to cause aldosterone synthase deficiency is less than those 
reported to cause II P-hydroxylase deficiency. 
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TYPE I 
Mutation Ex on Putative 3D Effect in vitro Reference 
Location 
Val35del5bp 1 A-helix Truncated protein Mitsuuchi et a! 
(1993) 
6bp duplication 3 Between C'- Complete loss of activity Kayes-W andover et 
153 D helix a! (2001) 
Glu255STOP 3 G-helix Truncated protein Peter et a! (1997) 
Tyr265STOP 3 G-helix Truncated protein Lopez-Siguero et a! 
(1999) 
Leu324Gln 6 I-helix Undetermined Lopez-Siguero et a! 
(1999) 
Arg384Pro 7 P1-4 Complete loss of activity Geley et a! (1995) 
Val3 86Ala/Glu 7/3 p 1-4/E'-helix Complete loss of activity Lopez-Siguero et a! 
188Asp (1999) 
Leu461Pro 8 L-helix Complete loss of activity Nomoto et a! 
(1997) 
Arg173Lys/ 7/3/3 P1-4/D-and t 11 P and 18-hydrox, Portrat-Doyen et a! 
Glu198AspN al E-helix no 18-oxidase activity (1998) 
386Ala 
Table 1.4a. Individual and combined mutations in CYPJJB2 causing Type 1 
aldosterone synthase deficiency (CM0-1) 
TYPE II 
Mutation Ex on Putative 3D Effect in vitro Reference 
Location 
V al3 86AlaJ Arg 7/3 p 1-4/between 0.2% activity ofWt Pascoe eta! (1992) 
181Trp D-andE-helix 
Thr185Ile 3 E-helix t 180H No 180x Peter et a! (1998) 
Lisurek eta! (2004) 
Arg181 Trp/del 3/ BetweenD-E Complete loss of activity Zhang eta! (1995) 
C372 and K-helix 
Val386Ala/Thr3 7/5 I-helix Complete loss of activity Zhang eta! (1995) 
18Met 
Ex on 3+4 3/4 - Normal aldosterone Fardella et a! 
conversiOn (1996) 
T498A 9 C-terminus llP and 18-hydrox, Dunlop eta! (2003) 
no 18-oxidase activity 
Table 1.4b. Individual and combined mutations in CYPJJB2 causing Type 2 
aldosterone synthase deficiency (CM0-11) 
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Most of the mutations causing Type I aldosterone deficiency result in a complete loss 
of aldosterone synthase activity in vitro (see table 1.4a). They include the 5bp 
deletion in exon 1 that results in a premature stop codon (Mitsuuchi et al 1993), the 
nonsense mutation in exon 4 (E255X) which produces an enzyme lacking the haem 
binding domain (Peter et al1997), and a missense mutation in exon 8 (L461P) also 
thought to be important for haem-binding (Nomoto et al 1997). The substitution 
R384P also causes Type I deficiency (Geley et al1995). This arginine is conserved 
in all mitochondrial P450 enzymes and is thought to interact with the haem group 
(see previous section 1.14.2). A similar mutation has been identified in CYP llBI 
that also completely abolishes activity (Curnow et al1993). 
Many of the mutations causing type II deficiency, result in mildly impaired activity 
or only affect certain functions of aldosterone synthase (see table 1.4b ). For 
example, Thr185Ile increases 11 ~-hydroxylase activity while severely reducing 18-
hydroxylation and abolishing aldosterone synthase activity (Lisurek & Bernhardt 
2004). Interestingly, CYP 11B2 and CYP llBI are identical at this position. The 
substitution T498A retains 11 ~-hydroxylase and 18-hydroxylase activities but not 
18-oxidase activity, coinciding with the clinical diagnosis of type II deficiency 
(Dunlop et al2003). These mutations give insights into which residues are important 
for the different functions of aldosterone synthase. 
However, there is some inconsistency between the CYP II B2 activity as assessed in 
vitro and the clinical phenotype observed (Portrat-Doyen et al 1998). For example, 
the mutations reported by Zhang et al were present in a compound heterozygote with 
Arg181Trp/delC372 on one allele and Val386Ala/Thr318Met on the other. The 
clinical symptoms were suggestive of Type II aldosterone deficiency, with detectable 
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serum aldosterone and elevated IS-hydroxycorticosterone, but the mutants had no 
measurable aldosterone synthase activity in vitro (Zhang et al 1995). This may be 
explained by other in vitro studies demonstrating higher aldosterone production 
using a CYP 11 B1-containing vector compared to empty-vector, implying that 
CYP 11 B 1 may be capable of very low levels of aldosterone synthesis (Dunlop et al 
2003). However, the opposite situation occurs. The presence of mutations 
R173K/E198D/A386V produces a phenotype consistent with Type I aldosterone 
synthase deficiency but in vitro studies showed residual activity comparable to Type 
II deficiency (Portrat-Doyen et al 1998). Hence, the complications and dispute over 
the characterization of the two subtypes of aldosterone synthase deficiency. 
In several cases, the simultaneous presence of more than one homozygous mutation 
is required to produce the phenotype of aldosterone synthase deficiency. 
Individually, several mutants such as R173K, V386A, E198D or R181W have only 
modest effects on enzyme activity in vitro but produce much greater effects when 
present in combination, suggesting there is significant interaction between the mutant 
loci (Pascoe et al 1992b; Portrat-Doyen et al 1998; Zhang et al 1995). Indeed, 
R173K and V386M occur frequently in most populations studied, which supports 
their minor effects on enzyme activity. However, when present, together they must 
interact to induce a conformational change in the enzyme, resulting in altered 
activity. In some subjects with apparent clinical symptoms of aldosterone synthase 
deficiency, no mutation affecting P450aldo activity could be identified (White 2004). 
The causative gene(s) in these cases remains to be determined. 
The putative 3D locations of several of these mutants are within the conserved P450 
structural core, such as residues 173 (helix D), 318 (helix I), 324 (helix I), 386 
101 
(strand 4 of ~-sheet 1) and 461 (helix L), confirming an essential functional role of 
these regions of the enzyme. However, although these mutations give key insights 
into what residues are essential for enzyme function, they do not give enough 
information to explain fully the relationship between gene/protein structure and 
enzyme activity. 
All these Mendelian disorders are very rare and do not explain the overall blood 
pressure variation in the general population. However, they do provide an insight 
into the various pathways through which genetic variation can alter blood pressure. 
In the light of these rare syndromes it is of interest that a slightly impaired 11 ~­
hydroxylase function has been previously found in subjects with essential 
hypertension compared to controls. A study 20 years ago by de Simone and 
colleagues reported an increase in the levels of the precursor DOC following ACTH 
stimulation in hypertensive patients compared to controls (de Simone et al 1985). 
More recently, a similar observation was made in hypertensives from Italy who had 
an elevated ratio of 11-deoxycortisol to cortisol, which is a marker of 11 ~­
hydroxylase activity (Connell et al 1996). Section 1.10.2.1 described how 
dysregulated aldosterone synthesis, as determined by an elevated ratio of aldosterone 
to its principle trophin renin, appears to be a common feature of essential 
hypertension. Subsequent to the preceding discussion of widespread variation in 
CYP JJBJ and CYP JJB2, what is the possibility that similar genetic variant(s) 
contribute to the predisposition to essential hypertension? This is the subject of the 
final section. 
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1.16 Possible Genetic Basis for Hypertension with an 
Elevated ARR 
As mentioned previously there is now evidence that altered aldosterone production 
resulting in an elevated ARR may be a common feature of essential hypertension 
(Lim et al2002a). Hypertension with a raised ARR may be a subset of hypertension 
that develops gradually as a result of the interaction between environmental and 
genetic influences (Connell et al 2003). The potential role for corticosteroids in the 
development of hypertension has previously been discussed. The enzymes 
aldosterone synthase (encoded by CYP II B2) and 11 ~-hydroxylase (encoded by 
CYP JJBI) are responsible for the last stages in the synthesis of aldosterone and 
cortisol respectively. The monogenic forms of hypertension (section 1.15.2) and 
animal models such as the Dahl rat (section 1.15.1), mentioned previously, highlight 
both these genes as key candidates for hypertension. 
1.16.1 CYP11B2 Polymorphisms and Hypertension 
Two common variants have been described in the CYP II B2 gene (White & Slutsker 
1995). The first is a single nucleotide (cytosine/thymidine) substitution in the 5' 
promoter region at position -344C/T that disrupts a putative binding site for the 
steroidogenic factor SF -1. The other involves the second intron of CYP II B2, part of 
which is converted to the intron 2 sequence found in the adjacent gene CYP II BI. 
These variants are in tight linkage disequilibrium so that the common haplotypes are 
T/Conv (38%), C/Wt (45%) and T/Wt (16%) (Davies et al 1999). It has previously 
been reported that the SF -1 T allele and the intron conversion allele occur more 
frequently in hypertensive subjects than in normotensives (Brand et al 1998; Davies 
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et al 1999), especially those with a high ARR (Lim et al 2002b ), although this 
finding is not supported in all studies (Kupari et al 1998; Mulatero et al 2000). The 
association between the SF -1 T allele and blood pressure is supported by evidence of 
an epistatic interaction of this locus with the Y chromosome on the likelihood of 
developing higher blood pressure (Charchar et al 2002). These polymorphisms also 
appear to be associated with higher average aldosterone levels, as measured by 
excretion rates of its principle metabolite tetrahydroaldosterone (Davies et al 1999), 
as well as higher average plasma aldosterone levels (Paillard et al 1999). Again, this 
finding has not always been confirmed (Pojoga et al 1998). As mentioned 
previously, recent studies demonstrate that up to 15% of unselected patients with 
hypertension have a raised aldosterone to renin ratio suggesting that altered 
regulation of aldosterone production may be a common factor in essential 
hypertension (Lim et al 1999b ). However, in vitro studies suggest that, although the 
T allele at -344 has a 4 fold decreased affinity for SF-1, this has no effect on gene 
transcription (Bassett et al 2002). This strongly suggests that it is not the functional 
variant and that it may be in linkage disequilibrium with the as yet unidentified 
functional variant(s). The reduced binding of SF-1 may enable more to bind to a 
functional site elsewhere. 
1.16.2 CYP11B2 and altered llfl-Hydroxylation 
Other studies have focused on the relationships of these CYP II B2 polymorphisms to 
basal and ACTH-stimulated corticosteroid levels (Davies et al2001). No correlation 
was found between the genotypes of either polymorphism and basal corticosteroid 
levels. Similarly, no relationship of genotype was seen to the response of the end 
products cortisol and corticosterone to ACTH stimulation. However, their respective 
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precursors, 11-deoxycortisol and deoxycorticosterone, showed a significantly greater 
response to ACTH stimulation in those subjects with the SF-1 T allele and the IC 
conversion alleles. This suggests that these genotypes are associated with impaired 
11~-hydroxylase activity. A similar association was found between these alleles and 
plasma 11-deoxycortisol levels following ACTH stimulation in Finnish males 
(Hautanena et al 1998). The SF-1 polymorphism has also been shown to associate 
with markers of 11 ~-hydroxylase function in a normotensive population. In this 
case, the TT group showed increased excretion levels of tetrahydrodeoxycortisol 
(THS) and tetrahydrodeoxycorticosterone (THDOC), the principle metabolites of S 
and DOC respectively, compared to the CC group (Connell et al 1996). Several 
aspects of corticosteroid metabolism, including aldosterone excretion rate and 
markers of 11 ~-hydroxylase efficiency have been shown to be heritable (Inglis et al 
1999). Recent studies have also demonstrated that the excretion of THS is heritable 
(19.4%) and that the -344 T allele is more strongly associated with higherTHS levels 
than the C allele. (Connell et al 2004). Importantly, a slightly impaired 11 ~­
hydroxylase function is a consistent finding in subjects with essential hypertension 
compared to controls (Connell et al1996; de Simone et al1985; Honda et al1977). 
How could variations in CYP II B2 affect 11 ~-hydroxylase activity? One obvious 
explanation is that CYP II B2 polymorphisms are without effect but are in strong 
linkage disequilibrium (LD) with functional polymorphisms in CYP liB I. The 
CYP II B I gene encoding the enzyme 11 ~ hydroxylase is adjacent and homologous to 
CYP 11B2. It is possible, even likely, that the -344 and the intron conversion 
polymorphisms in CYP 11B2 are in linkage with variants in CYP liB I and that these 
are responsible for the observed phenotype of altered 11 ~-hydroxylase efficiency. 
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This is supported by experimental evidence of an association between the CYP II B2 
polymorphisms and urinary levels of tetrahydro-deoxycortisol (THS), the principle 
metabolite of S (Kennon et al 2004). Keavney et al have shown that the -344C/T 
and IC polymorphisms in CYP II B2 are in linkage disequilibrium with two 
polymorphisms in CYP 11 B I; a CTG to CTA substitution in codon 7 5 of ex on 1 and 
a G to A substitution in intron 3 (Keavney et al 2005). The association with urinary 
THS levels was found to be strongest with the exon 1 polymorphism, but this is a 
synonomous base change and so is unlikely to account for the biochemical 
phenotype of impaired 11 ~-hydroxylase deficiency. Another study recently found 
strong linkage disequilibrium between polymorphisms in CYP II B2 and 
polymorphisms in CYPIJBI; a nonsynonymous substitution (T to C) in codon 75 
and a G to A substitution in intron 6 (Ganapathipillai et al2005). Using the ratio of 
urinary THS to total cortisol metabolites (tetrahydroxycortisone (THE) + tetrahydro-
11-deoxycortisol (THF) + 5aTHF) as a marker of 11 ~-hydroxylase function, they 
reported a decreased 11 ~-hydroxylase activity in subjects with an increased ARR. 
The main CYP II B haplotypes identified also associated with 11 ~-hydroxylase 
efficiency, supporting the hypothesis that markers in CYP 11 B I account for 11 ~ 
hydroxylase activity in vivo. 
These findings provide strong evidence that the -344 CIT and IC polymorphisms in 
CYP IIB2 are in LD with genetic variants in CYP IIBI that account for the observed 
phenotype of impaired 11 ~-hydroxylation. However further fine mapping across the 
entire CYP II B locus is required to identify potential causative variants. 
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1.16.3 Altered 11{3-Hydroxylase Efficiency and Hypertension with a 
raisedARR 
If the -344 CIT and intron conversion polymorphisms identified in CYP JJB2 are in 
LD with functional variants in CYP II BI causing reduced 11 ~-hydroxylase 
efficiency, then how does this account for the association with increased aldosterone 
levels, hypertension and an elevated ARR? It seems plausible that mild long-term 
deficiency of 11 ~-hydroxylase activity may result in a resetting of the hypothalamic-
pituitary axis by causing a sustained mild increase in ACTH drive to the adrenal 
cortex to maintain normal plasma cortisol levels (Connell et al 2003). If as 
suggested this mildly impaired 11 ~-hydroxylase efficiency is genetically determined 
then it is effectively a minor variant of classical 11 ~-hydroxylase deficiency (see 
section 1.15.2.3). Lifelong exposure to a slightly enhanced ACTH drive to the 
adrenal cortex may eventually promote the development of hyperplasia of the zona 
glomerulosa and zona fasciculata, resulting in increased synthetic capacity for both 
cortisol and aldosterone. As mentioned previously adrenal gland hyperplasia is a 
common histologic finding in hypertensive patients at post mortem (Komiya et al 
1991). ACTH stimulates the expression of a number of genes required for 
aldosterone synthesis inlcuding StAR, P450scc (CYP JJA) and P450-21 hydroxylase 
(CYP2I) producing a potential increase in aldosterone synthetic capacity (Miller 
1988). In support of a role for ACTH in regulating aldosterone is recent research 
demonstrating that POMC-derived peptides are necessary to develop and maintain 
normal aldosterone production (Coll et al 2004). Although chronic ACTH 
stimulation has been shown to repress aldosterone synthesis (Oelkers 2000), these 
studies have used supraphysiological concentrations of ACTH, not equivalent to the 
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mild and chronic increase suggested here. In ACTH-dependent Cushing's disease, in 
which there is chronic sustained exposure of the adrenal cortex to ACTH, 
aldosterone levels are in fact neither suppressed or elevated (Whitworth et al 2000). 
In fact, ACTH increases the expression of a number of genes necessary for 
aldosterone production emphasizing the potential for enhanced aldosterone synthetic 
capacity and response to stimuli such as angiotensin II or potassium (Miller 1988). In 
hypopituitary patients the angiotensin IIIaldosterone response is blunted indicating 
that ACTH may be involved in setting the sensitivity of this relationship (Seifert & 
Oelkers 1981 ). Therefore the genetic change in 11 ~-hydroxylase efficiency may in 
the long term and in combination with other genetic and environmental factors, 
promote ACTH dependent adrenal zonal hyperplasia with an increased sensitivity of 
aldosterone to its main agonist Ang II resulting in hypertension with a raised ARR 
(Connell et al 2003; Freel & Connell 2004). In support of this are early studies 
demonstrating a good blood pressure response to dexamethasone in patients with 
essential hypertension, suggesting that ACTH was sustaining production of a 
hypertensinogenic adrenal steroid (Hamilton et al 1979). Also endogenous levels of 
the adrenal androgen dehydroepiandrosterone sulfate (DHEAS), which is regulated 
by ACTH, are increased in subjects with hypertension (Schunkert et al1999b ). 
1.17 Aims 
Genetic variation in CYPJJB2 (-344 CIT and intron conversion polymorphisms) has 
been linked to two key corticosteroid phenotypes in essential hypertension; raised 
ARR and decreased 11 ~-hydroxylase efficiency. It is unclear exactly how variation 
in CYP II B2 can alter the biochemical function encoded by a neighbouring gene 
(CYP JJBI) but the hypothesis that shall be investigated is that the -344 CIT and 
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Intron conversion variants in CYPJJB2 are in linkage with variants in CYPJJBJ that 
account for the reduced 11 ~-hydroxylase efficiency. 
The aim of this study was to investigate the way in which genetic variation at the 
CYP JJBJIB2 locus leads to altered 11~-hydroxylase function through detailed 
analysis of the pattern of genetic variation across the whole locus. This will 
hopefully enable the identification of variants across the CYP 11 B 1 I B2 locus that are 
in LD with the -344 CIT and IC polymorphisms. The functional effects of any 
variants identified will be tested in vitro in order to determine the genetic variation 
responsible for the observed phenotype of impaired 11 ~-hydroxylation. 
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CHAPTER2 
Materials and Methods 
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2.1 Functional Effects of Mutations in CYPJJBJ 
2.1.1 Single Stranded Conformational Polymorphism method 
The method of single stranded conformational polymorphism (SSCP) was used in 
our laboratories to screen for mutations in the coding region of the CYP II B I gene by 
Mrs Christine Holloway and Dr Angela Fisher. Each exon was amplified by PCR 
from genomic DNA using radiolabelled primers (Oswel DNA Service, Southampton, 
UK) (table 1, appendix 2). Each 25-!lL PCR contained 1.5 mM MgCh, 0.25 mM 
dNTPs, 12.5 pmol each primer and 1 Unit of thermostable Taq DNA polymerase 
(Promega Corp., Southampton, UK) and was denatured at 94C for 3 min, followed 
by 30 cycles of 94°C for 1 min, 55°C annealing for 1 min and 72°C extension for 1 
min, and a final incubation of 72°C for 7 min. The annealing temperature varied 
depending on the melting temperature of the primers being used. In most cases the 
PCR amplicon was greater than 250bp so an appropriate restriction enzyme was used 
for digestion to produce smaller fragments to ensure increased sensitivity of the 
SSCP analysis (table 1, appendix 2). The PCR products were denatured and 
separated by electrophoresis (30W, 6h, room temperature) on a non-denaturing 7.5% 
polyacrylamide gel. Autoradiographs of the gels were produced and the banding 
pattern of the individual patients compared to determine sequence variants. The 
presence of any identified mutations were then confirmed by automated sequencing 
using the ABI Big Dye Terminator v3.1 Cycle Sequencing Kit (PE Applied 
Biosystems, Foster City, CA, USA) (see section 2.2.6). For exons 2, 3, 4 and 7 it 
was not possible to selectively amplify CYP 11 B I without CYP 11 B2 so if variants 
were identified in these areas by SSCP the products were subcloned into pGEM 
easy/T-vector (Promega) prior to sequencing. 
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In this way, 8 missense mutations were identified in CYP II B I, altering the encoded 
amino acid in exons 1, 2 and 3 at the following locations: R43Q, L83S, H125R, 
P135S, F139L, L158P, L186V and T196A. Mutant R43Q results in the replacement 
of the 11 ~-hydroxylase-specific residue with the corresponding aldosterone 
synthase-specific residue. To examine the functional effect of these mutations in 
vitro they were recreated by site-directed mutagenesis and transfected into human 
placental JEG-3 cells (see section 2.1.4). 
2.1.2 Site-Directed Mutagenesis 
The eDNA encoding human 11~-hydroxylase (CYP IIBI), in the vector pCMV4 was 
kindly provided by Professor Perrin White. The eDNA insert was 1.5kb and the 
vector was 4.8kb. CYP 1J BI missense mutations previously detected by SSCP were 
constructed in vitro by site-directed mutagenesis (SDM) of the cloned eDNA. This 
was performed using the Quick-Change SDM kit (Stratagene Ltd, Cambridge, UK). 
Mutation of nucleotides encoding amino acids arginine 43, leucine 83, histidine 125, 
phenylalanine 139, leucine 186, proline 135, leucine 158 and tyrosine 196 was 
performed using specific sense and antisense mutagenic oligonucleotide primers 
which were designed individually according to the desired mutations (MWG-
Biotech, Ebersberg, Germany) (table 2, appendix 2). 
2.1.2.1 SDM PCR protocol 
SDM was performed according to the kit's standard protocol. Briefly, the component 
reagents were assembled in a reaction tube and then incubated on a thermal cycler 
according to the amplification protocol. 
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Component Volume 
Reaction Buffer ( 1 OX) 5 ~-tl 
DsDNA template (1 Ong/1-tl) 4~-tl 
Sense Primer (12 5 ng/ ~-tl) 1 ~-tl 
Antisense Primer (125ng/~-tl) 1 ~-tl 
dNTP mix ( 4mM) 1 ~-tl 
Nuclease free water (nfH20) 37~-tl 
Pfu Turbo DNA Polymerase (2.5U/~-tl) 1 ~-tl 
Total volume 
Amplification protocol 
2. 95°C 
3. 55°C 
4. 68°C 
30 seconds 
30 seconds 
1 minute 
14 minutes 
50 ~-tl 
Initial Denaturation 
Denaturation 
Annealing 
Extension 
Steps 2, 3 and 4 were repeated for 12 cycles. 
2.1.2.2 Digestion of parental DNA template 
Following temperature cycling, the product was treated with 1 ~-tl (1 0 U/~-tl) of the 
endonuclease Dpnl for 1 hour at 37°C. Dpnl specifically digests methylated DNA 
such as that which originates from bacteria. It therefore digests the parental DNA 
template but leaves the newly synthesized mutation-containing DNA intact. 
2.1.2.3 Transformation of Supercompetent Cells 
Epicurian Coli XL1-Blue supercompetent cells (50~-tl) (Stratagene Ltd, Cambridge, 
UK) were transformed with 4~-tl ofDpnl-treated sample DNA by heat pulsing for 45 
seconds in a water bath at 42°C. The cells were then grown in NZY+ broth at 37°C 
for one hour. The transformation reaction was plated onto LB/ampicillin plates 
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(50)-Lg/ml) and incubated overnight (>16 hours) at 37°C. Single transformed colonies 
were used to inoculate overnight incubations, which were shaken at 37°C overnight 
at 225 rpm in 5ml ofLB/ampicillin (l).lg/ml) broth. 
2.1.2.4 DNA Purification 
Plasmid DNA was purified from the overnight incubations usmg a QIAprep 
Miniprep Kit (QIAGEN Ltd, West Sussex, UK). The cultured LB was transferred to 
a 1.5ml Eppendorf tube and centrifuged at maximum speed for 2 minutes in a 
tabletop centrifuge to pellet the bacterial cells. The cell pellets were resuspended in 
250J.!l Buffer Pl. To lyse the cells, 250J.!l Buffer P2 was added and mixed by gently 
inverting the tube. 350J.!l Buffer N3 was added and mixed immediately by inverting 
the tubes. The samples were centrifuged for 10 minutes at maximum speed in a 
tabletop microcentrifuge. The supernatants were transferred into a QIAprep Spin 
Column and centrifuged at top speed for 1 minute. The flow-through was discarded 
and the column washed by adding 0.5ml Buffer PB and centrifuging at top speed for 
1 minute. The wash step was repeated with 0. 75ml Buffer PE, and the column was 
centrifuged for an additional minute to remove residual wash buffer before being 
placed in a clean 1.5ml microcentrifuge tube. DNA was eluted by adding 50J.!l nfl-hO 
to the center of the QIAprep column, letting it stand for 1 minute, and then 
centrifuging it for 1 minute at top speed. The plasmid DNA minipreparations were 
stored at 4°C until required for further analysis. 
2.1.2.5 Restriction Digestion 
Restriction analysis was performed on the plasmid DNA, usmg the restriction 
enzyme BamHI, to assess quality and identify vectors containing the appropriate 
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insert. This enzyme linearizes CYP JJBI eDNA by hydrolysing it at a single site to 
produce a fragment of 6.3kb. 2f..ll of plasmid DNA minipreparation ( ~ 1 OOng/f..ll) was 
combined with 0.5f..ll ofBamHI, 2f..ll Buffer J, 0.2f..ll ofBSA and 15.3f..ll ofnfl-I20 in a 
sterile 0.2ml PCR tube. The reaction mixture was incubated at 3rC for 2 hours. The 
size of digestion product was analysed by electrophoresis of the whole reaction on a 
1% agarose gel for 40 minutes at 1 00 V. 
2.1.2.6 Confirmation of Mutations 
Colonies of plasmids containing the insert as identified by restriction digestion were 
sequenced using the automated sequencing method described in Section 2.2.6. The 
entire insert was sequenced using the primers; V6776, V6777 that bind to the vector 
and N4019 that binds to the eDNA (see table 3, appendix 2), to confirm the 
presence of the desired mutations and to confirm that no additional mutations were 
introduced inadvertently. 
2.1.3 Large-scale Plasmid Preparations 
Large scale plasmid preparations were performed usmg a Plasmid Midi Kit 
(QIAGEN Ltd, West Sussex, UK). A single colony from a freshly-streaked selective 
plate was grown in a starter culture of 5ml LBroth containing the appropriate 
selective antibiotic for ~8 hours at 3 7°C with vigorous shaking. The starter culture 
was diluted Ill 00 in selective LBroth and grown at 3 7°C with vigorous shaking for 
~ 16 hours. The bacterial cells were then harvested by centrifugation at 6000 x g for 
15 minutes at 4°C. The bacterial pellet was resuspended in 4ml of Buffer Pl. The 
lysis reaction was initiated by addition of 4ml Buffer P2 and inverting the tube 4-6 
times. The solution was then incubated at room temperature for 5 minutes. Next 
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4ml of chilled Buffer P3 was added, the solution mixed immediately by inversion of 
the tube 4-6 times and then incubated on ice for 20 minutes. The solution was 
centrifuged at 16000 x g for 40 minutes at 4°C. A QIAGEN-tip column was 
equilibriated by applying 4ml of Buffer QBT and allowing the column to empty by 
gravity flow. The lysate supernatant was applied to the column and allowed to enter 
the resin. The QIAGEN column was washed with 2 x 1 Oml Buffer QC. The DNA 
was then eluted by addition of 5ml Buffer QF. The DNA was precipitated by adding 
3.5ml isopropanol to the elute, this was mixed and centrifuged immediately at 16000 
x g for 20 minutes at 4°C. The supernatant was discarded and the DNA pellet 
washed with 2ml of 70% ethanol and centrifuged at 16000 x g for 1 0 minutes. Again 
the supernatant was discarded, the pellet air-dried for 2-4 hours and the DNA 
redissolved in 200).ll nfl-hO. 
2.1.4 DNA Quantification using PicoGreen method 
PicoGreen dsDNA Quantitation Reagent (Molecular Probes, Leiden, Netherlands) is 
an ultra-sensitive fluorescent nucleic acid stain for quantitating double-stranded 
DNA ( dsDNA). It is more sensitive than the commonly used method of measuring 
absorbance at 260nm and avoids the interference caused by contaminants commonly 
found in nucleic acid preparations such as nucleotides, single-stranded nucleic acids 
or proteins. 
Sufficient 1xTE buffer was prepared for the experiment from a 20x stock (Molecular 
Probes kit). Serial dilutions of samples were pipetted onto a black microassay plate 
(1 OO).ll/well). A DNA standard solution (2).lgl).ll) was made by diluting 1 O).ll of stock 
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(100 ).lg/ml) lambda DNA in 490J..Ll TE. This was used to produce a DNA standard 
curve in duplicate by loading the following onto a plate: 
TE (J..Ll) DNA Standard (J..Ll) Final DNA cone 
0 100 1mg/ml 
50 50 500ng/ml 
90 10 100ng/ml 
98 2 20ng/ml 
100 0 Blank 
A working solution of the PicoGreen Reagent was prepared by making a 1 :200 
dilution of the concentrated stock in TE buffer being careful to maintain the solution 
in the dark, as PicoGreen is light sensitive. 1 OO).ll of this working solution was added 
to each standard/sample. The plate was then covered in foil to protect it from the 
light, incubated at room temperature for 5 minutes and then the fluorescence 
measured using a Wallac Victor 1420 Multilabel Counter (PerkinElmer Life 
Sciences, Boston, MA, USA). 
2.1.5 Transient Transfection system 
2.1.5.1 JEG-3 Cells 
Human JEG-3 choriocarcinoma placenta cells (American Type Culture Collection) 
do not normally produce corticosteroids so are suitable for transfection with either of 
the 11 ~-hydroxylase or aldosterone synthase genes. Their inability to produce 
aldosterone or cortisol was confirmed by incubating them with culture medium that 
did or did not also contain the steroidogenic precursors 11-deoxycorticosterone 
(DOC) and 11-deoxycortisol (S) respectively and testing the medium for steroid 
production using HPLC (High-performance liquid chromatography). One mam 
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advantage of these cells is that they have endogenous adrenodoxin, the cofactor 
essential for the activity of many steroidogenic enzymes. This removed the need to 
co-transfect with adrenodoxin. 
2.1.5.2 JEG-3 cell maintenance 
JEG-3 cells were cultured at 37°C in 5% C02 in Minimum Essential Medium Eagle's 
(Sigma-Aldrich) supplemented with 10% fetal bovine serum (Sigma-Aldrich), 1% 
sodium pyruvate (1 OOmM) (GIBCO) and 1% penicillin/streptomycin (5000U/ml) 
(GIBCO). 
2.1.5.3 Subculturing procedure 
Cells were passaged upon reaching 80-90% confluence. The culture medium was 
removed and the cells rinsed with phosphate buffered saline solution (PBS). 
Trypsin-EDT A solution (Sigma-Aldrich) was added to cover the cells and they were 
incubated at 37°C for 5 minutes to facilitate the dispersal of the cells. 5 ml of 
complete growth medium was added to inactivate the trypsin and the cells were 
pelleted at 1500rpm for 5 minutes. The cells were resuspended in complete growth 
medium and aliquoted into new flasks according to the desired subcultivation ratio. 
2.1.5.4 Handling procedure for frozen cells 
Cells grown to approximately 90% confluence were typsinized and pelleted as before 
and resuspended in complete growth medium supplemented with 10% dimethyl 
sulfoxide (DMSO). Aliquots were transferred to cryovials, which were then frozen 
gradually over 24 hours in a Nalgene cryo 1 °C freezing container. These were then 
transferred to a liquid nitrogen freezer for long-term storage. When frozen cells were 
required, they were removed from the liquid nitrogen and the vials thawed by gentle 
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agitation in a 37°C water bath for 2 minutes. The vial was decontaminated with 70% 
ethanol. The cells were transferred under sterile conditions to a 75cm2 tissue culture 
flask containing 5ml of prewarmed growth medium and incubated at 37°C in 5% 
C02. 
2.1.5.5 Transfection protocol 
1.5x105 JEG-3 cells were plated in 2ml of growth medium on 6-well plates and 
incubated at 37°C overnight to achieve approximately 80% confluence. 
Cell Count 
Cell counts were done using a Bright Line Haemocytometer (Sigma-Aldrich). Cells 
were removed from the flasks using Trypsin-EDT A solution as if being subcultured 
and spun as before to pellet the cells. The cells were then resuspended in lml of 
complete growth medium. 20).11 of resuspended cells were transferred to a sterile 
centrifuge tube and diluted with 230).11 of Hanks Buffer (Sigma-Aldrich). 250).11 of 
Trypan Blue solution (Sigma-Aldrich) was added to stain the cells, inverted to mix 
and incubated at room temperature for 2-3 minutes. With the coverslip in place, a 
small amount of Trypan Blue-cell suspension mixture was transferred to both 
chambers of the haemocytometer. For each chamber of the haemocytometer, the 
numbers of viable cells (i.e. unstained cells) in the lmm centre square and the four 
lmm comer squares were counted and the mean calculated. Each square of the 
haemocytometer, with coverslip in place, represents a total volume of O.lmm3 or 
104cm3. Since lcm3 is equivalent to approximately lml, the subsequent concentration 
per ml (and the total number of cells) is determined using the following calculation: 
Cells/ml =the average count per square x dilution factor x 104 x 1 (original val) 
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After calculating the number of cells per ml the amount of cell stock needed per well 
to achieve the correct number of cells (1.5 x 105 cells/well/2ml medium) was 
determined and the cells plated onto 6-well plates. 
Transfection mix 
Transfection was carried out using 6fll Fugene (Roche Diagnostics, Mannheim, 
Germany) and 3flg of wildtype or mutant plasmid in MEM/Eagle's for 24 hours for 
each well of a 6-well plate. The pGL3 control vector (0.1 flg) was added as a reporter 
gene to measure transfection efficiency. The transfection mix for each well 
contained: 
Component 
MEM (no additives) 
Fugene 
plasmid DNA 
pGL3 control plasmid 
Total volume 
Amount/well 
up to 100fll 
6.0fll 
3.0flg 
0.1flg 
lOOfll 
A master-mix was prepared for the wildtype and mutant constructs. The components 
were added in the order above, the tubes tapped to mix and incubated at room 
temperature for 30 minutes. 1 OOfll of transfection mix was dropped into the growth 
medium of each well and the plates swirled to mix. Cells not exposed to any 
transfection mix were used as a negative controL 
2.1.5 .6 Steroid Incubation 
After 24 hours the transfection medium was removed and replaced with 4 ml of 
growth medium supplemented with either DOC or 11-deoxycortisol over a range of 
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Cells were incubated with medium in the absence or presence of substrate for a 
further 24 hours. All transfections were performed 6 times. The steroid-containing 
medium was removed for HPLC analysis and the cells lysed for protein 
measurements (PIERCE, Perbio Science, Northumberland, UK) and luciferase 
activity (Promega Corp.) (see section 2.1.6). 
2.1.6 Measurement of Transfection Efficiency 
Luciferase activity (Promega Corp.) and protein concentration (Pierce) were 
measured on cell lysates following the manufacturers' protocols. The luciferase 
acitivity measured in relative light units (RL U) ranged from 1 x 1 04 to 1 x 105 across all 
samples and the range of total cell protein levels was 0.5 to 1.2 (arbitrary units). 
Transfection efficiency was determined by converting protein levels and luciferase 
activity into RLU per unit of total cell protein. These transfection values were then 
converted to a proportion of the highest transfection value. The generated correction 
factors ranged from 0.2 to 2 and the corresponding steroid results were corrected 
accordingly. 
2.1.6.1 Preparation of celllysates 
Cell lysates were prepared using Reporter Lysis Buffer (RLB) (Promega Corp.). 
After removal of steroid-containing medium, cells were washed with PBS and any 
residual traces of PBS were then removed. 0.5ml of 1xRLB was added to each well 
of the 6-well plates. The plates were placed at -70°C for 10 minutes and then thawed 
at room temperature. The cells were removed by pipetting the RLB over them 
several times and transferred to a prechilled 1.5ml Eppendorf tube. They were 
centrifuged at full speed in a microcentrifuge for 2 minutes. Lysates were stored at-
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70°C until required. The supernatant was assayed directly for luciferase activity 
whereas the whole cell lysate was used for determination of protein content. 
2.1.6.2 Measurement of Luciferase Activity 
Luciferase activity was determined using the Steady-Glo® Luciferase Assay system 
(Promega Corp.). A 10ng/mlluciferase (Luc) standard stock was prepared using 1x 
Cell Culture Lysis Reagent (CCLR) (Promega Corp.) containing 1mg/ml BSA. This 
was used to produce the following concentrations of standard in duplicate: 
Vol of stock (ul) 
0 
6.25 
12.5 
25 
50 
100 
1 x CCLR (ul) 
100 
93.75 
87.5 
75 
50 
0 
Final Cone (ng/ml) 
0 
0.625 
1.25 
2.5 
5 
10 
1 OO)ll of each standard replicate or sample was pi petted on to a white micro well 
plate. 1 OO)ll of the Steady-Glo Luciferase Assay reagent was added to each 
standard/sample. This was mixed well and incubated at room temperature for 5 
minutes. The light emmitted was measured using a Wallac Victor 1420 Multilabel 
Counter (PerkinElmer Life Sciences, Boston, MA, USA). 
2.1.6.3 Measurement of protein levels 
Protein levels were determined with the Pierce BCA (bicinchoninic acid) Protein 
Assay (PIERCE, Perbio Science, Northumberland, UK). A set of bovine serum 
albumin (BSA) protein standards were prepared in the range 20-2000)lg/ml using the 
same diluent as the samples (RLB) (Promega Corp.) as follows: 
122 
Vial Vol of Diluent (RLB) Vol and Source of BSA Final BSAConc 
A 0 300!-ll Stock 2000!-lg/ml 
B 125!-ll 375!-ll Stock 1500!-lg/ml 
c 325!-ll 325!-ll Stock 1000!-lg/ml 
D 175!-ll 175!-ll of vial B dilution 750!-lg/ml 
E 325!-ll 325!-ll ofvial C dilution 500!-lglml 
F 325!-ll 325!-ll ofvial E dilution 250!-lg/ml 
G 325!-ll 325!-ll ofvial F dilution 125!-lg/ml 
H 400!-ll 1 OO!ll of vial G dilution 25!-lg/ml 
I 4001-ll 0 Blank 
25!-ll of each standard or unknown sample replicate was pipetted on to a clear 96-well 
plate. A BCA Working Reagent (WR) was prepared by mixing 50 parts of BCA 
Reagent A with 1 part of BCA reagent B. 200!-ll of the WR was added to each well 
and mix thoroughly for 30 seconds. The plate was covered and incubated at 37°C for 
30 minutes. It was then cooled to room temperature and the absorbance measured at 
562nm using a Wallac Victor 1420 Multilabel Counter (PerkinElmer Life Sciences, 
Boston, MA, USA). The protein concentration was determined from the standard 
curve. 
2.1. 7 RNA-Bee Isolation of RNA 
2.1.7.1 Cell Lysis 
After the removal of the culture medium, cells were lysed directly in the culture dish 
by the addition of 1ml of RNA-Bee™ RNA isolation reagent (Biogenesis, Poole, 
UK) to 5 x 106 cells. The lysates were passed through a pipette several times to 
ensure complete lysis and transferred to a 1.5ml Eppendorf tube. 
2.1. 7.2 Phase Separation 
To separate the lysate into aqueous and organic phases, chloroform was added (0.2ml 
per 1ml ofRNA-Bee) and the tube shaken vigorously for 15-30 seconds. The sample 
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was then stored on ice for 5 minutes before being centrifuged at 12,000 x g for 15 
minutes at 4 °C. The upper colorless aqueous layer was carefully removed and 
transferred to a clean tube without touching the lower blue phenol-chloroform phase 
containing DNA and protein. 
2.1.7.3 RNA Precipitation 
Isopropanol (0.5ml) was added and the sample stored at room temperature for 5-10 
minutes. It was then centrifuged at 13,000 x g for 5 minutes at 4°C.- The RNA 
precipitate, which is often not visible before centrifugation, forms a white/yellow 
pellet at the bottom of the tube. 
2.1.7.4 RNA Wash 
The supernatant was removed and the RNA pellet washed with 75% ethanol in a 
volume equal to the starting amount of RNA-Bee. The tube was vortexed to dislodge 
the pellet from the side of the tube and centrifuged for 5 minutes at 7,500 x gat 4°C. 
2.1.7.5 RNA Solubilization 
The RNA pellet was briefly air-dried (5-10 minutes) to remove residual traces of 
ethanol but not allowed to dry completely as this greatly reduces its solubility. Each 
RNA sample was dissolved in 20fll nfl-hO by passing the solution through a pipette 
tip several times then stored at -70°C. 
2.1.7.6 DNase Treatment 
Each RNA solution was treated with DNA-free™ (Ambion, Huntingdon, UK) to 
remove any DNA contamination. 0.1 vol of 10 x DNase I buffer and lfll (2 units) of 
DNase I was added to each sample. The samples were mixed and incubated at 37°C 
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for 20-30 minutes. 5j.ll of DNase Inactivation reagent was then added and the 
samples mixed well. They were then incubated for 2 minutes at room temperature, 
flicking the tube once during the incubation to mix. The samples were centrifuged at 
10,000 x g for 1 minute to pellet the DNase inactivation reagent and the RNA 
transferred to a new tube. The RNA was then stored at -70°C. 
2.1.8 RNA Quantification using RiboGreen® method 
The RiboGreen® RNA quantitation kit (Molecular Probes, Leiden, Netherlands) 
allows reliable detection of RNA in solution, with a sensitivity that is orders of 
magnitude greater than UV absorbance readings. 
2.1.8.1 Sample Preparation 
A 1 x Tris-HCl ethylenediaminotetraacetic acid (EDTA) buffer working solution (1 x 
TE) was prepared by diluting 20 x TE buffer with nfl-hO. The RNA sample 
solutions were diluted 2000-5000 fold in 1 x TE. 1001-11 of each diluted RNA sample 
was loaded into a well of a 96-well black microplate (Nalge Nunc International, 
Hereford, UK). 
2.1.8.2 RNA standard curve 
The ribosomal RNA standard, provided at 1 OOj.lg/ml in the RiboGreen kit, was 
diluted 50-fold in 1 x TE to make a 2j.lg/ml working solution. This was diluted in the 
black microplate as shown: 
125 
Vol ().!1) of Vol ().!1) of Final RNA V ol().!l) of TE 2 ).!g/ml RNA Diluted RiboGreen Concentration Stock Solution Reagent 
5 100 100 1000ng/ml 
50 50 100 500ng/ml 
90 10 100 100ng/ml 
98 2 100 20ng/ml 
100 0 100 Blank 
2.1.8.3 Reagent Preparation 
An aqueous working solution of the RiboGreen reagent was prepared by diluting an 
aliquot of the concentrated dye solution stored in anhydrous dimethylsulfoxide 
(DMSO) into 1 x TE using sterilized polypropylene plasticware, 200-fold. 1 00).!1 of 
the working solution was loaded into each well and mixed with the RNA sample 
solution. The plate was foil-wrapped to protect it from light and incubated for 
approximately 5 minutes at room temperature. 
2.1.8.4 Fluorometry counting 
The plate was loaded manually on to a Wallac Victor 1420 Multilabel Counter 
(PerkinElmer Life Sciences, Boston, MA). The template layout within the 
Workstation software was configured to describe the group and type of each well on 
the virtual microplate. The machine measured the fluorescent emission of the 
samples at wavelength 535nm after excitation at 485nm. RNA concentrations were 
then calculated for each sample, compensating for the dilution factor of each diluted 
sample. 
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2.1.9 Real-time quantitative reverse transcriptase-polymerase chain 
reaction (QRT-PCR) 
One-step real-time QRT-PCR was performed using the LightCycler System (Roche 
Diagnostics, Mannheim, Germany) and the LightCycler RNA Master Hybridization 
Probes kit (Roche Diagnostics). A homologous mRNA standard for human 
CYP 11 B I was prepared from commercially available adrenal eDNA using specific 
primers, hBlsense (exon 8) and hBlantisense (exon 9) (MWG-Biotech, Ebersberg, 
Germany) (table 4, appendix 2), following the protocol previously published for rat 
standard (Ye et al 2003). The same primers were used in the RT-PCR reaction. 
CYP II B I sequence-specific hybridization probes were designed and synthesized by 
TIB Molbiol (Berlin, Germany). These consisted of a fluorescein probe and a 
LightCycler Red probe (see table 4, appendix 2). 
A master mix solution was prepared in a 1.5ml Eppendorf tube on ice by adding the 
reaction components in the order given below. The standard reaction required to 
perform a single colour detection takes place in a 20j..tl volume. The amount in the 
"volume" column was multiplied by the number of reactions to be cycled, plus one 
additional reaction. 
Component Volume Final cone. 
H20, PCR grade 6.2, .. tl 
Mn(0Ac)2 stock solution, 50mM l.3f.!l 3.25mM 
B1 Fluorescin (FL) 0.4f.!l 0.2f.!M 
B 1 LightCycler Red705 dye (LC) 0.4f.!l 0.2f.!M 
Primer HB 1 sense l..Of.!l 0.5f.!M 
Primer HB 1 antisense l..Of.!l 0.5f.!M 
LightCycler RNA Master Hybridization Probes, 2.7 x cone 7.5f.!l 1 X 
Total volume 19)..11 
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This was mixed gently and 19!J,l of master mix pipetted into a precooled LightCycler 
Capillary (Roche Diagnostics, Mannheim, Germany). l!J,g (at l!J,g/!J,l concentration) 
of the RNA template was added to the capillary. A control reaction was also 
constructed by replacing the RNA with nfl-hO (water blank). The capillaries 
containing the samples were placed in a holder and centrifuged at 700g for 5 seconds 
in a standard bench top centrifuge (Roche Diagnostics) before being placed in the 
rotor of the LightCycler Instrument (Roche Diagnostics). The cycle programs were 
performed in the order: 
1) Reverse Transcription (R T) 
2) Denaturation 
3) Amplification 
4) Cooling 
The cycle parameters were as follows: 
Cycle Program Data RT Denaturation Amplification Cooling 
Cycles 1 1 45 1 
Analysis Mode None None Quantification None 
Temperature Targets S1 S1 S1 S2 S3 S1 
Target Temperature (0 C) 61 95 95 58 72 40 
20 
Incubation time 30 s 1 s 15 s 13 s 30 s 
mm 
Temperature Transition Rate ("C/s) 20 20 20 20 2 20 
Secondary Target Temperature (0 C) 0 0 0 0 0 0 
Step Size (0 C) 0 0 0 0 0 0 
Step Delay (Cycles) 0 0 0 0 0 0 
Acquisition Mode None None None Single None None 
The annealing temperature of the CYP II BI probes was 58°C. Fluorescent data are 
collected during the single acquisition phase. lml aliquots of sequential tenfold 
mRNA standard dilutions were used to construct a standard curve. The sample copy 
128 
number was extrapolated from the standard curve at the base of the sample's crossing 
point. Each sample was measured three times and a water blank was included in 
each run. 
2.2 Screening of CYPJJBJ and CYPJJB2 genes for 
Polymorphisms in a Normotensive Population 
2.2.1 Study Subjects 
Normotensive subjects were selected from a WHO survey of cardiovascular risk 
factors (MONICA IV), which was a random sample of the north Glasgow patient 
lists of 30 general practitioners (Fraser et al1999). Study subjects completed a health 
questionnaire and attended for a structured medical examination to assess overall 
cardiovascular risk. Approval was obtained from the appropriate ethics committee. 
The study group consisted of 238 male and 201 female subjects aged 36 to 57. They 
were all normotensive with a fairly narrow blood pressure range within the group. 
These subjects had already been genotyped for, and were selected according to, the 
CYP 11B2 -344 CIT and intron Conversion (IC) variants. The IC alleles are 
designated wildtype (Wt) for the CYP 11B2 intron 2 sequence or conversion (Con) 
when the intron 2 sequence of CYP II B I has been introduced. 
2.2.2 Polymerase Chain Reaction amplification of CYPJJBJ 
Subjects were selected who were homozygous at both the -344 CIT and IC loci. 
Twenty-six subjects were selected for genetic analysis; TTIConCon (10), CCIWtWt 
(10) and TTIWtWt (6). The aim was to have ten subjects in each genotype group but 
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only six of the 439 subjects were TT/WtWt and none were CC/ConCon, which 
reflects the population frequencies of these haplotypes. 
Miss Donna M Wilkinson and Dr. E. Marie Freel were responsible for the 
amplification and sequencing of the CYP 11B2 gene within these subjects. The 
amplification of CYP IIB2 was split into 3 separate PCRs: (i) from the 5' region to 
intron 4 (~5Kb); (ii) exon 5 to exon 9 (~3Kb); (iii) the 3'UTR (~1.5Kb). The 
sequences of the primers (MWG-Biotech, Ebersberg, Germany) used for these 
reactions are listed in table 5, appendix 2. 
The CYP IIBI gene was amplified in two reactions encompassing: 
i) the 5' promoter region to ex on 9 ( ~ 7kb) 
ii) the 3'UTR (~750bp). 
HPLC-purified synthetic oligonucleotides were designed usmg the published 
sequences of CYPllBI and CYP11B2 (see appendix 1) and obtained from a 
commercial source (MWG-Biotech, Ebersberg, Germany). Primers were generally 
between 20-24 base pairs and had approximately 50% GC ratios (see table 5, 
appendix 2). The melting temperature (T m) of each of the pnmers was 
approximately 60°C. 
2.2.3 PCR Protocols 
Both PCRs were performed using the Expand High Fidelity PCR System (Roche 
Diagnostics, Mannheim, Germany). This system is composed of a unique enzyme 
mix with proof-reading capability to avoid the unwanted introduction of PCR-
generated mutations. 
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5 'UTR to Exon 9 PCR 
Two separate reaction master-mixes were prepared in sterile 1.5ml Eppendorf tubes 
on 1ce. 
MIX 1 
Component Volume/Tube (J.!l) Final Concentration 
Template DNA 
dATP (lOmM) 
dCTP (10mM) 
dGTP (lOmM) 
dTTP (10mM) 
Sense primer, 10).!M (B1 5'UTR) 
Antisense primer, 1 OJ.!M (B 1 Exon9 AS) 
nflhO 
Total 
MIX2 
1.0 
0.5 
0.5 
0.5 
0.5 
0.75 
0.75 
8.0 
12.5).!1 
Component Volume/Tube (J.!l) 
1 OX Buffer (15mM MgCh) 2.5 
Expand High Fidelity Enzyme mix 0.75 
nfl-hO 9.25 
Total 
(20-1 OOng/).!1) 
200J.!M 
200J.!M 
200J.!M 
200J.!M 
300J.!M 
300nM 
Final Concentration 
1 x (1.5mM MgCh) 
2.6 U/reaction 
A 'blank' reagent control was prepared which contained all the necessary components 
for PCR but replaced template DNA with nflhO. The total reaction volume was 25).!1. 
The reaction mixes were subsequently combined on ice in single 0.2ml thin-walled 
amplification tubes (ABgene, Surrey, UK) before being placed in a 96-well 
AlphaTM sample block powered by the PTC-225 DNA Engine Tetrad® Cycler with 
heated lid (MJ Research, Waltham, MA, USA). Amplification cycles and reaction 
conditions were as follows: 
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Amplification Protocol 
1. 94°C 2 minutes Denaturation 
2.94°C 15 seconds 
3.65°C 30 seconds Amplification (1 0 cycles) 
4. 68°C 8 minutes 
5.94°C 15 seconds 
6.65°C 30 seconds Amplification (20 cycles) 
7.68°C 8 minutes+ 5sec/cycle 
8. 72°C 7 minutes Extension 
3'UTRPCR 
Two separate reaction master-mixes were prepared on ice, as above, the only 
difference being the primers used (see table 5, appendix 2): 
-Sense primer (M6635) 
-Antisense primer (B13'UTR+500) 
Again the total reaction mix was 25!-ll. The reaction mixes were combined and kept 
on ice before being placed in an Alpha ™ sample unit of a DNA Engine Tetrad® 
Peltier thermal cycler. The amplification cycles and reaction conditions for this 
reaction were as follows: 
Amplification Protocol 
1. 94°C 2 minutes Denaturation 
2.94°C 15 seconds 
3. 55°C 30 seconds Amplification ( 1 0 cycles) 
4. 72°C 1 minutes 
5.94°C 15 seconds 
6.55°C 30 seconds Amplification (20 cycles) 
7. 72°C 1 minutes+ 5sec/cycle 
8. 72°C 7 minutes Extension 
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2.2.4 Determination of PCR products 
1g ofagarose (Invitrogen, Paisley, UK) was added to 1 x TAE buffer (lOOml), mixed 
and heated in a 650W microwave oven for 60 seconds. After 3 minutes of cooling, 
1 J..Ll of ethidium bromide (1 Omg/ml) was added and mixed in. The agarose was then 
poured into gel moulds with Teflon combs and allowed to set for 20 minutes before 
combs were removed. Gels were submerged in 1 x TAE buffer in standard 
electrophoresis tanks (Wide Minis Sub Cell Agarose gel apparatus) (Bio-Rad 
Laboratories, Hercules, CA, USA). 10J..Ll of PCR product was loaded with 5J..Ll of 
loading dye onto the agarose gel. The DNA molecular weight marker Hyperladder I 
(Bioline, London, UK) was also loaded in a separate well. The gel was then resolved 
at 95V for 40 minutes. DNA bands were visualized under a UV light. 
2.2.5 PCR clean-up 
Prior to sequencing, PCR products were cleaned to remove excess dNTPs and 
primers, using the enzymes Shrimp Alkaline Phosphatase (SAP) and Exonuclease I 
(Exoi). SAP removes the phosphate groups from excess dNTPs remaining from the 
PCR reaction; Exoi digests the single stranded PCR primers into dNTPs and their 
phosphate groups are removed by the SAP. 15 J..Ll of PCR product was transferred to 
sterile, thin walled PCR (0.2ml) tubes. 1J..Ll SAP (1 U/J..Ll) and 0.5J..Ll Exoi (20U/J..Ll) 
were added and the samples incubated at 37°C for 30 minutes followed by 10 
minutes at 80°C on the Tetrad® thermal cycler. 
2.2.6 Automated Cycle Sequencing 
Automated sequencing was performed using the ABI Big Dye Terminator v3.1 Cycle 
Sequencing Kit (PE Applied Biosystems). The technique is an adaptation of the 
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dideoxy termination method of sequencing. The primers used for sequencing the 
entire CYP 11 B 1 gene are shown in table 6, appendix 2. 
Sequencing reaction set-up 
Sequencing reactions were set up in 96-well plates containing the following: 
Template (50-lOOng) x ~-tl 
Sequencing Primer (3.2pmo11~-tl) 1.0~-tl 
Ready Reaction mix 0.5~-tl 
Sequencing Buffer 3.8~-tl 
Distilled Water (up to final vol20~-tl) x ~-tl 
After setting up gradients of template volumes it was found that for the 5' to exon 9 
(7kb) PCR, the optimal volume of template for sequencing was 2~-tl ( ~ 1 OOng) 
whereas only 1~-tl (~ SOng) was required for the 3' UTR (750bp). The sequencing 
reactions were then incubated on an Alpha ™ sample unit of a DNA Engine Tetrad® 
Peltier thermal cycler as follows: 
Reaction conditions 
1. 96°C 
2. 50°C 
3. 60°C 
45 seconds 
25 seconds 
4 minutes 
Sequencing reaction clean-up 
(These 3 steps are repeated 25 times.) 
Keeping the sequencing reactions m the 96-well PCR plates, a sodium 
acetate/ethanol precipitation was performed as follows. 
A solution of sodium acetate (NaOAc) in 95% ethanol (EtOH) in the ratio 2~-tl 3M 
NaOAc: 50~-tl 95% EtOH was prepared and 50~-tl of this solution added to each 
sequencing reaction. The plate was then sealed and inverted a few times to mix. The 
sample were incubated at room temperature for 15 minutes to precipitate the 
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extension products. The plate was centrifuged for 30 minutes at 6000 x g and the 
supernatant immediately discarded. The plate was centrifuged again whilst inverted 
on a paper towel for 30 seconds at 500 x g to remove all residual traces of 
supernatant. 150~-tl of 70% ethanol was added to each well and the plated sealed and 
inverted again before being centrifuged at 6000 x g for 10 minutes. Again the 
supernatant was removed by centrifuging the inverted plate. 
2.3 Genotyping of CYPJJBJ S'UTR Polymorphisms in a 
Hypertensive Population 
Two novel polymorphisms within the 5' UTR of CYPllBI (-1889 G/T and -1859 
A/G) were identified during sequencing of CYP II B locus within the normotensive 
cohort. The entire MRC BRitish Genetics of HyperTension (BRIGHT) study 
population (n = 4020) were genotyped for these polymorphisms to assess their 
frequency and phenotypic associations in a large hypertensive population. A random 
subgroup of 512 unrelated subjects were selected for further analysis of 
corticosteroid metabolites. 
2.3.1 Study Subjects 
The MRC BRitish Genetics of HyperTension (BRIGHT) study is a large multi centre 
investigation into the genetic basis of hypertension comprising > 2500 affected 
sibling pairs and trios. Hypertensive subjects were recruited from primary care with 
entry to the study being dependent on a pre-treatment blood pressure of 
> 145/95mmHg (mean of 3 readings) which lies within the top 5% of the population 
BP distribution in the UK. Subjects with a body mass index (BMI) >30 were 
excluded from the study. Full details of the recruitment strategy have been published 
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elsewhere (Caulfield et a/2003). The local ethics committees of the partner institutes 
granted ethical approval for the study and fully informed written consent from all of 
the participants was obtained. 
2.3.2 Nested PCR Protocol 
In order to increase specificity of the genotyping, a nested PCR (i.e. PCR 
amplification of the PCR product using specific primers) was performed. The initial 
reaction amplified a 2kb region specific to CYP 11 B I and the second reaction used 
this product as a template to specifically amplify the region of interest (~350bp). In 
both reactions, a heat-activated thermostart Taq polymerase (ABgene, Surrey, UK) 
was used. The sense and anti-sense primers (MWG-Biotech, Ebersberg, Germany) 
used in both reactions are outlined in table 7, appendix 2. 
PCR Amplification I 
Component Volume (J..ll) 
Buffer(10x) 250 
MgCb (25mM) 150 
dNTPs 500 
B15'UTR (sense) 100 
B1prom-260 (antisense) 100 
Thermostart Taq polymerase 25 
nfiH20 875 
Total 2000 
Final Cone 
1x 
1.5mM 
200J.!M each 
400nM 
400nM 
1.25U 
This was mixed and 20).!1 of master mix added to 5).!1 of BRIGHT template DNA 
(5ng/)..ll), which had been pre-plated onto 96-well PCR plates. The amplification 
reaction was performed on a 96-well Alpha TM sample block powered by the PTC-
225 DNA Engine Tetrad® Cycler with heated lid (MJ Research, Waltham, MA, 
USA). The cycling parameters were as follows: 
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1. 95 oc 15 minutes 
2. 95 oc 30 seconds 
3. 60 oc 30 seconds X 35 
4. 72 oc 3 minutes 
5. 72 oc 7 minutes 
Steps 2, 3 and 4 were repeated 35 times. The PCR products were then diluted 1:10 in 
nfl-hO and 1 )ll used as a template for a second PCR reaction. Again a mastermix 
was prepared on ice, this time in a 5ml universal tube: 
PCR Amplification 2 
Component 
Buffer (1 OX) 
MgC12 (25mM) 
dNTPs 
B15'7-32 (sense) 
Bl393-369 (antisense) 
Thermostart Taq polymerase 
nfH20 
Total 
Volume (Ill) 
250 
150 
500 
100 
100 
12.5 
1287.5 
2400 
Final Cone 
1x 
1.5mM 
200)-LM each 
400nM 
400nM 
0.625U 
This was mixed and 24).!1 of master mix pipetted into the wells of a fresh 96-well 
PCR plate. 1 )ll of a 1: 10 dilution of PCR amplification mix 1 was then added to 
serve as the template. The amplification conditions were as the same as before, 
except that the number of cycles was reduced to 20. 
PCR clean-up 
The PCR products were then cleaned using a NucleoFast® 96 PCR clean-up system. 
The NucleoFast® 96 PCR clean-up system is designed to retain PCR products on an 
ultrafiltration membrane under vacuum whilst contaminants ( dNTPs, primers and 
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salts) are filtered to waste. The PCR samples (25f.tl) were centrifuged briefly before 
being transferred to a NucleoFast® 96 PCR plate. The plate was placed on a vacuum 
manifold and a vacuum was applied until the samples had passed into the plate. To 
wash the samples, 1 OOf.tl of nfl-hO was dispensed into each well and the vacuum 
applied until the water had passed through the membrane. 50f.tl of nfH20 was 
pipetted directly on to the membrane of the NucleoFast® plate. The water was 
pipetted up and down several times before being transferred to a clean 96-well PCR 
plate and stored at 4°C until required. 
Determination of genotypes 
Each of the samples were sequenced by the automated sequencing method mentioned 
in section 1.2.6, using 6f.tl of NucleoFast PCR product and the primer B 1 prom-
1750(as) (table 6, appendix 2). 
2.3.3 Urinary Corticosteroid Metabolite Measurements 
Miss Mary C. Ingram performed the urinary corticosteroid measurements. 24-Hour 
urine samples were collected in plain plastic containers without preservative. 
Aliquots of urine were stored at -20°C. Excretion rates of steroid metabolites were 
measured by gas chromatography/mass spectrometry using the method of Shackleton 
(Shackleton 1993) with minor modifications. 
2.4 Analysis of CYPJJBJ 5'UTR polymorphisms in vitro 
2.4.1 Luciferase Reporter Gene System 
The effects of the 2 polymorphisms identified in the 5' region of CYP JJBJ were 
investigated using a reporter gene system. The CYPJJBJ 5' region (1937bp) was 
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cloned into the pGL3 Basic vector (Promega Corp.) by Mrs Christine Holloway. This 
vector lacks a eukaryotic promoter sequence and so expression of luciferase activity 
in cells transfected with this plasmid depends on insertion and proper orientation of a 
functional promoter upstream of the luciferase gene. This construct (pB 1-193 7) was 
used as a template for production of each of the variants to be studied. 
2.4.1.1 SDM 
The -1889 G/T and -1859 A/G polymorphisms were recreated by SDM following the 
method described in section 2.1.1. Specific sense and antisense mutagenic 
oligonucleotide primers were designed individually according to the desired 
mutations (MWG-Biotech, Ebersberg, Germany) (table 8, appendix 2). These were 
designed against the template sequence (appendix 1) to produce the alternative 
alleles for each polymorphism. Once these had been created, one construct was used 
as a template for the alternative pair of primers so that all 4 combinations of the 
alleles were created. The entire insert in each case was sequenced to confirm the 
presence of the desired mutations and that no unwanted base changes had been 
incorporated. 
2.4.1.2 Y-1 cell maintenance 
To analyze the CYP II BI 5' UTR reporter gene expression, cells were required that 
possess all the necessary transcription factors to bind the CYP II B I 5'UTR or 
regulatory region and transcribe the luciferase gene. Therefore an adrenal cell line 
was used. 
Y-1 mouse adrenal cells (American Type Culture Collection) were cultured at 37°C 
in 5% C02 in F-12K Nutrient Mixture, Kaighn's Modification (GIBCO) 
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supplemented with 15% horse serum (GIBCO), 2.5% fetal bovine serum (Sigma-
Aldrich) and 1% penicillin/streptomycin (5000U/ml) (GIBCO). The subculturing and 
handling procedures were as reported for the JEG-3 cells in sections 2.1.4.2 and 
2.1.4.3. 
2.4.1.3 Transfection Protocol 
Cells were plated at 3.5x105 cells/well in 6-well plates and incubated for 24 hours 
prior to transfection. Transfection was carried out using 6f.ll Fugene (Roche 
Diagnostics, Mannheim, Germany) and 1 f.!g of wildtype or mutant plasmid in 
MEM/Eagle's (2ml) for 42 hours. The pSV-~-Galactosidase (pSV-~-Gal) control 
vector (0.04f.lg) (Promega Corp.) was added as a marker of transfection efficiency. 
Cells transfected with the pGL3 basic vector not containing any insert and cells not 
exposed to any transfection mix were used as negative controls. 
2.4.1.4 Agonist stimulation 
Following transfection for 42 hours, the transfection medium was removed and 
replaced with 2ml of growth medium containing agonist: either ACTH (1 f.!M) or 
Forskolin (lOf.!M) (Sigma-Aldrich). Cells were treated with agonist for 6 hours. 
The cells were then lysed and luciferase activity measured as in section 1.1.5.2 
(Promega Corp.). Protein (PIERCE) and ~-galactosidase activity (Promega Corp.) 
measurements were used to determine transfection efficiency and cell number and 
the luciferase results were corrected accordingly. 
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2.4.2 Measurement oftransfection efficiency 
Preparation of cell lysates 
Cells lysates were prepared as in section 2.1.5.1 using 250 ).d ofRLB. 
Measurement of protein levels 
Protein levels were determined using the BCA Protein Assay (PIERCE) following 
the protocol described in section 2.1.5.3. 
2.4.2.1 Measurement of B-Galactosidase Activity 
~-Galactosidase activity was measured using the Tropix® Galacto-Light Plus™ 
chemiluminescent reporter gene assay system (PE Applied Biosystems). ~­
Galactosidase activity was determined in cell extracts transfected with the pSV -~­
Gal reporter gene. A lyophilized ~-galactosidase standard (Sigma-Aldrich) was 
reconstituted to 1mg/ml in 0.1M sodium phosphate (pH 7.0) containing 0.1% BSA 
(Sigma-Aldrich). This was diluted to a 1ng/f.ll stock solution in lysis solution 
(1 OOmM potassium phosphate, 0.2% Triton X-1 00) containing 0.1% BSA with a pH 
of 7.8. Standards (20!J.l) in the range 4 to 20ng as well as a 'blank' consisting of only 
lysis solution, were plated in duplicate alongside each of the samples (20!J.l) on a 
white 96-well plate. The chemiluminescent Galacton-Plus® substrate (100 x 
concentrate) was diluted 1:100 with Reaction Buffer Diluent and 70!J.l of the 
resulting reaction buffer added to each well. Samples were then mixed and 
incubated at room temperature for 1 hour. During this time the substrate Galactan-
Plus (a 1,2-Dioxetane) becomes cleaved by the enzymatic activity of the ~­
galactosidase contained in the sample, as the conditions (pH 7 .8) are optimal for 
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bacterial p-galactosidase. The reactions were terminated by the addition of 1 OOJ..Ll 
Accelerator II, which increases the pH to > 12, triggering light emission. Light 
emission was measured immediately at 475nm using a Wallac Victor 1420 
Multilabel Counter (PerkinElmer Life Sciences, Boston, MA, USA). 
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CHAPTER3 
Functional Effects of Mutations within the 
llB-Hydroxylase (CYPJJBJ) gene 
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3.1 Introduction 
Recent studies showing that up to 15% of unselected patients with hypertension have 
a raised aldosterone to renin ratio suggest that altered regulation of aldosterone 
production may be a common factor in essential hypertension (Fardella et al 2000; 
Gordon et al 1994b; Lim et al 1999b; Loh et al 2000; Rayner et al 2000). Two 
common variants (-344 CIT and intron conversion) in the aldosterone synthase 
( CYP II B2) gene have previously been associated not only with aldosterone levels 
and hypertension but also with markers indicating an impaired 11 P-hydroxylase 
efficiency, the enzyme product of the CYP JJBI gene (see section 1.16). However, 
in vitro studies suggest that the -344 CIT has no effect on gene transcription, 
suggesting that it is not the functional variant and may therefore be in linkage 
disequilibrium with an as yet unidentified functional variant, possibly in CYP II BI 
(Bassett et al 2002). 
3.2 Aims 
The aims of this study were to identify polymorphisms in CYP II B I that associate 
with hypertension and a raised ARR and therefore might contribute to the genetic 
component of these phenotypes. The functional significance of any variants 
identified was then investigated in vitro. 
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3.3 Methods 
3.3.1 Subjects 
Four groups of subjects, normotensive controls, unselected essential hypertensive 
subjects or hypertensive subjects with either a high (2: 750) or low ARR (:S 200) were 
screened for mutations. Each group comprised 40 subjects. The normotensive 
controls were selected randomly from the Scottish Adult Twin Study (Inglis et al 
1999). This study contained data from 146 pairs of adult twins, aged 31-83 years. 
Only one twin from each pair was selected for mutation detection. The selected 
controls had no previous history of hypertension; in each subject in this group, blood 
pressure was < 140/90 mmHg at a screening visit. The unselected essential 
hypertensive subjects were chosen at random from a total of 138 patients recruited 
from the Blood Pressure Clinic at the Western Infirmary, Glasgow (Davies et al 
1999). All were aged <64 years and had high blood pressure confirmed by 3 
independent measurements of > 160/90 before initiation of treatment. The low and 
high ARR subjects were randomly selected from a total of 375 patients referred to 
the Tayside Hypertension Clinic at Ninewells Hospital, Dundee (Lim et al 2002b ). 
They were aged 18-80 years and all had blood pressures > 160/90 mmHg, confirmed 
over a period of at least 3 months before referral. Both high and low ARR groups 
had mean aldosterone levels within the normal range with no significant difference 
between the groups. Therefore, renin levels largely determined the differences in 
ARR (see table 3.1). 
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3.3.2 Identification of Mutations 
The coding regions of CYP llBI were initially screened by SSCP (single-stranded 
conformation polymorphism), and the presence of any mutations confirmed by direct 
sequencing by Mrs Christine Holloway and Dr Angela Fisher. The effect of each of 
these on enzyme activity was determined in vitro. 
3.3.3 Investigation of enzyme activity in vitro 
Each of the mutants was prepared by site-directed mutagenesis using the Quick-
Change site-directed mutagenesis kit (Stratagene Ltd, Cambridge, UK) and the 
pCMV4-Bl plasmid as a template (section 2.1.1). Large scale purified preparations 
of the pCMV 4-B 1 wildtype, each of the mutants and the pGL3 control plasmid were 
made, analysed by restriction digestion and sequenced (sections 2.1.1, 2.1.2, 2.2.6). 
Transient transfection was carried in JEG-3 cells (section 1.1.4). Cells were 
incubated with or without substrate (S or DOC) at a range of concentrations for 24 
hours. The incubation medium was then removed for steroid analysis by HPLC. 
Cells lysates were prepared for protein and luciferase measurements to determine cell 
number and transfection efficiency and steroid results were corrected appropriately 
(section 2.1.5). RNA was extracted from cells transfected with the wildtype gene or 
each of the mutant constructs for quantitative RT-PCR to compare CYP 11 Bl RNA 
transcript levels (sections 2.1.6 to 2.1.8). 
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3.3.4 SFJ (-344 CIT) genotyping 
The subjects were already genotyped for the SF1 (-344 CIT) polymorphism by PCR 
and Haeiii restriction digestion following the conditions previously described 
(Davies et all999). 
3.3.5 Statistical Analysis 
Although the sample sizes for the transfection experiments were relatively small (n = 
6) they all passed the Kolmogrov-Smimov normality test indicating a Gaussian 
distribution and that parametric testing was suitable. Statistical comparison of mean 
steroid levels over the range of substrate concentrations was accomplished by 2-way 
analysis of variance (ANOV A). Comparison of fold differences compared to 
wildtype for each of the mutants at a single substrate concentration was 
accomplished usmg a 2-sample t test. The mRNA expression rates were not 
normally distributed even when log-transformed and so were analyzed by the Mann-
Whitney nonparametric test. For all analyses, p < 0.05 was required for statistical 
significance. 
3.3. 6 Ethics 
The local ethics review commitees approved the patients' recruitment and subsequent 
genetic studies. 
3.3. 7 Modelling 
The protein structure of 11 ~-hydroxylase (P45011 p) has yet to be determined and so, 
to give some idea of where the mutant amino acids lie in relation to important 
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functional regions of the protein, the best 3D model possible was produced using the 
information currently available. 
The P450 superfamily proteins all have a similar folded structure (Nelson and 
Strobel 1989). This enables tentative modelling of unknown proteins on the basis of 
those crystal structures that have been determined. Krone et al confirmed that 
P450u 13 follows the general topography of the P450 superfamily, and out of the 
known crystal structures, mammalian CYP2C5 had the highest structural similarity 
(Krone et al2005). Therefore, the structure of CYP2C5 (PDB accession code 1DT6) 
was used as a template for the 3D model ofP450lll3· 
The amino acid sequences of P450u 13 (CYP JJBJ) and 21-hydroxylase (CYP2C5) 
were aligned using the MultiAlin multiple sequence alignment (Corpet 1988). 
Human 11~-hydroxylase contains 503 amino acids and mammalian (rabbit) 21-
hydroxylase contains 473 amino acids. P450 1113 has 24 residues at its N-terminus that 
constitute the mitochondrial targeting sequence. These are not present in 21-
hydroxylase as it is a microsomal P450; the alignment begins after this targeting 
sequence. 
The structure of CYP2C5 was imported into QUANTA (Accelyrs, San Diego, CA, 
USA) and according to the sequence alignment, amino acid residues were exchanged 
in the template. Refinement and energy minimization were carried out by 
REFMAC5 (Murshudov et al 1997) and the model validated by PROCHECK 
(Laskowski et al1993). 
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3.4 Results 
3.4.1 Subjects 
Both the low and high ARR groups had mean aldosterone levels within the normal 
range. The mean aldosterone level was 406 ± 54.29pmol/l for the low ARR (~ 200) 
group and 503 ± 40.26pmol/l for the high ARR (2: 750) group (see table 3.1). 
Therefore, differences in their plasma renin levels accounted for the differences in 
ARR. The renin level for the low ARR group was 4.81 ± 0.7 compared to 0.23 ± 
0.03 for the high ARR group. 
Aldo (pmol/1) PRA (ngAl/ml/hr) ARR 
Mean± SEM Mean± SEM Mean± SEM 
ARR~200 406 ± 54.29 4.81 ± 0.7 124 ± 8.14 
ARR2: 750 503 ± 40.26 0.23 ± 0.03 4089 ± 831.54 
Table 3.1. Mean plasma aldosterone (Aldo) levels and renin activity (PRA) for 
the hypertensive groups stratified by ARR 
3.4.2 Mutation Detection 
No mutations were identified that differed in frequency between the four groups of 
subjects. However, eight missense mutations were identified in CYP 11 B I, which 
alter the encoded amino acid. These were located in exons 1, 2 and 3: R43Q, L83S, 
H125R, P135S, Fl39L, L158P, L186V and T196A. Mutant R43Q results in the 
replacement of the 11 ~-hydroxylase-specific residue with the corresponding 
aldosterone synthase-specific residue. Each of the mutations were identified in 
individual subjects apart from L158P, which was identified in two subjects. Mutants 
P135S, F139L and T196A were identified in the same subject (see table 3.2). 
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Ex on Mutant Base change Amino acid change Group 
1 
2 
3 
3 
3 
3 
3 
3 
R43Q CGG-CAG Arginine - Glutamine ARR> 750 
L83S TTG-TCG Leucine - Serine Unselected Hypertensive 
H125R CAC-CGC Histidine - Arginine Unselected Hypertensive 
P135S* CCT-TCT Proline- Serine Control 
F139L* TTC- CTC Phenylalanine - Leucine Control 
L158P CTC- CCC Leucine - Proline ARR < 200/ Control 
L186V CTG-GTG Leucine - Valine Unselected Hypertensive 
T196A* ACC- GCC Threonine - Alanine Control 
Table 3.2 CYPJJBJ Missense Mutations 
All mutations were identified in individual subjects, apart from L158P, which was 
identified in 2 subjects. 
* All of these mutants were identified within the same subject 
3.4.3 Restriction Digestion of Plasmids 
Plasmid DNA was digested using the restriction enzyme BamHI to assess quality and 
the presence of an insert of appropriate size. This enzyme linearizes CYP llBI 
eDNA by hydrolysing it at a single site to produce a fragment of 6.3kb. BamHI 
digests are shown in figure 3.1. 
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6,000 bp ----. 
4,000 bp ----. 
1,000 bp ----. 
L Wt R43Q L83S Hl25R Pl35S F139L L158P L186V Tl96A 
Figure 3.1 BamHI digests ofpCMV4-Bl wild-type and mutant plasmids 
Analysed on a 1% agarose gel stained with ethidium bromide. BamBI linearises 
CYP liB I eDNA to generate a 6.3kb band. A single band of the correct size 
confirms the presence of the CYP 11 B I eDNA insert. Lane L contains 5 f!l 
HyperLadder I (Bioline, London, UK). 
3.4.4 Confirmation of Mutations 
The presence of each of the mutants (see table 3.2) was verified by sequencing using 
the automated sequencing method described in section 2.2.6. The entire insert was 
sequenced to rule out the incorporation of any unwanted mutations. Sequence data 
are shown in figures 3.2a to h. Sequencing revealed that the construct containing 
the L83S mutant had an extra unwanted mutation (see figure 3.2b) but, as this did 
not change the encoded amino acid, the construct was deemed suitable for use. 
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l.A) 
R43Q 
Wt 
l.C) 
H125R 
Wt 
ATGC C CA GCGTCCA 
AT CCCC A C T CC A 
AT ecce C T CC A 
GTGGGC G CAAATG1 
T C C AAA T 1 
GTGGGCACAAATG1 
\ 
T C A C AAA T 1 
., 
I. 
l.B) 'ACGA T T C GGGAGGA! 
' A C ATT C A A 
L83S 
'ACGACTTGGGAGGA! 
' A C A CTT A A 
Wt 
;AATGGG T CTGAATC 
l.D) AA T T CT AA T 
P135S 
;AATGGGCCTGAATC 
AA T CC T AA T 
Wt 
Figure 3.2 A to D. Sequences confirming presence of mutations R43Q, L83S, 
H125R and P135S respectively compared to wildtype pCMV 4-Bl. 
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l.E) 
F139L 
Wt 
l.G) 
L186V 
Wt 
"GGCGC C TCAACCG 
C CC T C AA CC 
TGACC GTGGACG 
T A CC T A C 
TGACCCTGGACG 
T A CCC T A C 
l.F) 
L158P 
Wt 
GTTCC C CCCGAT 
TT CCCCCC A T 
'I \ 
GTTCCTCCCGAT 
TT CC T CCC A T 
l.H) C A C T A C G C C A T A G A A 
C A C T A C CC AT A AA 
T196A 
C A CT A C A CC AT A AA 
Wt 
Figure 3.2 E to H. Sequences confirming presence of mutations Fl39L, L158P, 
L186V and T196A respectively compared to wildtype pCMV4-Bl. 
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3.4.5 SFJ (-344 CIT) genotyping 
The frequency of the -344 alleles was determined for each of the 4 populations, as 
shown in table 3.3. There was an overall 6% failure rate in the genotyping. The 
distribution of genotypes was as expected from previous studies (Davies et al1999). 
Group 
Normals 
Unselected Hypertensives 
ARR>750 
ARR<200 
cc 
6 (0.18) 
8 (0.21) 
6(0.15) 
8 (0.20) 
TC 
19 (0.57) 
23 (0.60) 
22 (0.55) 
17 (0.43) 
TT 
8 (0.24) 
7(0.18) 
12 (0.30) 
15 (0.38) 
Table 3.3 Genotype distribution for SFl (-344 CIT) site 
%C 
47% 
52% 
43% 
41% 
%T 
53% 
48% 
57% 
59% 
Chi-squared analysis revealed no significant difference in gene frequencies between 
groups (X2 = 4.59, degrees of freedom= 6, P = 0.59). 
3.4. 6 Steroid Conversions 
Graphs of the steroid products, cortisol (F) and corticosterone (B), against a range of 
substrate concentrations, 11-deoxycortisol (S) and 11-deoxycorticosterone (DOC) 
respectively, for the wildtype 11 ~-hydroxylase and with each of the mutants are 
shown in figures 3.3 to 3.10. All steroid results were corrected for transfection 
efficiency values. These were calculated by converting protein levels and luciferase 
activity of cell lysates to relative light units (RLU) luciferase per unit of protein. 
These values were then converted to fold differences of the mean wildtype control 
transfection. A comparison of the fold difference to wildtype was made for each of 
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the mutants at the lowest substrate concentration to give a rough idea of the potency 
ofthe effects. 
3 .4.6.1 Effects of Mutants over a range of substrate concentrations 
The potency of the effects of the 8 mutations on 11 ~-hydroxylation of both substrates 
over a range of concentrations fell roughly into 3 groups (see figures 3.3 to 3.10). 
Severe inactivation with regard to both substrates 
Mutants L158P and L83S both severely reduced 11~-hydroxylase conversion ofboth 
substrates (S and DOC) at all concentrations tested (figures 3.3a and b and 3.4a 
and b). Their activities vary between absolutely no conversion at the lowest 
substrate concentration to a very small level of product observed (approximately 1 to 
3% that ofthe wildtype) at the highest concentration ofS and DOC tested. 
Partial inactivation; similar response for both substrates 
Mutant Pl35S greatly reduced the conversion of substrate S with product formation 
between approximately 2 to 10% that of the wild type over the range of substrate 
concentrations (figure 3.5a). The effect on DOC conversion was less severe with 
product levels that varied between 10 to 40% that of the wild type with increasing 
substrate concentration (figure 3.5b). The F139L (figure 3.6a and b), R43Q (figure 
3.7a and b) and T196A (figure 3.8a and b), mutants resulted in product levels that 
were approximately 30% to 50% of the appropriate wildtype product with little 
variation in the potency of the effect over the range of substrate concentrations. 
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Markedly different effects for the two substrates 
The H125R mutant had a substrate-specific effect, reducing conversion of S to F 
when compared to the wildtype (figure 3.9a) but not conversion of DOC to B 
(figure 3.9b). The extent ofthe reduction in the conversion ofS to F was maintained 
over the range of concentrations tested. The mutant L186V also had a substrate 
specific effect; it increased the conversion of S to F over the range of concentrations 
tested compared to the wildtype (figure 3.10a) but did not significantly affect the 
conversion of DOC to B (figure 3.10b ). The magnitude of the increase in product 
formation was maintained over the various concentrations of S. There appeared to 
be an increased product formation compared to wildtype at the lowest concentrations 
of DOC tested. However, over the range of concentrations tested this was not 
significant. 
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A 
B 
Figure 3.3 Effects of mutant L158P (Leucine-Proline) 
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Effects of mutant Ll58P on the conversion of S to F (A) and DOC to B (B) 
compared to wild type pCMV4-Bl. Results are expressed as a fold difference ofthe 
Wildtype product at 0.1~-tM substrate Values are the mean± SEM (n = 6). A two-way 
ANOV A was used to compare the wildtype and mutant over the range of 
concentrations studied; the resulting p values are shown. 
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Figure 3.4 Effects of mutant L83S (Leucine-Serine) 
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Effects ofmutant L83S on the conversion ofS to F (A) and DOC to B (B) compared 
to wild type pCMV 4-B 1. Results are expressed as a fold difference of the Wildtype 
product at 0.1 )lM substrate. Values are the mean ± SEM (n = 6). A two-way 
ANOV A was used to compare the wildtype and mutant over the range of 
concentrations studied; the resulting p values are shown. 
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A 
B 
Figure 3.5 Effects of mutant P135S (Proline-Serine) 
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Effects of mutant Pl35S on the conversion of S to F (A) and DOC to B (B) 
compared to wild type pCMV 4-B 1. Results are expressed as a fold difference of the 
Wildtype product at O.lf.lM substrate. Values are the mean± SEM (n = 6). A two-
way ANOV A was used to compare the wildtype and mutant over the range of 
concentrations studied; the resulting p values are shown. 
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Figure 3.6 Effects of mutant F139L (Phenylalanine-Leucine) 
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Effects of mutant F139L on the conversion of S to F (A) and DOC to B (B) 
compared to wild type pCMV4-B l. Results are expressed as a fold difference of the 
Wildtype product at 0. 1 ~M substrate. Values are the mean ± SEM (n = 6). A two-
way ANOV A was used to compare the wildtype and mutant over the range of 
concentrations studied; the resulting p values are shown. 
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Figure 3.7 Effects of mutant R43Q (Arginine-Glutamine) 
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Effects of mutant R43Q on the conversion of S to F (A) and DOC to B (B) compared 
to wild type pCMV 4-B 1. Results are expressed as a fold difference of the Wildtype 
product at O.lJ.LM substrate. Values are the mean ± SEM (n = 6). A two-way 
ANOV A was used to compare the wildtype and mutant over the range of 
concentrations studied; the resulting p values are shown. 
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Figure 3.8 Effects of mutant T196A (Threonine-Alanine) 
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Effects of mutant Tl96A on the conversion of S to F (A) and DOC to B (B) 
compared to wild type pCMV4-Bl. Results are expressed as a fold difference of the 
Wildtype product at O.lJ.!M substrate. Values are the mean± SEM (n = 6). A two-
way ANOVA was used to compare the wildtype and mutant over the range of 
concentrations studied; the resulting p values are shown. 
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Figure 3.9 Effects of mutant H125R (Histidine-Arginine) 
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Effects of mutant H125R on the conversion of S to F (A) and DOC to B (B) 
compared to wild type pCMV4-Bl. Results are expressed as a fold difference ofthe 
Wildtype product at 0.1 J.!M substrate. Values are the mean ± SEM (n = 6). A two-
way ANOV A was used to compare the wildtype and mutant over the range of 
concentrations studied; the resulting p values are shown. 
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Figure 3.10 Effects of mutant L186V (Leucine-Valine) 
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Effects of mutant H125R on the conversion of S to F (A) and DOC to B (B) 
compared to wild type pCMV4-Bl. Results are expressed as a fold difference of the 
Wildtype product at O.l)lM substrate. Values are the mean± SEM (n = 6). A two-
way ANOV A was used to compare the wildtype and mutant over the range of 
concentrations studied; the resulting p values are shown. 
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3.4.6.2 Comparison of fold differences in product formation 
Comparing the fold differences of each of the mutants to the wildtype at a single 
concentration allows a rough comparison of the severity of each of the mutants. This 
was done at the lowest concentration of substrate (O.lf..LM) which should maximise 
the distinction between differences in affinity (see table 3.4). Using this method, the 
potency of the effects of the 8 mutations on 11 ~-hydroxylation fell roughly into 4 
groups: 
Severe inactivation with regard to both substrates 
The p values indicate that the mutants L83S, L158P and P135S have the most 
detrimental effects, with very poor conversion from S to F observed for L83S and 
P135S and no conversion of DOC. There was no conversion of either substrate for 
L158P. 
Partial inactivation; similar response for both substrates 
The mutants R43Q and F139L and T196A have less severe effects on enzyme 
function, resulting in partial reduction in conversion of both S and DOC. 
Markedly different effects for the two substrates 
The mutant H125R has a substrate specific effect with a significant inhibition of the 
conversion of S to F but not of DOC to B. 
Increased activity with regard to both substrates 
Mutant L 186V has a unique effect, resulting in an increase in the conversion of both 
substrates. 
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Mean F Production Mean B Production 
Mutant Fold diff p value Fold diff p value 
to Wt±SEM to Wt± SEM 
L158P no activity 0.000 no activity 0.000 
L83S 0.02 ± 0.01 0.000 no activity 0.000 
Pl35S 0.06 ± 0.01 0.001 no activity 0.000 
R43Q 0.53 ± 0.05 0.009 0.07 ± 0.01 0.002 
Fl39L 0.27 ± 0.03 0.002 0.47 ± 0.04 0.003 
T196A 0.35 ± 0.13 0.042 0.43 ± 0.06 0.018 
H125R 0.63 ± 0.04 0.022 0.6 ± 0.06 NS 
L186V 5.59 ± 2.09 0.002 3.07 ± 0.35 0.007 
Table 3.4. Mean product levels as a fold difference of the wildtype product ± 
SEM for each of the mutants. Results for both the conversion of S to F and DOC 
to B are shown at 0.1~-tM substrate. The p values represent a comparison between the 
mutant and wildtype product levels using an unpaired 2-Sample t test. 
NS = non-significant 
In most cases, these observations are in agreement with the effects observed over the 
range of substrate concentrations. However, when comparing the range of 
concentrations using ANOVA, the mutant L186V only had a significant effect on the 
conversion of S to F and not on the conversion of DOC to B. In contrast, when 
comparisons are made at only the 0.1~-tM substrate concentration, there was a 
significant increase in the conversion of both substrates. 
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3.4. 7 QRT-PCR 
Real time QRT-PCR shows that the levels of CYP liB I transcript do not differ 
significantly between the wildtype plasmid and the mutant constructs studied 
(figures 3.11 and 3.12). Thus, the expression levels within the cells are likely to be 
similar and any observed changes in 11~-hydroxylase activity can be attributed to 
structural changes in the enzyme and not to changes in gene expression rate and 
subsequent protein production. 
3.4.8 Modelling 
A putative 3D Model of 11 ~-hydroxylase was generated using homology modelling 
techniques (see figure 3.13). From the model the mutant residues can be assigned to 
particular regions of the molecule: 
Residue 
43 
83 
Putative 3D location 
Rope/loop flanking helix 
(exterior of molecule) 
Roop/loop flanking helix B 
Effect on 11~-hydroxylation 
A Partial reduction 
Severe reduction 
125 Roop/loop between helices Band C Substrate specific (t S to F) 
135 Helix C Partial reduction 
139 Helix C Partial reduction 
158 Start ofhelix D Severe reduction 
186 Start of E' helix Substrate specific ( i S to F) 
196 Start of helix E Partial reduction 
Table 3.5 Putative 3D locations of each of the mutant residues 
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Figure 3.11 QRT -PCR Amplification Curve 
Amplification curve displaying fluorescence values versus cycle number. Serial 10-
fold dilutions of CYP llBI mRNA standard are shown in black. Sample copy 
number for the wildtype and each of the mutants was extrapolated from the standard 
curve on the base of the samples crossing point. This is a representative curve that 
was repeated 3 times. A negative control (water blank) and also RNA extracted from 
untransfected cells was included in each run. 
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Figure 3.12 CYPJJBJ mRNA levels 
Levels of CYP 11 B I mRNA from cells transfected with wild type pCMV 4-B 1 and 
each of the mutant constructs. Values are expressed as mean mRNA copy 
number/mg total RNA ± SD from 3 independent experiments. Each of the mutants' 
mRNA copy number was compared to the wildtype using the nonparametric Mann 
Whitney test. 
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Figure 3.13 Homology Model of 11J3-Hydroxylase 
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3-Dimensional model of the structure of human 11 J3-hydroxylase showing the 
positions of each of the mutant residues in relation to the active site containing the 
haem. 
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3.5 Discussion 
These experiments investigated the presence of genetic polymorphisms in the 
CYP II B I gene. In particular they were concerned with whether such variation was 
associated with raised blood pressure and ARR and whether it affected the 
CYP 11 BI-dependent activity, 11 ~-hydroxylation. Several novel mutations were 
identified in the four groups of subjects, normotensive controls, unselected essential 
hypertensives or hypertensive subjects with either a high (2:: 750) or low ARR (:S 
200) that markedly change enzyme efficiency. However, their frequency was similar 
in normotensive and hypertensive groups and did not markedly differ when the low 
and high ARR groups were compared. It has previously been reported that the T 
variant of the -344 CIT polymorphism of the adjacent CYP II B2 gene is found in 
higher frequency in hypertensive subjects, particularly in those with a raised ARR 
(Brand et al 1998; Davies et all999; Lim et al 2002b ). This study was not powered 
to look for such an association; the study subjects were chosen on the basis of 
phenotype not genotype. The frequency of the T allele was very similar within the 
four groups (see table 3.3). It is therefore more likely that patients selected on the 
basis of genotype associated with a raised ARR might identify specific mutations 
that are linked to the development of this type of hypertension. In addition, this 
study examined only the coding region of CYP II B I and so it is possible that other 
mutations exist in the untranslated regions, either 5' or 3' of the gene, or located at 
exonlintron boundaries that may alter splicing, which associate with a raised ARR. 
These regions therefore require further investigation (see Chapter 4). 
Although the variants identified did not appear to associate with hypertension or 
ARR, they had marked and varied effects on the activity of the resulting enzyme. It 
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could be argued that these changes in enzyme function are due to altered levels of 
expression of the modified proteins. However real time quantitative RT-PCR (QRT-
PCR) was used to measure and compare CYP llBI transcript levels between the 
mutants and the wildtype. No significant differences were detected (figures 3.11 and 
3.12). It would have been preferable to perform Western Blotting to demonstrate 
that protein expression was similar but, at the time of this study, a suitable antibody 
for 11 ~-hydroxylase was not readily available. An alternative approach would have 
been to use a construct containing a tag ( eg. histidine tag) which would generate a 
labelled gene product. A commercially-available antibody raised against this label 
could then be used for Western Blotting. However the construct used in the present 
study was in a form that would have entailed a lot of extra cloning work and it was 
felt that the sensitivity of the RT-PCR approach made it the preferred method. 
Although the QRT-PCR technique does not give any indication of changes in 
expression levels, it confirms that the transcription of the mutant and wildtype 
cDNAs are similar, supporting the proposal that the observed changes in 11 ~­
hydroxylase substrate conversion are due to structural changes in the protein. The 
effects of all the mutations will therefore be determined by the difference in the 
physical properties of the amino acids exchanged as well as the locus of the mutant 
residue within the protein. 
The mutants L158P and L83S both severely reduced 11~-hydroxylase conversion of 
both substrates S and DOC over a range of concentrations (figures 3.3 and 3.4). 
Both mutations change the polarity of the encoded amino acid. The L158P mutant 
would also change the structure of the protein chain; the large cyclic proline residue 
would introduce a bend not present in the wildtype L158 form. A similar effect on 
the protein conformation would result from the P135S mutation, which agam 
172 
decreased conversion of both substrates, although the effect on S conversiOn was 
much more pronounced than the effect on DOC conversion (figure 3.5). The mutant 
T196A also results in a change of polarity of the encoded amino acid. It has a more 
subtle effect than the previous mutants, resulting in product levels that are 30 to 40% 
compared to wildtype (figure 3.8). Fl39L and R43Q have a similar effect, reducing 
the level of product formation to between approximately 30 to 50% compared to the 
wildtype enzyme (figures 3.6 and 3.7). F139L is a fairly conservative change in 
amino acid, but R43Q might result in an altered charge. Arginine (R) often forms 
salt bridges through hydrogen bonding with negatively charged amino acids that are 
important for protein stability Disruption of this stability may account for the 
decreased enzyme function. The H125R mutation resulted in substrate-specific 
alterations in enzyme function, whereby conversion of S to F was decreased 
compared to the wildtype but DOC to B conversion was unaffected (figure 3.9). 
This suggests that a histidine at this position is important for the interaction with S. 
The mutant L186V had a unique effect that was also substrate-specific, increasing 
conversion of S to F but not that of DOC to B (figure 3.10). This is a fairly 
conservative amino acid change and how it alters the protein environment to favour 
increased S conversion is unclear. 
In addition to the different physical properties of the amino acid at a given locus, the 
proximity of the locus to an important functional site will also alter enzyme 
efficiency and substrate specificity. More detailed understanding of the structure-
function relationships of P45011 f3 awaits elucidation of its 3-dimensional (3D) 
structure but some preliminary deductions can be made from the known structures of 
other cytochrome P450 enzymes. Studies of bacterial homologues suggest that P450 
enzymes consist of a number ofhelices (A-L) (Ravichandran et all993) (see section 
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1.14). The haem in cytochrome P-450 enzymes is located between helices I and L. 
The P450 superfamily proteins have a conserved structural core (Presnell sr 1989) 
and so it is possible to use known crystalline P450 structures as templates for others. 
Homology modelling ofP450ll~ suggests that the I helix (residues 301-331) contains 
many hydrophobic amino acids and is the putative active site (Be1kina et al 2001). 
None of the mutations investigated in this study are located within this putative 
active site but they all clearly alter enzyme activity. It is possible that they disrupt 
one of the six proposed substrate recognition sites (SRS 1-6) or that they alter the 
flexibility of the protein, affecting substrate access to the catalytic domain (Gotoh 
1992). 
Generating a 3D model of 11 ~-hydroxylase using the structure of the mammalian 
microsomal protein 21-hydroxylase (CYP2C5) as a template (Williams et al 2000) 
enabled these mutant residues to be assigned to particular regions of the molecule 
(see figure 3.13 and table 3.5). From these putative 3D locations and results from 
previous structure-function studies, it is possible to speculate on the reason for some 
of these alterations in enzyme function. 
Mutant R43Q 
Residue Arg43 is located near theN terminus of the protein, which may be involved 
in protein-membrane interaction (Belkina et al 2001). Interestingly, a homozygous 
mutation at the adjacent locus (Pro42Ser) results in the non-classical form of 11 ~­
hydroxylase deficiency with only partially reduced activity (see section 1.15.2.3) 
(Joehrer et al 1997). It seems likely that, if present as a homozygote, the mutation 
R43Q could produce a similar phenotype. 
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Mutant H125R 
Residue 125 is located among a cluster of glycines ( G 123, G 128 and G 134) 
conserved in both 11 ~-hydroxylase and aldosterone synthase. These glycines are 
thought to be involved in the flexibility of the loop between helices B and C that 
contains the substrate recognition site 1 (SRS1) (see section 1.14.3) (Gotoh 1992; 
Krone et al 2005). Mutations within this region may alter substrate specificity and in 
fact mutant H125R appears to decrease the affinity for substrate S with no effect on 
DOC. 
Mutants P 135S and Fl39L 
Residue 135 may form a bond with the haem moiety (see figure 3.13). Mutation at 
this locus, especially such a dramatic change as removal of the large orientation-
changing cyclic proline residue (P135S), may alter the haem orientation and 
therefore the efficiency of electron transport in the oxidase reaction (see section 1.7). 
Residues 135 and 139 appear to be located within helix C, which is thought to form 
part of the substrate access channel. Again, mutations within this region have been 
asssociated with 11~-hydroxylase deficiency, both classical (Val129Met) and non 
classical (Asn133His) types (Geley et al1996; Joehrer et al1997). 
Mutant LJ86V 
Mutant L186V has a substrate specific effect but does not appear to be located within 
one of the proposed substrate recognition sites (see section 1.14.3) (Gotoh 1992). In 
the bacterial P450cAM, residue 186 helps to maintain the substrate access channel in 
the closed conformation by binding to residue Asp251 in the I helix. Mutation of 
these residues favors substrate binding by allowing easier diffusion of the substrate 
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into the active site (Deprez et al 1994). Mutation at locus 186 (L186V) in human 
P4501lp may also have a similar effect on the binding of S as it increases the 
conversion of S compared to wildtype. This is a substrate specific effect as the 
conversion ofDOC is not affected (figure 3.10). 
Mutations L83S, Ll58P and TI96A 
Mutations L158P, which is situated at the start of helix D, and L83S that lies in the 
loop just before helix B, severely reduce enzyme activity (figures 3.1 and 3.2). 
Residue 196 is located in helix E and also reduces enzyme activity but to a lesser 
extent (figure 3.8). From their putative positions and the information in the 
literature, the reasons for these effects are not entirely clear. Mutations at these sites 
may alter the position of the helix and change protein conformation. This may 
position the haem in an orientation less favourable for the 11 ~-hydroxylation of S or 
DOC. As mentioned previously, all these changes would result in a change in 
polarity and the L158P may also alter the geometry of the protein chain that might 
account for their detrimental effects on enzyme activity. 
In summary, although these speculations are useful in partially accounting for the 
effects of sequence changes, a more complete explanation requires the determination 
of a high-resolution x-ray structure of P45011 p. None of the residues investigated are 
located within the putative active site of P450 11 p but do markedly alter enzyme 
function. Their location provides further clues to the structure-function relationships 
of cytochrome P450 enzymes. Fisher et al similarly showed that changes in residue 
147 of P450aldo or P450 11 p, also distant from the active site, reduced activity (Fisher 
et a/2000). 
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Cytochrome P450 enzymes are unlike most other enzymes. They can bind more than 
one substrate, making them an exception to the classic 'lock and key' principle of the 
specificity of enzyme function. P450 11 ~ is particularly varied in the range of 
substrates on which it may perform both liP- and 18- (and possibly 19-) 
hydroxylation. The different effects of the mutations investigated in this study on S 
and DOC hydroxylation may give important insights into enzyme mechanisms. The 
substrates S and DOC differ by the presence and absence respectively of a 17 a-
hydroxy group, giving them different polarity and therefore affecting their interaction 
with the (hydrophobic, hydrophilic) amino acids of the substrate-binding site. The 
substrate-specific effect of the mutants H 125R and L 186V suggests that these 
residues play an important role in the interaction of the 17a-hydroxyl group of S 
with the enzyme. 
Since the initial work was conducted for this study, techniques to perform high-
throughput screening by direct sequencing have become available. Our own 
experience, and that of others examining the CYP II B locus in normotensive subjects, 
suggests that variation across the entire region is high (Cargill et al 1999; Halushka 
et al1999). Each ofthe mutations identified was in subjects who were heterozygous, 
so that a normal CYP IIBI allele was present. No subject had clinical symptoms of 
11 P-hydroxylase deficiency, although more detailed biochemical phenotyping was 
not performed. As yet no individual with this disorder has been identified as 
homozygous for these mutations. The mutations causing 11 P-hydroxylase 
deficiency are distributed across the entire gene but with a slightly higher frequency 
in exons 2, 6, 7 and 8 (Curnow et al1993; Geley et al1996) (see section 1.15.2.3). 
The causative mutations can be insertions, deletions, nonsense or missense mutations 
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that usually result in a complete loss of enzymatic activity. A residual 11 ~­
hydroxylase activity of 3% is insufficient to prevent the clinical symptoms of classic 
11 ~-hydroxylase deficiency (Krone et al2005). 
A total of 8 mutations were identified in 160 subjects screened (and other studies 
have also identified a high frequency variation). The carrier rate for mutations 
within this gene that would be predicted to cause significant alteration of 11 ~­
hydroxylation efficiency within the population may be in the order of 3 to 5%. This 
might be expected to give rise to a compound heterozygote rate of 1 in 2500 live 
births. However, the reported rate of severe hydroxylase efficiency in a Caucasian 
population is very much lower than this (White et al 1994). One possibility is that 
that severe mutations, such as L83S and L158P, are embryonically lethal so that the 
live birth rate would be substantially lower than this. However this seems unlikely as 
even complete loss of 11 ~-hydroxylase is not lethal in utero due to maternal cortisol 
crossing the placenta. Alternatively, it is possible that a substantial number of 
compound heterozygotes carry mutations that reduce but do not abolish 11 ~­
hydroxylase activity, resulting in a form of non-classical 11 ~-hydroxylase 
deficiency. As mentioned previously mutations causing a nonclassical form of 11 ~­
hydroxylase deficiency have been identified more recently, that cause partially 
disrupted enzyme activity in vitro to 15-37% of the wildtype (see section 1.15.2.3) 
(Joehrer et al 1997). In this circumstance, the phenotype is less severe, so that the 
classic presentation of virilising congenital adrenal hyperplasia in early life is not 
present. Less marked reduction in 11 ~-hydroxylase activity gives rise to a milder 
phenotype, possibly associated with the development of hirsutism and/or 
hypertension in later life. The mutations R43Q, P135S, F139L and T196A appear to 
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reduce 11 ~-hydroxylase substrate conversion to approximately 30 to 50% of the 
wildtype. It seems likely that, if these were present as homozygotes, they would also 
result in a nonclassical phenotype. Interestingly, the mutants Pl35S, Fl39L and 
T196A were all identified in a single subject. It is possible these and other mutations 
have not been identified due to the milder phenotype of this form of the disorder. 
The mutant H125R causes a mild reduction in the conversion of S to F with no effect 
on the conversion of DOC to B. How this would manifest itself in vivo is unclear. 
The identification of as many as 5 mutants in 160 subjects that appear to partially 
reduce the conversion of substrate to product in vitro suggests that subtle forms of 
11 ~-hydroxylase deficiency may be more common than has been generally 
perceived. Other studies have, indeed, reported that altered 11-hydroxylation 
efficiency is a common feature of patients with essential hypertension, although such 
studies have not carried out a systematic examination ofthe CYPJJBJ gene (Connell 
et al 1996; de Simone et al 1985; Honda et al 1977). Analysis of the polymorphic 
variation of a much larger hypertensive population, with more extensive phenotypic 
data will allow a better determination of the true frequency of the variance as well as 
in association between polymorphisms and phenotypes such as hypertension with 
mineralocorticoid features. 
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CHAPTER4 
Haplotype Analysis of the CYPJJBJ/2 Locus 
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4.1 Introduction 
As described in section 1.16.3, the -344 CIT and intron conversion (IC) variants in 
CYP II B2 have been consistently associated with an impaired 11 ~-hydroxylase 
efficiency (Davies et al2001; Hautanena et al1998; Kennon et al2004). It is likely 
that this seemingly paradoxical association can be explained by linkage 
disequilibrium (LD) between these CYP II B2 variants and key polymorphisms in 
CYP11BI that could account for this phenotype. The -344 CIT and IC variants are 
indeed in linkage with polymorphisms in CYP II BI, specifically in exon 1 (225 G/ A, 
Leu75Leu), intron 3 (2803 A/G) and intron 6 (4265 G/A) (Ganapathipillai et al2005; 
Keavney et al 2005). The CYP II B haplotypes identified in each study associated 
with 11 ~-hydroxylase efficiency. However, the CYP 11 BI polymorphisms identified 
were either synonymous exonic or intronic and so are unlikely to account for the 
biochemical phenotype of impaired 11 ~-hydroxylase efficiency. Therefore, further 
fine mapping across the CYP II B locus is required to identify potential causative 
variants. 
4.2 Aims 
The aims of this study were to investigate the way in which genetic variation at the 
CYP 11 B I 12 locus may lead to altered 11 ~-hydroxylase function through detailed 
analysis of the pattern of genetic variation across the whole locus. Through this it 
was also possible to determine the haplotype structure and extent of linkage 
disequilibrium across the entire CYP II B locus. 
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4.3 Methods 
4.3.1 Samples 
Genomic DNA was taken from a group of normotensive subjects already genotyped 
for the -344C/T and IC polymorphisms. Twenty six subjects were selected for 
genetic analysis; TT/ConCon (10), CC/WtWt (10) and TT/WtWT (6) (sections 2.2.1 
and 2.2.2). 
4.3.2 PCR and Sequencing 
The CYP II BI gene from -2kb of the 5' untranslated region (UTR) to the end of exon 
9 was amplified as a single PCR amplicon of approximately 7kb. The 3'UTR (750bp) 
was amplified separately (section 2.2.3). Genetic variants were identified by direct 
sequencing of the PCR products (section 2.2.6) in collaboration with other members 
of the group who sequenced the CYP 11B2 gene of the same subjects to determine the 
pattern of linkage across the entire CYP II B locus. 
4.3.3 Haplotype analysis 
A Bayesian statistical method implemented m PHASE v 2.1 
(http://www.stat.washington.edu/stephens/software.html) was used to construct 
phased haplotypes from phase-unknown genotype data. Linkage disequilibrium 
(LD) statistics (D' and r2) were generated using the programme EMLD 
(http://reguest.mdacc. tmc.edul~ghuang/Software/pub.htm, which calculates LD 
between all possible pairs of genetic variants from unrelated individuals. This was 
further investigated using GOLD, which provides a graphical overview of LD 
(http://www.sph.umich.edu/csg/abecasis/GOLD/) 
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4.4 Results 
4.4.1 PCR of5'UTR to Exon 9 ofCYPllBl 
The 5' UTR and coding region of CYP II B I was amplified using the oligonucleotides 
Bl 5'UTR (s) and Bl exon 9 (as) to produce a fragment of approximately 7kb (see 
figure 4.1 ). 
Samples 1-4 Blank 
10,000 bp _____. 
4,000 bp _____. 
1,000 bp _____. 
Figure 4.1. 7kb PCR fragments from 4 different MONICA samples resolved on 
a 1% agarose gel. Lane 1 contains 5!-!1 HyperLadder I (Bioline, London, UK). 
Indicidual bands of the correct size indicate specificity. No band for the 
control/blank reaction indicates no contamination. 
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4.4.2 PCR of3'UTR ofCYPIJBJ 
The 3'UTR of CYP llBI was amplified usmg the oligonucleotides M6635 and 
B13'UTR+500 (as) to produce a fragment of approximately 750bp (see figure 4.2). 
10,000 bp ___. 
4,000bp--. 
1,000bp-+ 
400bp-+ 
Samples 1-8 Blank 
Figure 4.2. 750bp PCR fragments from 8 different MONICA samples resolved 
on a 1% agarose gel. Lane 1 contains 5J.Ll HyperLadder I (Bioline, London, UK). 
Individual bands of the correct size indicate specificity. No band for the 
control/blank reaction indicates no contamination. 
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4. 4. 3 Polymorphism identification 
Polymorphisms were identified by direct sequencing of the genes. An example of 
electropherograms of the 5'UTR of CYP IJBI, from subjects in each of the groups, 
are shown in figure 4.3. The sequence variation across the CYP JIB locus was fairly 
high. For the purposes of this study, only the polymorphisms that differed between 
the three -344/IC genotype groups, in all subjects of the group, were chosen for 
further analysis (see figure 4.4). A total of 83 biallelic polymorphisms were 
identified across the entire CYP II B locus ( 44,631 bp) that showed association with 
the -344 CIT and IC variants in CYP 11 B2 (see figure 4.5). Out of the 83 
polymorphisms, 64 were located within the CYP II B2 gene and 19 were located 
within the CYP 1J B I gene. They were spread throughout the genes' exons, introns 
and their nearby untranslated regions (UTR), with the highest frequency in the 
intronic regions. 
185 
A 
TT/ConCon 
CC/WtWt 
TT/WtWt 
B 
TT/ConCon 
CC/WtWt 
TT/WtWt 
-1889 
GTCTGTTAAG 
-1859 
TGTATAAGAA' 
T T AT AA AA ' 
~TTTTTGTAC G ~TGATTTTGTA 
~ TTTTT T A C T ATTTT T A 
Figure 4.3. Sequence analysis showing two single nucleotide variants within the 
S'UTR of CYPllBJ. Results are shown from one subject from each of the 3 groups. 
A) G toT substitution at position -1889. B) A toG substitution at position -1859. 
186 
ACCTTCCAGGAACT ~ GGCCCATTTT 
ACCTTCCAGGAACT GGCCCATTTT 
ACCTTCCAGGAACT GGCCCATTTT 
ACCTTCCAGGAACT GGCCCATTTT 
TT/ConCon AC CTTC CAGGAACT ~ GGCCCATTTT 
ACCTTCCAGGAACT GGCCCATTTT 
ACCTTCCAGGAACT GGCCCATTTT ACCTTCCAGGAACT ~ GGCCCATTTT 
ACCTTCCAGGAACT ~ GGCCCATTTT 
ACCTTCCAGGAACT GGCCCATTTT 
ACCTTCCAGGAACT GGCCCATTTT 
ACCTTCCAGGAACT GGCCCATTTT 
ACCTTCCAGGAACT .,.GGCCCATTTT 
ACCTTCCAGGAACT GGCCCATTTT 
CC/WtWt ACCTTCCAGGAACT GGCCCATTTT 
ACCTTCCAGGAACT GGCCCATTTT 
ACCTTCCAGGAACT GGCCCATTTT 
AC CTTC CAGGAACT ~ GGCCCATTTT 
ACCTTCCAGGAACT GGCCCATTTT 
ACCTTCCAGGAACT GGCCCATTTT 
!!.CCTTCCAGGAACT f GGCCCATTTT 
!!.CCTTCCAGGAACT R .,.GGCCCATTTT 
TT/WtWt !!.CCTTCCAGGAACT GGCCCATTTT 
!!.CCTTCCAGGAACT GGCCCATTTT 
!!.CCTTCCAGGAACT GGCCCATTTT 
!!.CCTTCCAGGAACT GGCCCATTTT 
Figure 4.4. Sequence alignment of the three groups showing the presence of a 
CTG to CTA synonymous (Leu to Leu) polymorphism in codon 75 of exon 1, 
CYPJJBJ. 
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5' SF1 IC 3' 
(8) (18-41) 
llUUllll UUlUU~lUUU Ul UUUH UU U ll UUUl Ull lU l 
CYP1182 CYP11B1 
Figure 4.5. The positions of the 83 variations identified across the CYPJJB locus. The SF1/-344C/T (No.8) and the intron conversion 
(IC) (Nos. 18-41) variants are marl{ed. 
4.4.3.1 CYP II B2 Polymorphisms 
Sixty four polymorphisms were identified in CYP II B2 that associate with the -344 
CIT and IC polymorphisms (see figure 4.6a). Most ofthe polymorphisms identified 
were in intronic regions, particularly intron 2. The majority of these were associated 
with the intron conversion variant previously described by White & Slutsker, 1995, 
which is marked on the diagram (see figure 4.6a and table 4.1). This actually 
includes variants 18-42, spanning approximately 240bp, where the CYP II B2 residue 
has been replaced by the corresponding CYP liB I residue. This includes an 8bp 
deletion (AGAGCTGC) that corresponds to the conversion allele allowing easy 
identification. Of the remainder, three single base substitutions were found in exons 
3 and 6. Two of these are synonymous changes with no effect on amino acid 
sequence; Phe168Phe and Arg374Arg. These mutations have been previously 
described by the National Center for Biotechnology Information (NCBI), accessible 
on the dbSNP website (http://ncbi.nlm.nih.gov/SNP), with the identification 
numbers; rs 4546 and rs4538 respectively. The third coding variant, at codon 173 
(rs4539), does cause an amino acid change from Lys to Arg but has been shown to 
have no effect on aldosterone synthase activity in vitro (Fardella et al1996a; Portrat-
Doyen et al 1998). Four variants were identified in the 3'UTR region. Finally, 
seven single base substitutions were identified in the 5'UTR region of CYP 11B2, 
which can be linked to the -344/IC genotype. The pattern of association of these 
polymorphisms with the -344 CIT and IC variants is shown in table 4.1. 
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4.4.3.2 CYP 11 B I Polymorphisms 
Nineteen polymorphisms were identified in CYP llBI that associate with the -344 
CIT and IC polymorphisms in CYP11B2 (see figure 4.6b). As with CYPJJB2, most 
were within intronic regions (introns 2, 3, 4, 5, 6 and 8). Two of the single 
nucleotide substitutions in exons 1 and 2 have previously been described by NCBI. 
Both of these are synonymous changes; Leu75Leu and Asp82Asp (rs6410 and 
rs5283 respectively). The exon 1 polymorphism and two of the identified intronic 
variants (Int3 2776 A/G and Int 6 4224 TIC) (see table 4.2) are the polymorphisms 
previously found to associate with the -344 CIT and IC variants (Ganapathipillai et al 
2005; Keavney et al 2005). Two novel polymorphisms were identified within the 
5'UTR at positions -1889 (G/T) and -1859 (A/G) upstream of the transcription start 
site. When the polymorphisms are separated into alleles to look at the pattern of 
association with the -344/IC genotype, it can be seen that most of the polymorphisms 
associate with the T/Conv haplotype (as shown in red on table 4.2). 
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A) CYP11B2 Identified Polymorphisms 
F168F 
TIC CIT 
GIT AIG 
GIA ATIGC GIA 
Gl A (-344) TIC CT ~~A J 
G/C err CIT AIG AIG AIG T/1C/T 
S'_UT_R__,'-T"""';~~~'Itfi1~ .:-r-+--r'r-T-.P..-I·.tij lH'!Iil-z-"rr$1---il~---,~r-=,.:...niHBl--1•9 
l l 
CIT CIT 
AfT 
AI( AIG A/Gl CIT 
GIC CIG I CIT CIT 
GIA Intron 
Conwrsion R173K 
B) CYPllBl Identified Polymorphisms 
TIC AIG 
1 C CIG INS 
CIA 
R374R 
GIT 
TIA 
-1889 -1859 
GIT AIG GIC CIT GIT TIC CIT GIT 
5 'UTR ,. , , t r-- 2 3 4 s -~ 6 7 8 
r TIC GIA CIT TIC GIA 
GIA TIC 
L75L D82D 
GIC 
TCC 
INS 
GIA 
13'UTR 
GIT 
AIG 
3'UTR 
9 
Figure 4.6. Diagram showing the positions of the identified polymorphisms and 
the nucleotide variants in a) CYPJJB2 and b) CYPJJBJ. Previously reported 
polyrnorphisms are shown in red. 
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CYPJJB2 alleles 
Location 5' 5' 5' 5' 5' 5' 5' 5' Int2 Int2 
Position -1667 -1651 -1513 -1472 -663 -645 -470 -344 830 1049 
TT/ConCon c c c G A T c T A T 
CC/WtWt G T T A T c T c G c 
TT/WtWt G CIT c G A c c T G c 
Location Int2 Int2 Int2 Int2 Int2 Int2 Int2 Int2 Int2 Int2 
Position 1097 1461 1746 1750 1751 1782 1839 2095 2096 2100 
TT/ConCon G A G c - A A G c c 
CC/WtWt c G A G CT G G A T T 
TT/WtWt G G G c - A A A T T 
Location Int2 Int2 Int2 Int2 Int2 Int2 Int2 Int2 Int2 Int2 
Position 2101 2108 2110 2112 2114 2115 2117 2120 2122 2124 
TT/ConCon A T G G T 
-
L 8bp - - -
CC/WtWt G A A A A G - A T c 
TT/WtWt G A A A A G - A T c 
Location Int2 Int2 Int2 Int2 Int2 Int2 Int2 Int2 Int2 Int2 
Position 2151 2240 2241 2252 2259 2264 2268 2269 2271 2287 
TT/ConCon A G T c T c c c - c 
CC/WtWt G c c G G A T G T T 
TT/WtWt G c c G G A T G T T 
Location Int2 Int2 Int2 Int2 Int2 Ex3 Ex3 Int3 Int3 Int4 
Position 2316 2328 2374 2375 2399 2698 2712 2886 2888 3192 
TT/ConCon G G c A T c A c T T 
CC/WtWt T A A G c T G T c c 
TT/WtWt T A c A/G TIC c A c T TIC 
Location Int4 Int4 Ex6 Int6 Int6 Int6 Int6 Int6 Int6 Int6 
Position 3257 3270 6573 6603 6855 6876 6879 6885 6887 6954 
TT/ConCon A T c c T AT T c c A 
CC/WtWt G c A A T GC A G G G 
TT/WtWt AIG c A A G AT T c c G 
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Location 3' 3' 3' 3' 
Position 7615 7829 8066 8269 
TT/ConCon A - G G 
CC/WtWt G TCC T A 
TT/WtWt G TCC T G 
Table 4.1. The identified CYPJJB2 polymorphisms separated into alleles to 
show the pattern of linkage with the -344/IC genotypes. The positions are relative 
to the transcription start site ofCYPllB2. The -344 CIT and the IC (8bp deletion) 
variants are highlighted in light blue. The alleles that associate with the T /Con 
haplotype are shown in red and those that associate with the -344 C allele are shown 
in blue. For some polymorphisms the association was not clear, as subjects in the 
TT/WtWt group were heterozygous. 
CYPJJBJ Alleles 
Location 5' 5' Exl Ex2 Int2 Int2 Int2 Int2 Int2 Int2 
Position -1889 -1859 225 626 1052 1655 1800 1960 2265 2295 
TT/ConCon T G A c c c c A T T 
CC/WtWt G A G T G T T G c c 
TT!WtWt G A G c c T T G T c 
Location Int3 Int4 Int4 Int4 lotS Int6 Int6 Int6 Int8 
Position 2776 3223 3244 3342 3799 4224 4264 4381 4941 
TT/ConCon G T c c T T A T c 
CC/WtWt A G T T G c G G G 
TT!WtWt A G T T G c G G G 
Table 4.2. The identified CYPJJBJ polymorphisms separated into alleles to 
show the pattern of linkage with the -344/IC genotypes. The positions are relative 
to the transcription start site of CYP 11 B1 . The alleles that associate with the T /Con 
haplotype are shown in red and those that associate with the -344 C allele are shown 
in blue. 
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4.4.4 Linkage disequilibrium 
There was strong LD across the entire CYP liB locus (see figure 4.7). The LD 
decreased slightly with distance, with loci in CYP liB I being in stronger LD with 
each other than with loci in CYP II B2 and vice versa. The D' value was almost 
uniformly high across the entire locus, approaching the maximum of 1.0 across much 
of the region and decreasing to approximately 0.75 between pairs of loci spanning 
CYP liB I and CYP 11B2. The r2 value was slightly lower as it is more stringent and 
takes into account allele frequency. However, it was still within the top part of the 
range with a minimum value of approximately 0.5 and a maximum of approximately 
1.0. 
4.4.5 Haplotype analysis 
The theoretical number of haplotypes, assuming free recombination between the 83 
variants, is 9.671 x 1024 . Haplotype analysis using PHASE identified 136 haplotypes 
that were conserved across the entire region; most of which were of a very low 
frequency. Nine haplotypes had fequencies > 1%, describing 75% of chromosomes 
in the data set (see figure 4.8). Only four common haplotypes had frequencies of 
greater than 5% and accounted for 68% of chromosomes in the data set (see figure 
4.9). 
194 
A 
l42963B1 
l42403B1 
~1266B1 
~39677B1 
t36164B1 
J43270B2 
J22316B2 
rR-344B2 
B 
l42963B1 
l42403B1 
~1266B1 
~39677B1 
t36164B1 
J43270B2 
J22316B2 
rR-344B2 
1.00 
0.00 
5 Kb 25 Kb 
1.00 
0.00 
5 Kb 25 Kb 
Figure 4.7. Data plots extrapolating pairwise linkage disequilibrium across the 
CYPJJB region. A. Plot ofD'. B. Plot ofr2. 
195 
No Haplotype Pattern Freq % 
1 1112 12 1 2 122 1 2 11112 1112222 1 2 111122 1 22112 1122 1 211122 1 222 112 11111122211111122221122 1 2 1 0.202 >5 
5 1112 12 1 2 122 1 2 11112 1112222 1 2 111122 1 22112 1122 12 111221 222112 11111122211111122222 1 22 1 2 1 0.014 >1 
9 1112 12 1 2 122 1 2 11112 1112222 1 2 111122 1 22112 1122 12 11122 1 222112 1112 1122211111122221122 12 1 0.069 >5 
29 1112 111 2 122 1 2 11112 1112222 1 2 111122 1 22 112 1122 12 11122 1 22211211111122211111122221122 12 1 0.112 >5 
87 2 122111 2 21222 1111122211112 1 2222112 112211222 12 111222111112 1122222 112 112 1 2211122112 12 0.015 >1 
89 2122111 2 2 12221111122211112 1 2222112 112211222 12 111222 111112 1122222 11211222211122 112 1 2 0.011 >1 
132 222 12 12 1 2 112 12222 122211112 1 2222112 1122 1 22112 1222112 11222 1222222112 111111222112 112 12 0.012 >1 
133 222 12 1 2 1 2 1121 2222 122211112 1 2222112 1122 1 221121 222 112 11222 1222222112 12 1111222112 112 12 0.022 >1 
136 222 1 21 2 1 2112 12222 122211112 1 2222112 1122 1 221121 222 112 11222 12222221112222221111221121 2 0.297 >5 
t t 
[=344 C/T I [Ycsbpdel 1 
Figure 4.8. The 9 most common CYPllB haplotypes and their frequencies. Alleles coded 1 or 2 in alphabetical order. In the case of 
inse1iions/deletions, no insertion/deletion is 1; insertion/deletion is 2. The positions of the -344C/T and Intron conversion (8bp deletion) are 
shown. The 8bp deletion (2) is representative of the conversion allele whereas no deletion (1) is the wild type. 
CYP1182 CYP1181 
SF-1 IC(Sbp del) 
-645 -344 2117 7615 -1889 -1859 225 625 4941 
T T Conv A T G A C c Frequency 
0.202 
T T Conv 
0.069 
c T Conv 
0.112 
0.297 
Figure 4.9. Schematic diagram of the 4 common haplotypes with a frequency of 
> 5%. The association of the SF1/IC variants with the -1889 Gff and -1859 A/G 
polymorphisms is highlighted. The CYP 11B2 T!Wt allele combination was only 
present in the haplotypes with a frequency of> 1%. 
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4.5 Discussion 
This study demonstrates that overall the sequence variation across the CYP 11 B locus 
is high, supporting previous reports (Cargill et al 1999; Halushk:a et al 1999). Recent 
work has also suggested that the -344C/T and IC polymorphisms in CYP 11B2 are in 
linkage with specific polymorphisms in CYP 11 B 1, in ex on 1 (Leu7 5Leu ), intron 3 
(A/G) and intron 6 (G/A) (Ganapathipillai et al 2005; Keavney et al 2005). The 
present study also confirms this and further shows that there is tight linkage 
disequilibrium across the entire CYP 11 B locus. Several candidate SNPs have been 
identified that could account for the observed phenotypes associated with the -
344C/T and IC variants in CYP 11B2. 
Out of the 64 identified polymorphisms in CYP 11B2 found to be in linkage with the-
344/IC genotype, the only substitutions within the coding regions were either 
synonymous (F168F and R374R) or have previously been shown to have no effect on 
aldosterone synthesis (R173K) (Fardella et al 1996b ). However, there are many 
polymorphisms located within introns. These could potentially alter the splicing of 
the gene's primary transcript leading to altered protein synthesis. Although none are 
located directly within the splice junctions at the exon/intron boundaries they may 
disrupt the branch site that is also necessary for proper intronic splicing. These are 
splicing-related sites located deeper within the intron with the consensus sequence 
(CIU)N(CIU)U(A/G)A(CIU) where the emboldened A (adenosine residue) is 
invariant and conserved between all genes and N is any nucleotide (Madhani & 
Guthrie 1994). To determine whether any of the intronic polymorphisms have 
functional effects on splicing could be studied using a minigene system where the 
entire exonic and intronic regions are cloned into a vector. The wildtype and mutant 
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constructs would then be transfected into JEG-3 cells, the total RNA isolated and 
reverse transcriptase PCR performed. Sequencing the PCR product would determine 
any splice variants resulting from the allele variants. There is also increasing 
evidence that introns contain transcriptional control elements such as enhancers or 
repressors (Kleinjan & van Heynigen 2005). Therefore intronic polymorphisms can 
also affect gene regulation. Co-transfection of a reporter gene construct, containing 
the 5' regulatory region, with a vector containing alternate forms of an intron would 
determine whether there is any alteration in the transcriptional response. 
Interestingly, it has been demonstrated that regulatory elements can be as far as 1Mb 
up- or downstream of the transcription unit (Klein jan et al 2001; Lettice et a! 2002), 
therefore polymorphisms within CYP II B2 have the potential to affect the regulation 
of CYP 11 B I and vice versa. This would be an interesting theory to investigate. 
Especially to look at the influence of the IC variant in CYP II B2 on the regulation of 
CYP IIBI as many of the polymorphic alleles contributing to the IC originated in 
CYPllBI. 
Four variants were identified in the 3 'UTR of CYP II B2. Three of these were single 
base changes and the third was a 3bp (TCC) deletion. It is possible these variations 
affect RNA stability and therefore protein production. This could be tested using an 
in vitro coupled transcription/translation system followed by methods to quantify the 
RNA (RT-PCR) and protein (SDS-PAGE) produced and comparing the levels ofthe 
wild type to each of the variants. 
Seven single nucleotide substitutions were identified in the 5'UTR of CYP II B2. It is 
possible these could alter the transcriptional regulation of the gene, resulting in either 
increased or decreased expression. If this was the case, one or several of these 
199 
polymorphisms may account for the increased aldosterone levels that have 
previously been associated with the T/Conv haplotype. This hypothesis is to be 
tested in a separate study. 
Of particular interest to this study is that the -344C/T and IC variants in CYP 11 B2 
are in strong LD with genetic variants in CYP II B I. Of the 19 polymorphisms 
identified in CYP II B I, only two were located within the coding sequence and both 
of these were the synonymous changes, Leu75Leu and Asp82Asp. As mentioned 
previously, the Leu75Leu polymorphism in exon 1 has been found to be in LD with 
the -344 CIT and IC polymorphisms in CYP 11B2 and to strongly associate with an 
impaired 11 ~-hydroylase efficiency (Keavney et al 2005). However, this 
conservative polymorphism cannot, itself, account for the biochemical change. As in 
CYP 11B2, the majority of the polymorphisms were in intronic regions. The 
polymorphisms identified in intron 3 (2775 A/G) is located very close to the 
exonlintron boundary, only 12 residues away from the end of exon 3 and so may 
disrupt the splice site. The rest of the polymorphisms were located deeper within the 
introns. However, as mentioned previously, these could still potentially alter the 
splicing of the gene resulting m altered gene products. This reqmres further 
investigation. 
Two of the identified polymorphisms were located in the 5'UTR of CYPllBI at 
positions -1889 G/T and -1859 A/G. The subsequent experimental work of this 
thesis focuses specifically on these two polymorphisms (see Chapters 5 and 6). 
They do not change the amino acid sequence but may change the gene's 
transcriptional properties, altering its basal expression or response to stimuli. They 
may therefore account for the observed biochemical phenotype. Most of the 
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CYP II B I polymorphisms, including the -1889 G/T and -1859 A/G, show association 
with the T/Con haplotype, as shown in red in table 4.2. This is important, as it is 
these alleles that have previously been associated with an impaired 11 ~-hydroxylase 
efficiency. 
The tight LD across the CYP II B locus is confirmed by the presence of relatively few 
common haplotypes, with 4 haplotypes (frequency greater than 5%) accounting for 
68% of chromosomes in the data set (see figure 4.9). The T/Wt allele combination 
was not identified in haplotypes greater than 1%, probably due to the lower number 
of subjects in this group. The construction of haplotypes should enable the 
identification of 'tagging SNPs', to account for the observed haplotypes, allowing 
high throughput, efficient genotyping of the entire CYP II B locus. Although the 
sample size was small (26 subjects), previous work revealed that sample sizes of 23 
and 24 individuals provide a better than 99% chance of detecting SNPs of 5% 
frequency, and better than 87% chance for SNPs of 1% frequency (Crawford et al 
2004). If this is correct, our sample size is sufficient for accurate determination of 
haplotypes. However, the sample group in this study was selected according to their 
-344 CIT and IC genotypes and so confirmation of these haplotypes is required in a 
larger unselected group, more representative of the general population. The purpose 
of the haplotype analysis in the present study was to determine wherther or not and to 
what extent haplotypes existed across B 1/B2. Further studies are currently underway 
to define these haplotypes in unselected populations of normotensive and 
hypertensive subjects. This will allow a comparison of the frequencies of the 
common haplotypes to see if any are associated with the hypertensive phenotype. 
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This study strongly suggests that the impaired 11 ~-hydroxylase efficiency associated 
with the T/Con haplotype in CYP 11B2 is due to linkage with genetic variants in 
CYPllBJ. In particular, two novel single nucleotide substitutions (-1889 G/T and-
1859 A/G) in the 5'UTR of CYP JJBJ have been identified as key candidates due to 
their potential effects on gene expression. These polymorphisms will be investigated 
further to assess their frequency and phenotypic associations in a large hypertensive 
population as well as their functional effects in vitro. 
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CHAPTERS 
Investigation of the Frequency and Phenotypic 
Associations of the CYPJJBJ 5'UTR Polymorphisms 
in a Hypertensive Population 
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5.1 Introduction 
The SF1 -344 CIT polymorphism in CYP 11B2 has been previously associated with 
various cardiovascular phenotypes including hypertension with a raised ARR, 
increased plasma aldosterone levels as well as increased levels of its principle 
urinary metabolite tetrahydroaldosterone (THAldo) and left ventricular hypertrophy 
(L VH) (Brand et al 1998; Davies et al 1999; Delles et al 2001; Paillard et al 1999). 
However, these findings have not been consistently reported in all studies so that 
other investigators have reported no association or even an association with the 
contrasting allele (Kupari et al 1998; Pojoga et al 1998; Schunkert et al 1999a; 
Tsujita et al2001). In contrast, one ofthe most consistent observations appears to be 
an association with reduced 11 ~-hydroxylase efficiency (Davies et al 2001; 
Hautanena et al 1998; Kennon et al 2004). However, the molecular basis for this is 
unclear, given that the biochemical phenotype is due to altered activity of the protein 
encoded by the adjacent CYP liB I gene. As the -344 CIT polymorphism has been 
shown to have no effect in vitro it seems likely that it is in linkage with other 
polymorphisms that directly account for the observed phenotypes (Bassett et al 
2002). The study outlined in Chapter 4 established that there is strong linkage 
disequilibrium across the entire locus encompassing the 11 ~-hydroxylase ( CYP II B I) 
and aldosterone synthase ( CYP 11 B2) genes. Two novel polymorphisms were 
identified in the 5'UTR of CYPllBI (-1889 G/T and -1859 A/G) as potential 
candidates for the impaired 11 ~-hydroxylase efficiency previously associated with 
the -344 T allele. These were selected as key functional candidates due to their 
location in the 5' regulatory region of CYP II BI and their potential effects on enzyme 
transcription. It was therefore of interest to determine whether or not these 
polymorphisms do indeed associate with 11 ~-hydroxylase efficiency. 
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5.2 Aims 
The aim of this study was to investigate the frequency and phenotypic associations of 
the -1889 G/T and -1859 A/G CYP IIBI polymorphisms in a large hypertensive 
population. In particular, to focus on markers indicating impaired 11 ~-hydroxylase 
efficiency and their association with genotype. 
5.3 Methods 
5.3.1 Study subjects 
A large hypertensive study population was derived from the MRC BRitish Genetics 
of HyperTension (BRIGHT) study. The Bright Study is a large multicentre 
investigation into the genetic basis of hypertension, comprising > 2000 affected 
sibling pairs and trios. The primary aim of the study was to collect a large collection 
of affected sibling pairs to permit a genome wide scan to identify loci that might be 
involved in the development of hypertension. In this study, a range of phenotypes, 
including body mass index (BMI), blood chemistry and corticosteroid metabolite 
excretion were also measured. Hypertensive subjects were recruited from primary 
care with entry to the study being dependent on a pre-treatment blood pressure of 
> 145/95mmHg (mean of 3 readings). All had the onset of hypertension before 60 
years of age. Subjects with a BMI > 30 were excluded from the study. Full details 
of the recruitment strategy have been published elsewhere (Caulfield et al2003). 
For the present investigation, a random subgroup of 512 unrelated hypertensive 
subjects was selected for the analysis of urinary corticosteroid metabolite excretion 
rates. Full demographic information (as medians and inter-quartile ranges) on the 
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subjects included is shown in table 5.1. Ethical approval for the study was granted 
by the local ethics committees of the partner institutes and fully informed written 
consent from all of the participants was obtained. 
5.3.2 Genotyping of the CYPJJBJ 5'UTR Polymorphisms 
The entire BRIGHT study population (n = 3599) was genotyped for the -1889 G/T 
and -1859 A/G polymorphisms using a nested PCR method to increase specificity. 
Nested PCR protocol 
The initial reaction amplified a 2kb region specific to CYP liB I and the second 
reaction used this product as a template to amplify the region of interest ( ~400bp) 
specifically (see section 2.3.2). In both reactions, a heat-activated thermostart Taq 
polymerase (Abgene, UK) was used. The sense and anti-sense primers (MWG-
Biotech, Ebersberg, Germany) used in both reactions are outlined in appendix 2, 
table 7. 
5.3.3 Urinary Corticosteroid Metabolite Measurements 
Miss Mary C Ingram performed all the urinary corticosteroid measurements on the 
subset of the BRIGHT population (n = 512). Urine samples (24 hour) were collected 
in plain plastic containers without preservative. Aliquots of urine were stored at -
20°C. Excretion rates of steroid metabolites were measured by gas 
chromatography/mass spectrometry using the method of Shackleton (Shackleton 
1993) with minor modifications. The ratio of tetrahydrodeoxycortisol/total cortisol 
(THS/F) was used as an index of 11~-hydroxylase activity. 
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5.3.4 Statistics 
Whether the allele frequencies of -1889 G/T and -1859 A/G within the BRIGHT 
subgroup were in Hardy Weinberg equilibrium was determined using a Chi-squared 
test. The demographic and steroid excretion data did not follow a normal 
distribution and so were compared by non-parametric methods (Mann-Whitney test). 
5.4 Results 
5.4.1 Genotyping of -1889 G/Tand -1859 AIG 
Following optimisation of the nested PCR conditions each of the BRIGHT study 
samples, which had been pre-plated onto 96-well PCR plates (25ng/well), were 
amplified. This produced a PCR amplicon of 393bp as determined by agarose gel 
electrophoresis of a random selection of samples (12 to 16) from each plate (see 
figure 5.1). The PCR products were then sequenced (see section 2.2.6) using the 
primer B1prom-1750(as) (see table 6, appendix 2) to determine the -1889 and -1859 
genotypes. 
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1,000bp~ 
400bp~ 
200bp-.. 
BRIGHT Study Samples 1 to 14 
Figure 5.1. Nested PCR fragments (--- 400 bp) from 14 random BRIGHT 
samples, resolved on a 1% agarose gel. Lane 1 contains 5f..Ll HyperLadder I 
(Bioline, London, UK). Individual bands ofthe correct size indicate specificity. The 
lack of a band in lane 7 indicates a failure. In general the failure rate for each plate 
was approximately 10%. 
5.4.2 Demographic datafor BRIGHT sub-group 
Blood pressure and other relevant demographic data are shown in table 5.1; the 
population was significantly hypertensive but not significantly overweight. The only 
difference in characteristics of subject groups separated according to the -1889 or 
-1859 SNPs was with waist/hip ratio (-1889 GG vs. TT p = 0.015; -1859 AA vs. GG 
p = 0.013). 
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A) 
B) 
ALL -1889 GG -1889 GT -1889 TT p* 
SUBJECTS SUBJECTS SUBJECTS SUBJECTS 
n=437 n=116 n=223 n=98 
Age (years) 64 (57-70) 63(56-68) 64(58-71) 63(56-70) NS 
Mean SBP 181(153-191) 157(153-190) 183(153-193) 157(152-190) NS (mm/Hg) 
MeanDBP 1 03(98-11 0) 1 04(1 00-11 0) 1 03(98-11 0) 103(99-110) NS (mm/Hg) 
BMI 27(25-30) 27(24-30) 28(26-30) 27(25-30) NS 
(kg/m2) 
WHR 0.88 0.84 0.88 0.89 0.015 (0.81-0.93) (0.80-0.91) (0.81-0.94) (0.83-0.94) 
LVmass 68 69 67 67 
index (58-78) (58-79) (58-78) (57-76) NS 
ALL -1859 AA -1859 AG -1859 GG p** 
SUBJECTS SUBJECTS SUBJECTS SUBJECTS 
n=437 n=106 n=225 n=106 
Age (years) 64 (57-70) 63(56-68) 64(59-71) 63(56-70) NS 
Mean SBP 181(153-191) 157(153-190) 183(153-193) 169(153-190) NS (mm/Hg) 
MeanDBP 103(98-110) 104(100-110) 103(98-110) 103(99-110) NS (mm/Hg) 
BMI 27(25-30) 27(24-30) 28(26-30) 27(25-30) NS (kg/m2) 
WHR 0.88 0.84 0.88 0.89 0.013 (0.81-0.93) (0.80-0.91) (0.81-0.94) (0.83-0.94) 
LVmass 68 69 67 67 NS 
index (58-78) (58-79) (58-78) (57-76) 
Table 5.1. Demographic information on BRIGHT study sub-group separated 
by A) -1889 and B) -1859 genotypes. In each case the data did not follow a normal 
distribution and so were compared by the non-parametric Mann-Whitney test. 
SBP- systolic blood pressure, DBP-diastolic blood pressure, BMI-body mass index, 
WHR-waist-hip-ratio, L Vmass-left ventricular mass. 
*comparison between -1889 GG and TT homozygotes 
**comparison between -1859 AA and GG homozygotes 
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5.4.3 Genetic analysis ofCYPIIBI 
The frequencies of the -1889 (G-0.52, T-0.48) and -1859 (A-0.50, G-0.50) 
polymorphisms within the BRIGHT subgroup are illustrated in figure 5.2. The 
alleles of both -1889 G/T and -1859 A/G were in Hardy-Weinberg equilibrium with 
Chi-square values of0.91 and 0.82 respectively. 
5.4.4 Association with THS/Total F Metabolites 
The major urinary corticosteroid metabolites examined are listed in table 5.2. There 
was no significant difference in the excretion of the major aldosterone metabolite, 
THAldo or total androgen metabolite excretion for subjects homozygous for the 
-1889 G/T or -1859 A/G alleles. Importantly, there was also no significant 
difference in total cortisol metabolite excretion rate (nmol/24 hours) between the 
-1889 GG vs. TT (p = 0.4513) or -1859 AA vs GG (p = 0.2789) genotypes. The 
THS/ total F ratio (index of 11 P-hydroxylase activity) was significantly higher in 
-1889 TT homozygotes than in GG homozygotes (p = 0.025). A similar pattern was 
seen with the -1859 SNP, with GG homozygotes tending to have a higher ratio than 
AA homozygotes (p = 0.056) (table 5.2, figure 5.3). Figure 5.3 summarises the 
means of the THS/F ratios in all three genotype groups for both SNPs. There was no 
statistically significant difference between the -1889 TT and GT groups but the 
THS/F ratio remained significantly higher in the heterozygous group than the GG 
subjects (0.0 19). A similar pattern is seen for -1859, with no statistical difference 
between the GG and AG groups but a trend to a higher ratio in the heterozygous 
group than the AA homozygotes (p = 0.066). 
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Figure 5.2. Frequencies of A) the -1889 G/T and B) the -1859 A/G 
polymorphisms in the BRIGHT population subgroup. 
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A) 
B) 
Urinary Steroid ALL -1889 GG -1889 GT -1889 TT p* 
Metabolites SUBJECTS SUBJECTS SUBJECTS SUBJECTS 
(nmoles/24hrs) 
ALDOSTERONE 3 3 3 3 NS (THAldo) (2-6) (2-6) (2-6) (1-5) 
CORTISOL 
METABOLITES 1416 1305 1635 1385 NS (TOTAL F; (788-2670) (652-2532) (835-2824) (793-2701) 
THF+aTHF+THE) 
ANDROGEN 
METABOLITES 606 663 580 550 NS (TOTAL ANDRO; (318-1208) (276-1322) (322-1209) (340-1062) 
DHA+AETIO+ANDRO) 
11~-HYDROXYLASE 0.009 0.007 0.010 0.011 EFFICIENCY (0.005-0.014) (0.005-0.0 12) (0.006-0.015) (0.006-0.015) 0.024 (THS/TOT AL F) 
Urinary Steroid ALL -1859 AA -1859 AG -1859 GG p** 
Metabolites SUBJECTS SUBJECTS SUBJECTS SUBJECTS 
(nmoles/24hrs) 
ALDOSTERONE 3 3 3 ,., .) NS (THAldo) (2-6) (1-6) (2-7) (1-5) 
CORTISOL 
METABOLITES 1416 1245 1647 1399 NS (TOTAL F; (788-2670) (718-2314) (798-2754) (840-2705) 
THF+aTHF+ THE) 
ANDROGEN 
METABOLITES 606 636 580 630 NS (TOTAL ANDRO; (318-1208) (257-1317) (317-1213) (358-1062) 
DHA+AETIO+ANDRO) 
11~-HYDROXYLASE 0.009 0.007 0.009 0.010 EFFICIENCY (0.005-0.014) (0.005-0.012) (0.006-0.015) (0.005-0.0 16) 0.056 (THS/TOT AL F) 
Table 5.2. Urinary corticosteroid excretion separated according to A) -1889 
and B) -1859 genotypes 
THF: tetrahydrocortisol, (a)THE (allo) tetrahydrocortisone, 
DHA: dehydroepiandrosterone, Aetio: aetiocholanolone, Andro: androsterone 
THAldo:tetrahydroaldosterone, THS: tetrahydrodeoxycortisol, NS =non significant. 
Steroid results were compared by the non-parametric Mann-Whitney test. 
* comparison between -1889 GG and TT homozygotes 
**Comparison between -1859 AA and GG homozygotes 
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Figure 5.3. Box-whisker plots of 11~-hydro:xylase efficiency (THS/total F ratio) 
in all subjects stratified by the -1889 or -1859 genotypes. 
In each case comparisons of the tetrahydrodeoxycortisol (THS)/total cortisol (F) ratio 
between the genotype groups was analysed by non-parametric testing (Mann-
Whitney). 
213 
5.5 Discussion 
A consistent yet somewhat paradoxical association exists between variants in the 
CYPJJB2 gene (-344 CIT and IC) and markers of 11~-hydroxylase activity, which is 
the enzyme encoded by the highly homologous CYP JJBI gene (Davies et al 2001; 
Hautanena et al1998; Kennon et al 2004). It has been postulated that this is due to 
these CYP II B2 variants being in linkage disequilibrium (LD) with polymorphisms in 
CYP JJBI. Some previous studies (see section 1.16.1) identified polymorphisms in 
LD between CYP IIBI and CYP IIB2 but none could explain the biochemical 
phenotype. Therefore, in this study (see Chapter 4) the pattern of variation across 
the region was investigated in greater detail. 
The study in Chapter 4 confirmed that the overall sequence variation across the 
CYP II B locus is high and that there is strong LD across the entire region. Two 
interesting novel polymorphisms were identified in the 5'UTR of CYP II B I at 
positions -1889 G/T and -1859 A/G that may alter transcriptional regulation of the 
CYP 11 B I gene and therefore affect 11 ~-hydroxylation efficiency, the phenotype 
closely associated with the T/Conversion haplotype in CYP IIB2. 
This study of an unselected hypertensive population clearly demonstrates a 
significant association between these polymorphisms and the ratio of THS/total F 
metabolites, the index of impaired 11~-hydroxylase efficiency. Those subjects 
homozygous for the -1889 T allele showed lower 11 ~-hydroxylation efficiency 
(increased urinary THS/total F ratio) compared with those homozygous for the G 
allele. Similarly, subjects homozygous for the -1859 G allele had reduced 11 ~­
hydroxylation efficiency compared with those homozygous for the A allele. As 
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mentioned previously, it is these alleles (-1889 T and -1859 G) that are in linkage 
disequilibrium with the CYP JJB2 T/Con haplotype. Therefore, these results are in 
agreement with previous studies that found an association between the -344 T and IC 
conversion alleles and an impaired 11 P-hydroxylase efficiency. Importantly, there 
was no difference in urinary excretion of total cortisol metabolites between the two 
genotype groups for each SNP (see table 5.2). These findings support the hypothesis 
that, in -344 TT subjects, normal cortisol production is maintained by a subtle 
increase in ACTH drive to the adrenal cortex, which increases the availability of its 
deoxyprecursor 11-deoxycortisol (Connell et al2003). 
Reduced 11 P-hydroxylase efficiency is a common feature of hypertensive subjects. 
In 1985, de Simone and colleagues found a higher ratio of DOC/corticosterone and 
11-deoxycortisol/cortisol in hypertensive subjects compared to normotensive 
controls after ACTH stimulation (de Simone et al 1985). More recently, we have 
made a similar observation in hypertensive subjects in whom the plasma ratio of 11-
deoxycortisol/cortisol was elevated (Connell et al 1996). However, until now, the 
underlying genetic basis of this observation has not been explored. The results from 
the BRIGHT study confirm this phenotype of altered 11 P-hydroxylation efficiency 
within a sub-group from a large, severely hypertensive cohort separated according to 
genotype at -1889 and -1859 of CYP 11 B I (11 P-hydroxylase ). However, there was 
no significant difference in mean blood pressure between the genotype groups when 
the cohort was separated according to the -1889 and -1859 polymorphisms. This is 
perhaps not surprising as all the BRIGHT study subjects are significantly 
hypertensive (within the upper 5% of the blood pressure range) and so it seems 
unlikely that a predisposition to higher blood pressure would be detected. 
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There was no association found between the -1889 and -1859 polymorphisms and 
urinary excretion levels of THAldo. Our group has previously reported an 
association between the CYP 11B2 -344 T and IC conversion alleles and increased 
urinary excretion of THAldo (Davies et al 1999). Therefore, as the -1889 T and 
-1859 G alleles in CYP 11 BI are in LD with these CYP 11 B2 alleles, a similar 
association with THAldo might be observed. However, this was not the case (see 
table 5.2). A probable explanation for this is that many of the BRIGHT study 
subjects may be on antihypertensive medication that could alter their aldosterone 
levels including diuretics, ACE inhibitors and Ang II receptor blockers. Therefore, a 
more detailed analysis of a large case-control population, ideally of untreated 
hypertensives, is required to evaluate fully the contribution of variation across the 
CYP II B locus to aldosterone levels and hypertension and also the link between these 
phenotypes and the observed reduction in 11 ~-hydroxylase efficiency. 
Aldosterone is known to promote cardiac hypertrophy and fibrosis (Brilla et al 1990) 
(see section 1.9.1.4). Patients with primary aldosteronism are more likely to have left 
ventricular hypertrophy (LVH) than age- and sex- matched subjects with essential 
hypertension of similar severity (Rossi et al1997; Tanabe et al 1997). There have 
been conflicting reports of an association between the -344 CIT polymorphism and 
LVH (Delles et al 2001; Kupari et al 1998; Schunkert et al 1999a). Because the 
-344 and IC polymorphisms have previously been asssociated with increased 
aldosterone levels, the relationship between -1889 and -1859 genotype and LV mass 
was also investigated. No significant association with LV mass was found. This is 
perhaps not surprising as there was no association with aldosterone levels either. 
Also there was an incomplete data set, as many subjects did not have ECG criteria to 
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enable determination of their LV mass, resulting in a small sample size (n = 233). 
Again, analysis of a large case-control population would allow assessment of the 
association of genotype with hypertension and intermediate phenotypes such as 
aldosterone levels and markers of cardiovascular function such as LV mass. 
An interesting association was found between the -1889 G/T and -1859 A/G 
polymorphisms and waist/hip ratio (see table 5.2). Those subjects homozygous for 
the -1889 T allele showed higher waist/hip ratio than those homozygous for the G 
allele (p = 0.015). Similarly, subjects homozygous for the -1859 G allele had higher 
waist/hip ratios than those homozygous for the A allele (p = 0.013). The reason for 
this association is not entirely clear. An increased waist/hip ratio indicates an 
increased centralization of body fat stores. The positive correlation between cortisol 
and waist/hip ratio is well established (Fraser et al 1999; Marin et al 1992). This is 
highlighted by the phenotype of extreme cortisol excess (Cushing's disease) where 
there is grossly increased central obesity (see section 1.10.1). However there was no 
significant difference in cortisol levels between the -1889 or -1859 genotypes (see 
table 5.2). It is these same alleles ( -1889 T and -1859 G) that were also found to 
associate with an impaired 11 ~-hydroxylase efficiency and so cortisol levels may be 
maintained due to an mildly increased ACTH drive to the adrenal. Two possible 
explanations may therefore be considered. Firstly, a slight increase in ACTH 
production may have effects on the levels of other steroids such as the adrenal 
androgens. Obesity is known to be associated with variations in adrenal androgen 
synthesis, metabolism and action that differ according to sex. A recent study 
demonstrated an increased ACTH level in obese subjects and that this increased 
activity of the HP A axis correlates positively with androgen levels in obese women 
whereas the reverse association was observed for obese male subjects (Vicennati et 
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a! 2006). The explanation for these observations remains unclear. The second 
possible explanation is that sites of origin for corticosteroids other than the adrenal 
cortex might be affected by genetic variation in CYP II B I. It is of interest that there 
is increasing evidence of extra-adrenal expression of steroidogenic enzymes such as 
lip-hydroxylase (Davies & MacKenzie 2003) and the CYP IIBI gene was recently 
found to be transcribed in omental but not subcutaneous adipose tissue of the rat 
(MacKenzie et a! 2006). However, both its regulation and its physiological 
significance remain to be determined, but it could be speculated that the -1889 T and 
-1859 G variants are associated with altered expression of CYP 11BI in fat tissue 
resulting in an increased local production of corticosteroids. 
In summary, this study confirms that the -1889 G/T and -1859 A/G polymorphisms 
located in the 5' regulatory region of CYP II BI associate with liP-hydroxylase 
efficiency in a hypertensive population. It seems likely that the reduced liP-
hydroxylase efficiency previously associated with the -344 T and IC conversion 
alleles in CYP 11 B2 is due to linkage with the -1889 T and -1859 G alleles in 
CYP II B I. However, in vitro expression studies are required to determine whether 
the -1889 and -1859 polymorphisms have functional effects on CYP 11 B I 
transcriptional regulation. 
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CHAPTER6 
Functional Effects of the CYPJJBJ S'UTR 
Polymorphisms and their Association with 
Hypertension 
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6.1 Introduction 
As mentioned previously (see section 1.16.2), the -344 CIT and intron 2 conversion 
variants in the aldosterone synthase (CYP 11B2) gene are associated with increased 
levels of 11-deoxycorticosterone (DOC) and 11-deoxycortisol (S) (and their urinary 
metabolites) (Davies et al 2001; Hautanena et al 1998; Kennon et al 2004). This 
reflects a reduced efficiency of adrenal 11 ~-hydroxylase and is likely to be a 
consequence of variation in the adjacent and highly homologous CYP 11 B 1 (11 ~­
hydroxylase) gene. The studies described in Chapter 4 confirmed that there is 
strong linkage disequilibrium (LD) across the entire CYP11B locus and that the -344 
CIT and intron conversion variants in CYP 11 B2 are in LD with several variants in 
CYP 11 B1. Two of these were novel polymorphisms identified within the 5'UTR at 
positions -1889 (GIT) and -1859 (NG). The studies described in chapter 5 
demonstrated a significant association between these polymorphisms and the ratio of 
THSitotal F (a marker of 11~-hydroxylase function) in a cohort of subjects from the 
BRIGHT study. To test whether these polymorphisms can cause differences in 11 ~­
hydroxylase efficiency, their effects were studied in vitro. 
6.2 Aims 
The aims of this study were to determine the effects of the -1889 GIT and -1859 AIG 
polymorphisms on CYP 11 B 1 basal transcription and response to stimuli in vitro 
using a luciferase reporter gene system. 
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6.3 Methods 
6.3.1 Investigation of Reporter Gene activity in vitro 
All 4 combinations of the -1889 and -1859 alleles were created in vitro using the 
Quick-Change site-directed mutagenesis kit (Stratagene Ltd, Cambridge, UK) and 
the pB1-1937 plasmid as a template (section 2.1.4). The allele combinations of each 
construct and the CYP lJ B2 genotypes they associate with are shown in table 6.1. 
Large scale purified preparations ofthe pB1-1937 wildtype, each of the mutants and 
the psvpGal control vector were made, analysed by restriction digestion and 
sequenced (sections 2.1.1, 2.1.2, 2.2.6). Transient transfection was carried in Y-1 
adrenal cells (section 2.4.1). Cells were incubated with or without agonist; ACTH 
(lJ.lM), dibutyryl cAMP ((Bu2)cAMP) (lmM) or Forskolin (lOJ.lM) for 24 hours. 
Cell lysates were prepared and luciferase activity measured to determine reporter 
gene activity (section 2.1.5). Protein levels and p-galactosidase activity were also 
measured to determine cell number and transfection efficiency and the luciferase 
results were corrected appropriately (sections 2.1.5 and 2.4.2). 
Construct -1889 residue -1859 residue CYPJJB2 Association 
1 G A CC/WtWt, TT/WtWt 
2 G G Rarely seen 
3 T A Rarely seen 
4 T G TT/ConCon 
Table 6.1 Constructs used for transfections showing their -1889 and -1859 allele 
combinations and the CYP 11B2 genotypes they would associate with. 
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6.3.2 Statistics 
The in vitro expression results for each construct were compared to the appropriate 
control using an unpaired 2-sample t test. Whether the allele frequencies of -1889 
G/T and -1859 A/G within the BRIGHT case-control study were in Hardy Weinberg 
equilibrium was determined using a Chi-squared test. The demographic 
characteristics were not normally distributed and so a comparison of the cases versus 
controls wasdetermined using a Mann-Whitney test. In all circumstances, a p value 
of less than 0.05 was accepted as significant. 
6.3.3 Investigation of Transcription Factor Binding Sites 
To investigate whether the -1889 G/T and -1859 A/G polymorphisms reside within 
putative transcription factor binding sites, the DNA sequence surrounding them was 
analysed usmg the Transcription Element Search Software (TESS) 
(http://www.cbil.upenn.edu/tess) as well as the programme Matlnspector (Quandt et 
al1995). 
6.3.4 Study Subjects 
The BRIGHT case-control association study comprises 800 unrelated hypertensive 
subjects (from the total of> 2000 affected sibling pairs and trios) with 800 age- and 
sex- matched normotensive control subjects. Full demographic information (as 
medians and inter-quartile ranges) on the subjects included is shown in table 6.2. 
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CASES CONTROLS p value 
AGE (years) 60 (52-66) 60 (52-66) NS 
MEANSBP 
154 (141-249) 124 (116-132) < 0.0001 
(mmHg) 
MEANDBP 
93 (86-101) 77 (73-82) < 0.0001 
(mmHg) 
BMI (kg/m2) 27 (25-30) 25 (23-27) < 0.0001 
Table 6.2. Demographic information on BRIGHT case-control study sub-groups 
SBP- systolic blood pressure, DBP-diastolic blood pressure, BMI-body mass index, 
NS- non-significant. 
6.4 Results 
6.4.1 Restriction Digestion of Plasmids 
The pB1-1937 construct comprises the pGL3-Basic vector backbone (4.8 kb) 
(Promega Corp., Southampton, UK) and an insert of approximately 1.9kb. The 
plasmid DNA was digested using the restriction enzyme BamHI to assess quality and 
the presence of an insert of appropriate size. This enzyme does not cut the B 1 5' 
UTR insert but linearizes the pGL3-Basic vector by hydrolysing it at a single site to 
produce a fragment of approximately 6.7kb. BamHI digests are shown in figure 6.1. 
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1 2 3 4 
G+A G+G T+A G+T 
6,000 bp ..... 
4,000 bp ..... 
1,000 bp .... 
Figure 6.1. BamHI digests of pB1-1937 constructs 
Analysed on a 1% agarose gel stained with ethidium bromide. BamBI linearises the 
pGL3 Basic vector backbone to generate a 6. 7kb band. A single band of the correct 
size confirms the presence of the CYP JJBI eDNA insert. Lane L contains 5 !J.l 
HyperLadder I (Bioline, London, UK). 
6.4.2 Confirmation of Mutations 
The presence of each of the mutants was verified by sequencing using the automated 
sequencing method described in section 2.2.6. The entire insert was sequenced to 
rule out the incorporation of any unwanted mutations. Sequence data are shown in 
figure 6.2. 
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Construct 1 
G+A 
Construct 2 
G+G 
Construct 3 
T+A 
Construct 4 
T+G 
-1889 -1859 
AA GGTGTATAAGAATGCTTGTGATTTTTGTACA TGA 
AA T T AT AA AA T CTT T ATTTTT T A CA 
AA GGTGTATAAGAATGCTTGTGATTTTTGTAC G TGA 
AA T T A T AA AA T CTT T ATTTTT T A C T A 
1~,· ' A ~ lj I~ J 
AA T GTGTATAAGAATGCTTGTGATTTTTGTACA 
AA T T T A T AA AA T CTT T ATTTTT 
~ ti l \~~ ~ 
TGTATAAGAATGCTTGTGATTTTTGTAC G 
AA T CTT T A TTTTT T A C 
TGA 
T A 
.rJ 
I 
Figure 6.2. Electropherograms confirming the incorporation of the desired 
mutations in each of the pBl-1937 constructs. 
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6.4.3 Transcriptional actvity in vitro 
Investigation of the -1889 G/T and -1859 A/G single base changes using luciferase 
reporter gene constructs revealed no significant effect on basal expression levels 
(figure 6.3). The construct containing the -1889 T and the -1859 G alleles had a 
significantly reduced response to stimulation with 1J.-LM ACTH (p = 0.001) when 
compared to the wildtype allele combination -1889 G and -1859 A (figure 6.4). The 
other 2 constructs (G + G and T +A) also appeared to have a reduced response to 
ACTH stimulation compared to the wildtype (G + A) but this did not quite reach 
statistical significance (G + G p = 0.092, T + G p = 0.088). Treatment with 1mM 
(Bu2)cAMP failed to stimulate reporter gene activity (figure 6.5). Treatment with 
10J.-LM Forskolin produced a similar pattern to that of ACTH. Construct 4 (T + G) 
had a significantly reduced response to forskolin compared to the wildtype construct 
1 (figure 6.6 p = 0.025). Again, constructs 2 (G + G) and 3 (T +A) appeared to have 
a slightly reduced response to stimulation compared to wildtype but this was not 
statistically significant (G + G p = 0.514, T + G p = 0.311 ). 
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Figure 6.3. Effects of the -1889 G/T and -1859 A/G variants on basal 
transcriptional activity 
Y -1 adrenocortical cells were transfected with luciferase reporter constructs 
containing pB 1-193 7 (1 J...Lg) with various combinations of the -1889 and -1859 alleles 
for 48 hours. Construct 1, referred to as the wildtype (-1889 G and -1859 A), is most 
commonly associated with the CC/WtWt and TT/WtWt CYP11B2 genotypes. 
Construct 4 ( -1889 T and -1859 G) contains the alleles found in linkage with the 
CYP 11 B2 TT /Con Con genotype. Results are expressed as a percent of the wild type 
(construct 1) activity. The results represent the mean ± SEM of data from six 
independent experiments, each with an n of 3 to 9. Each construct was compared to 
the wild type (construct 1) using an unpaired 2-sample t test. 
No significant difference was observed between the constructs under basal 
conditions. 
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BASAL 1 J.tMACTH 
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Figure 6.4. Effects of the -1889 G/T and -1859 A/G variants on transcriptional 
activity in response to ACTH. 
Y -1 adrenocortical cells were transfected with luciferase reporter constructs 
containing pB1 -1937 (lJ..!g) with various combinations of the -1889 and -1859 
alleles. Construct 1, referred to as the wildtype (-1889 G and -1859 A), is most 
commonly associated with the CC/WtWt and TT/WtWt CYP11B2 genotypes. 
Construct 4 (-1889 T and -1859 G) contains the alleles found in linkage with the 
CYP JJB2 TT/ConCon genotype. Following transfection for 42 hours cells were then 
incubated with ACTH (1 J..!M) for 6 hours. Results are expressed as a percent of the 
basal reporter activity of the wildtype (construct 1) and represent the mean± SEM of 
data from three independent experiments, each with an n of 3 to 9. The results for 
each construct were compared to the appropriate control (basal or stimulated 
wildtype) using an unpaired 2-sample t test. 
* P <0.001 compared with G+A stimulated 
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Figure 6.5. Effects of the -1889 GIT and -1859 AJG variants on transcriptional 
activity in response to dibutryl cAMP. 
Y -1 adrenocortical cells were transfected with luciferase reporter constructs 
containing pB1 -1937 (lf.!g) with various combinations of the -1889 and -1859 
alleles. Construct 1, referred to as the wildtype (-1889 G and -1859 A), is most 
commonly associated with the CC/WtWt and TT/WtWt CYPJJB2 genotypes. 
Construct 4 (-1889 T and -1859 G) contains the alleles found in linkage with the 
CYP JJB2 TT/ConCon genotype. Following transfection for 42 hours cells were then 
incubated with dbcAMP (lmM) for 6 hours. Results are expressed as a percent of 
the basal reporter activity of the wildtype (construct 1) and represent the mean ± 
SEM of data from two independent experiments with ann= 3 and n = 6 respectively. 
The results for each construct were compared to the appropriate control (basal or 
stimulated wild type) using an unpaired 2-sample t test. 
No significant difference was observed between any of the constructs stimulated with 
dbcAMP. 
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Figure 6.6. Effects of the -1889 G/T and -1859 A/G variants on transcriptional 
activity in response to Forskolin. 
Y -1 adrenocortical cells were transfected with luciferase reporter constructs 
containing pBl-1937 (l~g) with various combinations of the -1889 and -1859 
alleles. Construct 1, referred to as the wildtype (-1889 G and -1859 A), is most 
commonly associated with the CC/WtWt and TT/WtWt CYP11B2 genotypes. 
Construct 4 (-1889 T and -1859 G) contains the alleles found in linkage with the 
CYP 11 B2 TT/ConCon genotype. Following transfection for 42 hours cells were then 
incubated with forskolin (10 ~M) for 6 hours. Results are expressed as a percent of 
the basal reporter activity of the wildtype (construct 1) and represent the mean ± 
SEM of data from three independent experiments, each with an n of 3 to 9. The 
results for each construct were compared to the appropriate control (basal or 
stimulated wildtype) using an unpaired 2-sample t test. 
* P = 0.036 compared with G+A stimulated 
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6.4.4 Transcription Factor Binding Sites 
Analysis of the sequence surrounding the -1889 G/T and -1859 A/G polymorphisms 
revealed that they disrupt several putative transcription factor binding sites. 
Comparison of the likelihood scores of the identified binding elements and 
investigation of which transcription factors were most likely to be found in 
steroidogenic tissues suggested that the most likely binding sites were an Sp 1 site 
encompassing residue -1889 and a half GRE encompassing residue -1859 (figure 
6.7). 
6.4.5 Frequency of -1889 GIT and -1859 A/G in BRIGHT case-
controls 
The allele frequencies for both -1889 G/T (0.546/0.454 vs. 0.562/0.438) and -1859 
AIG (0.524/0.476 vs. 0.527/0.473) were almost identical in the hypertensive and 
normotensive control groups (see table 6.3). The alleles of both -1889 G/T and 
-1859 A/G were in Hardy-Weinberg equilibrium in both groups, with Chi-square 
values of 0.002 and 0.04 respectively in the hypertensive group and 3.79 and 1.04 
respectively in the control group. 
-1889 G -1889 T - 1859 A -1859 G 
CASES 0.546 0.454 0.524 0.476 
CONTROLS 0.562 0.438 0.527 0.473 
Table 6.3. Allele frequencies of -1889 G/T and -1859 A/Gin the BRIGHT case-
control association study 
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GR ~------------~ 
Putative Sp1 
Binding Site 
Putative 
HalfGRE 
Transcription Factor 
-1864/-1859 GR 
-1891/-1882 Sp1 
Binding Sequence 
TGTACA 
G 
AGGGcGTATA 
T 
Figure 6.7. Map of the novel putative transcription factor binding sites in the 
hCYPllBl S'UTR. The blue A and G represent the -1859 polymorphism and the 
red G and T represent the -1889 polymorphism. 
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6.5 Discussion 
The two novel single nucleotide polymorphisms (SNPs) identified in the 5'UTR of 
CYP 11 B 1 at positions -1889 (G/T) and -1859 (A/G) are in linkage disequilibrium 
(LD) with the -344 CIT and intron conversion variants in CYP 11 B2. These have the 
potential to alter transcriptional regulation of the CYP 11 B 1 gene and therefore may 
account for the observed biochemical phenotype of decreased 11 P-hydroxylation. 
This study investigated the effects of the -1889 G/T and -1859 A/G SNPs on 
CYP 11B1 gene transcription in vitro using a luciferase reporter gene system. The 
variants at each locus were tested individually and in combination. Their effects on 
basal expression as well as the response to various agonists were examined. No 
significant difference was observed between any of the constructs' basal expression 
levels. This is perhaps not surprising as a previous study examining the 
transcriptional regulation of human CYP 11 B1 gene indicated that the DNA region 
between -214 and -65 was sufficient for basal gene expression (Wang et al 2000). 
Regions upstream of this (up to -11 02bp) had no effect on basal expression levels. 
Treatment with (Bu)2cAMP had no effect on the reporter gene activity of any of the 
constructs. However, previous studies report a lack of cell responsiveness to this 
cAMP analogue in some Y -1 cell strains (Clyne et al 1996). ACTH is the main 
regulator of CYP 11 B1 expression in vivo. It stimulates expression of the 
steroidogenic enzymes and steroid hormone production through activation of the 
cAMP signalling pathway. Forskolin is a small molecule agonist of adenylate 
cyclase which bypasses the ACTH receptor by binding directly to adenylate cyclase 
and increasing cAMP synthesis. Compared to 'wild type' (-1889 G and -1859 A), 
the construct containing the -1889 T and -1859 G alleles halved reporter gene 
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activity m response to the agonists ACTH and forskolin, indicating reduced 
transcription (see figures 6.3 to 6.6). The individual base changes represented by 
constructs 2 and 3 (G + G or T + A) also had a slightly reduced response to either 
ACTH or Forskolin stimulation when compared to wildtype but this did not reach 
statistical significance. This suggests there is an interaction between the -1889 T and 
-1859 G variants resulting in a reduced transcriptional efficiency. This might occur 
if they are located within the binding sites of co-operative transcription factors (see 
below). These results support the urinary steroid results from Chapter 5, which 
indicated that the -1889 T and -1859 G alleles were associated with an impaired 
11 P-hydroxylase efficiency. They strongly suggest that the reduced 11 P-
hydroxylation associated with the T /Con haplotype in CYP 11 B2 is due to linkage 
with the -1889 T and -1859 G variants in CYP IIBI. 
To investigate why these variants are important for transcriptional regulation of 
CYP II B I, the sequence surrounding them was analysed computationally for putative 
transcription factor binding sites. Several possible candidates were generated. The 
most promising of these were a putative Sp1 (selective promoter factor 1) binding 
site (-1891/-1882) and a half GRE (-1864/-1859) encompassing the -1889 G/T and 
-1859 A/G polymorphisms respectively. Sp1 belongs to a large family of protein 
factors that all recognize similar sequences and have similar transactivation 
properties (Hagen et al 1992; Kingsley & Winoto 1992). Sp 1 regulates the 
transcription of many genes; it stimulates the cAMP-dependent transcription of 
steroidogenic genes including bovine CYP llAI (P450scc), human StAR gene, 
CYP I7 (P450cl7) and ferrodoxin (Lin et al2001; Liu & Simpson 1997; Sugawara et 
al2000; Yeh et al2000). Sp1 usually binds to the DNA sequence GGGGCGG with 
high affinity (Letovsky & Dynan 1989). However, variant G-rich sequences that 
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deviate by at least one nucleotide and bind Sp 1 with lower affinity seem to be 
sufficient for steroidogenic transcription (Y eh et al 2000). 
The close proximity of the Sp1 binding site and the half GRE is of great interest as 
glucocorticoid binding sites can act synergistically with binding sites for other 
transcription factors, including Sp 1 (Schule et al 1988; Strahle et al 1988). The 
significance of the half GRE is unclear. However, as mentioned in Chapter 1, 
steroid/GR complexes have been shown to bind composite GREs comprised of GRE 
and a binding site for another transcription factor such as AP 1 (Diamond et al 1990; 
Pearce & Yamamoto 1993; Zhang et al 1991 ). In these instances, it is thought that 
both DNA binding by the steroid/GR complex and protein-protein interactions with 
other factors are required to determine transcription. Whether a half GRE is 
sufficient for steroid/GR binding and whether the half GRE and the Sp 1 sites are 
close enough to establish an interaction remain to be determined. It will be of 
interest to determine whether these putative transcriptional factor binding sites are 
capable of altering function. Electrophoretic mobility shift assay experiments would 
determine whether Sp 1 and a steroid/GR complex are capable of binding to these 
putative binding sites and whether this binding is disrupted by the presence of the 
-1889 T and -1859 G variants respectively. 
To investigate the role of the half GRE, it would be interesting to determine the 
effect of the synthetic glucocorticoid, dexamethasone, on the reporter gene 
expression of each of the constructs. This would test whether the presence of the 
-1859 G variant that appears to disrupt the half GRE alters the transcriptional 
response. However, as there seems to be an interaction between the -1889 T and 
-1859 G variants following stimulation, the effect of dexamethasone on the response 
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to ACTH or forskolin stimulation should also be tested. It is possible that, in 
response to stimulation, there is an increased activation of Sp 1. Therefore, it would 
also be interesting to investigate the effect on reporter gene expression, for each 
construct, of cotransfecting with an expression vector containing Sp 1. The combined 
effect of cotransfecting with Sp 1 and incubating with dexamethasone in the absence 
or presence of ACTH should indicate whether there is any interaction between the 
two proposed binding sites. 
11~-Hydroxylase efficiency is mildly impaired in subjects with essential 
hypertension compared to controls (Connell et al 1996; de Simone et al 1985). The 
-344 T and IC conversion alleles have been shown to occur more frequently in 
hypertensive subjects, particularly those with a raised ARR (Lim et al 2002b ). As 
mentioned in Chapter 4, the -344 CIT and IC polymorphisms are also in LD with 
other variants in CYP 11 B2 that may also alter the relationship between aldosterone 
and Ang II. 
To determine if the CYP11B1 -1889 G/T and -1859 A/G polymorphisms are 
associated with hypertension, their frequencies were compared in a subset of the 
BRIGHT study with age and sex matched controls (see table 6.2). There was no 
apparent difference in allele frequencies between the hypertensive and normotensive 
control groups for either polymorphism (see table 6.3). This may indicate that, 
although they may account for the intermediate phenotype of reduced 11 ~­
hydroxylase efficiency, they are not directly associated with hypertension. However, 
a more detailed analysis of a large case-control population using haplotype tags is 
required to evaluate fully the contribution of the CYP 11 B locus to hypertension. 
Additionally, a more detailed stratification of sub-phenotypes within essential 
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hypertension will be required before the contribution of single gene loci can be 
determined. For example, it is possible that one or more of the novel SNPs identified 
in CYP II B2 have effects on enzyme activity or expression, resulting in increased 
aldosterone levels that have previously been associated with the T/Con haplotype. 
Recent reports that 10 to 15% of patients with essential hypertension have a raised 
ARR suggest that altered aldosterone regulation may be a relatively common feature. 
This study demonstrates that the -1889 G/T and -1859 A/G polymorphisms in 
CYP 11 B I that associate with reduced 11 ~-hydroxylase efficiency are in LD with 
those variants in CYP II B2 that associate with higher aldosterone levels. How the 
two effects are related requires further investigation. 
In conclusion, the -1889 G/T and -1859 A/G polymorphisms in the 5'UTR of 
CYP II B I have significant effects on gene transcription. This is the first time that 
single nucleotide polymorphisms in the regulatory region of CYP II B I have been 
shown to have a major effect on gene transcription. This study strongly suggests that 
the impaired 11~-hydroxylase efficiency previously associated with the -344 T and 
IC alleles in CYP II B2 is due to linkage with these two novel polymorphisms in the 
5' regulatory region of CYP II BI. 
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CHAPTER 7 
General Discussion 
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Hypertension and cardiovascular disease are maJor human health issues with 
important yet undefined genetic components. In Chapter 1, the case was made that 
corticosteroids, and in particular aldosterone, are central influences in these 
processes. Aldosterone can cause both hypertension and cardiac remodelling and 
recent studies using the ARR as a screening tool suggest that altered aldosterone 
regulation may be a relatively common feature of essential hypertension (see 
sections 1.9.1, 1.10.2 and 1.16). Moreover, genetic variants in the aldosterone 
synthase, CYP 11 B2, gene (-344 CIT and I C) correlate both with increased 
aldosterone levels and raised blood pressure in many studies. However, these 
probably do not explain either biochemical or clinical differences for two reasons. 
Firstly, when tested in vitro, the -344 CIT polymorphism did not influence 
aldosterone synthesis. Secondly, the biochemical phenotype most consistently 
associated with these variants was altered 11 ~-hydroxylation efficiency, which draws 
attention to the homologous gene CYP llBI (see section 1.16.2). It was plausible to 
suggest that the association of increased aldosterone levels and reduced 11 ~­
hydroxylase efficiency with the -344 CIT and IC variants is indirect through other 
linked genetic variations. The studies described in this thesis have addressed this 
question. Are the two phenomena, altered aldosterone levels and altered 11 ~­
hydroxylation, separate or linked? Polymorphic variation across the entire 
CYP JJB2/BI region was evaluated. The functional significance of some newly 
identified variations was tested. Finally, preliminary evaluation of possible clinical 
importance was made. 
An important and unequivocal observation that can be made from these studies is 
that there is a high degree of sequence variation within the CYP II B I and CYP II B2 
genes. Despite the potential this gives for many haplotypes, the degree of linkage 
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disequilibrium is so great that most alleles fall within four common haplotypes. This 
identified many polymorphic differences in both genes that are linked to the -344 
CIT and IC variants in CYP 11B2. Therefore, if any of these polymorphisms are 
functional, it is possible that they could explain the biochemical and clinical changes 
associated with these variants. 
The mutations identified in Chapter 3, within the coding region of CYP 11 B I, had 
effects on biochemical activity, causing either increased or decreased enzyme 
activity that in some cases was substrate specific. Although attempts were made to 
determine the locations of these mutants within the protein these were necessarily 
speculative. If the precise 3D crystal structure of 11 ~-hydroxylase was available, the 
specific effects of the different mutants could be valuable in deciphering 
structure/function relationships. 
No clinical associations (with hypertension or ARR) could be made in this study. 
This could imply either that they are not relevant or that the study was not of a design 
to identify a relationship. The study could be improved and developed in several 
ways. Firstly, only the coding regions of CYP II BI were screened. Further mutations 
could exist in the untranslated regions, either 5' or 3' of the gene, or located at 
exon!intron boundaries that may alter splicing, which might associate with 
hypertension and a raised ARR. These studies are currently underway. Secondly, the 
mutation detection was performed by SSCP. Whilst a useful and sensitive technique, 
it has certain disadvantages. The method can be prone to both false positive and 
false negative results. In this instance, the false positives are less of a problem as the 
presence of mutations was confirmed by sequencing. However, false negative results 
mean that important mutations may have been overlooked. The more recent 
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introduction of very stringent, high throughput sequencing methods would remove 
the risk of false positive or negative results and also reduce the labour intensity if the 
study were to be repeated. Finally, the T variant of the -344 CIT polymorphism of 
the adjacent CYP 11 B2 gene has previously been found in higher frequency in 
hypertensive subjects with a raised ARR but this was not the case in the current 
study. An important point is that the investigation outlined in Chapter 3 was not 
powered to look for such an association; the study subjects were chosen on the basis 
of phenotype not genotype. It is therefore more likely that patients selected on the 
basis of genotype associated with a raised ARR might identify specific mutations 
that are linked to the development of this type of hypertension. Therefore, the rest of 
the experimental work of this thesis focused on examining the linkage between the 
-344 CIT and IC variants and other polymorphisms in CYP 11 B2 and CYP 11 B 1 and 
their functional effects and clinical relevance. 
Many novel variants were identified in CYP 11 B2 that are linked to the -344 CIT and 
IC variants. Most of these were within the introns and 3'UTR of CYP 11B2 and their 
functional effects remain to be determined. Of particular interest was the 
identification of 7 SNPs within the 5' regulatory region of CYP 11 B2. Due to their 
potential to alter gene transcription, it is hypothesized that they may provide the link 
between the apparently non-functional -344 CIT polymorphism, increased 
aldosterone levels and hypertension with a raised ARR. Analysis of their effects in 
vitro using reporter gene constructs and investigation of their clinical associations 
will determine if this is indeed the case. However, these were not examined further 
in the present study. 
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An important and new finding described in this thesis is that the -344 CIT and IC 
variants in CYP II B2 are in strong LD with many genetic variants in CYP II B I. Two 
novel and interesting polymorphisms were identified in the 5' regulatory region of 
CYP IIBI at positions -1889 (G/T) and -1859 (A/G). These were found to associate 
with an impaired 11 ~-hydroxylase efficiency in a hypertensive population and to 
significantly alter the transcriptional response of CYP IIBI to stimulation by ACTH 
or Forskolin in vitro (Chapters 5 and 6). Therefore, it seems plausible that it is 
these polymorphisms that account for the observed variations in 11 ~-hydroxylase 
efficiency in vivo. These studies strongly suggest that the reduced 11 ~-hydroxylation 
previously associated with the T/Con haplotype in CYP IIB2 can be explained by 
linkage with the -1889 T and -1859 G variants in the 5' regulatory region of 
CYPIIBI. 
Evidence of a slightly reduced 11 ~-hydroxylase efficiency is a consistent finding in 
subjects with essential hypertension compared to normotensive controls. However, 
preliminary investigation of the -1889 G/T and -1859 A/G polymorphisms in the 
BRIGHT case-control population failed to show any association with hypertension 
(see Chapter 5). Therefore, further studies are required to determine the link 
between this biochemical phenotype and hypertension. For example, a more detailed 
analysis of a much larger case control population with better phenotypic data would 
enable determination of their association with specific subgroups of hypertension 
such as hypertensives with a raised ARR. Also, investigation of an association 
between the common CYP II B haplotypes and hypertension would determine more 
fully the contribution of this region to hypertension. 
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These studies have provided an explanation, with good experimental evidence, for 
the decreased 11 P-hydroxylation efficiency associated with the -344 CIT and IC 
variants; linkage with the CYP IIBI -1889 GIT and -1859 AIG 5' UTR 
polymorphisms. Can these variants also explain the link to raised aldosterone levels? 
One explanation for the increased aldosterone levels and blood pressure associated 
with the -344 CIT is a linkage with other CYP 11B2 5' UTR polymorphisms. Such 
polymorphisms have been identified here but whether they alter aldosterone 
synthesis remains to be determined. An alternative hypothesis that has previously 
been speculated, is that altered 11-hydroxylation efficiency, that is genetically 
determined, might give rise to a phenotype of mineralocorticoid hypertension as a 
result of a long-term but very mild increase in ACTH drive to the adrenal cortex, to 
maintain normal plasma cortisol levels (see section 1.16.3). The results presented in 
this thesis support this theory; analysis of the steroid results in the BRIGHT 
population according to the -1889 GIT or -1859 AIG polymorphisms revealed no 
significant difference in urinary cortisol metabolite excretion between genotypes but 
an increase in THS excretion rate in the -1889 T and -1859 G groups (see Chapter 
5). It has been postulated that this subtle increase in ACTH drive results in an 
enhanced aldosterone synthetic capacity of the adrenal cortex and response to stimuli 
such as angiotensin II or potassium, leading to the phenotype of hypertension with a 
raised ARR (see section 1.16.3). To investigate this hypothesis, it would be 
interesting to compare the ACTH levels of untreated hypertensive patients separated 
according to either CYP JJBJ or CYP JJB2 genotypes or the main CYP liB 
haplotypes. The sensitivity of their aldosterone response to an extremely low dose of 
exogenous ACTH, following suppression of endogenous levels with the synthetic 
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steroid dexamethasone, would determine if there is a link between ACTH drive and 
aldosterone synthesis. However, the impact of a small decrease in 11 ~-hydroxylase 
efficiency could be more fully determined in an animal model. For example rats 
given a very low dose of the 11 ~-hydroxylase inhibitor, metyrapone, would enable 
determination of the full effects of this enzyme inefficiency on adrenal structure and 
function, corticosteroid levels and blood pressure. 
Therefore although an explanation for the paradoxical link between CYP II B2 
variants and 11 ~-hydroxylase function has been provided, the causative link with 
hypertension and a raised ARR remains to be determined. 
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APPENDICES 
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Appendix 1: Nucleotide sequences of human CYPJJBJ and CYPJJB2 
Nucleotide Sequence 
The nucleotide sequences for human CYP llBJ and CYP 1JB2 were obtained from 
the Entrez Nucleotide database. The accession numbers for these sequences are as 
follows: 
CYPlJBJ CYP1JB2 
5' Flanking Region and exon 1 D10169 D10170 
Exon 1 and 2 M32863 D13752 
Intron 2 X85218 D13752 
Exons 3 to 8 M32878 D13752 
Ex on 9 and 3 'UTR M32879 M32881 
Exons are shown in bold and the untranslated regions and intron in lower case. The 
oligonucleotides used for PCR and sequencing, listed in appendix 2, are indicated by 
their name above the relevant highlighted sequence. Where oligonucleotide 
sequences overlap the second sequence is underlined as is the primer name. Sense 
and antisense oligonucleotides are indicated by> and< respectively. 
CYPJJBJ 
BlS'UTR> (B15'7-32 >) 
1 tcctt~QC:at cccttgtaag ttggattcct aagtatttta ttctctttga 
51 agcaattgtg aatgggagtt cactcatgat ttggcctctc tgtttgtctg 
101 ttaagggtgt ataagaatgc ttgtgatttt tgtacattga ttttgtatcc 
151 tagagcttgc tgaagttgct tatcagctta aggagatttt gggctgagac 
< B15'258-238 
201 aatggggttt tctagatata caatcatgtc cgtctgccaa acagagacaa 
251 tttgacttcc tcttttccta attgaatacc ctttatttcc ttctcctgcc 
301 taattgccct ggccagaact tccaacacta tgttgaatag gagtggtgag 
< B15'393-369 F81092 > 
351 agagggcatt cctgtcttgt accagc~~t:c acagggaatg cttccagttt 
246 
401 ttgaccattc agtatgatat tggctgtggg tttgccatag atagctctta 
451 ttattttgag atacgtccca tcaataccta atttattgag agtttttagc 
501 gtgaaggttg ttgaattttg tcaaaggcct tttctgcatc tattgagata 
551 atcatgtggt ttttgtcttt ggttctgttt atatgctgga ttacatttat 
F81093 > 
601 tgatttgcat atattgaacc agccttgcat cccagggatg aagcccactt 
651 gat.catggtg gataagcttt ttgatgtgct gctggattcg gtttgccagt 
701 attttattga ggatttttgc atcaatgttc atcaaggata ttggtctaaa 
751 attctctttt ttggttgtgt ctctgcccgg ctttggtatc aggatgatgc 
801 tggcctcata aaatgagtta gggaggattc cctctctttc tattgattgg 
F81094 > 
851 aatagtttca gaaggaatgg taccagttcc tccttgtacg tctggtataa 
901 ttcggctgtg aatccatctg gtcatggact ctttttggtt ggtaatctat 
951 tgattattgc cacaatttca gatcctgtta ttggtctatt cagagattca 
1001 acttcttact ggtttagtct tgggagagtg tatgtgtcga ggaatttatc 
1051 catttcttct agattttcta gtttatttgc gtagaggtgt ttgtagtatt 
F81095 > 
1101 ctctgatggt agtttgtatt tctgtgggat cggtggtgat atccccttta 
1151 tcatttttta ttgcatctat ttgattcttc tctctttttt tctttattag 
1201 tcttgctagc ggtctatcaa ttttgttgat cctttcaaaa aaccagctcc 
1251 tggattcatt aattttttga agggtttttt gtgtctctat ttccttcagt 
1301 tctgcactga ttttagttat ttcttgcctt ctgctagttt tgaatgtgtt 
1351 tgctcttgct tttctagttc ttttaattgt gatgttaggg tgtcagtttt 
1401 ggatctttcc tgctttctct tgtgggcatt tagtgctata aatttccctc 
1451 tacacactgc tttgaatgtg ttccagagat tctggtatgc tgtgtctttg 
1501 ttctcgttgg tttcaagaac atctttattt ctgccttcat tttgttacgt 
1551 acccagtagt cattcaggag caggttgctc agtttccatg taattgagcg 
F81097 > 
1601 gttttgagtg agtttcttaa tcctgagttc tagtttgatt gcactaaaat 
1651 ttttaaaaag taaaaaaaat acatgtggtt taatacaatt catgccaact 
1701 cattccctcg ttttttgcta taaaccttgc 
< Blprom-260(as) 
aaggagatga ataatccaag 
1751 gctcttggat aagataaggg ccccatccat cttgctcctc tcagccctgg 
1801 aggaggaggg agagtccttt tcccctgtct acgctcatgc acccccaatg 
F31463 > 
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1851 agfCcctgcc tccagccctg 
'~~~~-·· ... -- " 
acctctgccc tcggtctctc aggcagatcc 
1901 agggccagtt ctcccatgac gtgatccctc ccgaaggcaa ggcaccaggc 
1951 aagataaaag gattgcagct gaacagggtg gagggagcat tggaATGGCA Exl 
<B9865 
2001 CTCAGGGCAA AGGCAGAGGT GTGCATGGCA GTGCCCTGGC TGTCCCTGCA 
2051 AAGGGCACAG GCACTGGGCA CGAGAGCCGC CCGGGTCCCC AGGACAGTGC 
2101 TGCCCTTTGA AGCCATGCCC CGGCGTCCAG GCAACAGGTG GCTGAGGCTG 
2151 CTGCAGATCT GGAGGGAGCA GGGTTATGAG GACCTGCACC TGGAAGTACA 
2201 CCAGACCTTC CAGGAACTGG GGCCCATTTT CAGgtaaagc cctccctggc 
2251 cctcgctgga acacccagtg ccctgccctt gctgcccagg accctgccgg 
2301 gcactcagca ctgccattcc cagcaggtcc cggcactctg catcctttgg 
2351 aagagggaag atcgagcacg tgctgtctgt gcgctgcagg gcagggcatg 
2401 tgcagagcaa atgggagctc ggctgcagag agggcaggac tcagaggcac 
2451 tgaagttaag aggttccggg cagtcagcaa gagggcgttt agctgtgaag 
2501 ccgctaatcc aggagagggg agggtggaca ggagacactt tggattggga 
Y6265 > 
2551 ctgcagggtg gggccagcag ggactagacc ccgtccagca gggcctcctg 
2601 cttggcccca cagGTACGAT TTGGGAGGAG CAGGCATGGT GTGTGTGATG Ex2 
2651 CTGCCGGAGG ACGTGGAGAA GCTGCAACAG GTGGACAGCC TGCATCCCCA 
2701 CAGGATGAGC CTGGAGCCCT GGGTGGCCTA CAGACAACAT CGTGGGCACA 
< Y6266 
2751 AATGTGGCGT GTTCTTGCTg taagcggcga gctgagagct gggagcaggg 
2801 tggcagcctg gtgtaggggg gaggcgagag aggcaggacc caaaagcaca 
2851 tctgccctgg gcccctgtgg tgggcagtga gggtgagcac ccgacccaga 
2901 ggacggccat tccgtggggt cgtgtctgcc ctgtggttgg ggaagcaggg 
2951 cgtggtggag aaatgggcac gggcacctct gcagagaaga tgcagagcaa 
3001 tgagcccttc tgtgtagtga gaacccgctc tgcaccaacc ttggcggatg 
3051 ctttctcttg cggtctgggg actgtcttcc ataggtcaga aaactgaggc 
3101 ctgagaaggt actccactgg cccaggtcac aggctgagta ctgagcctgt 
3151 ggttcgccgg ggccgcagcc tccctcaggg cgctcagggt ccctgcagtc 
3201 ctggcaaacc ttcctgatgg ggacagtccg gggcaggagg caggtgggga 
Bl lnt2(3280) > 
3251 tgcaggtggc tggtggctcc attgttctca gaagc:aaggc ac:gaggtg~g 
248 
3301 gcggttgatg gcactgggga ggatgtttcc tggccctgcg agatgggcgg 
3351 ccgttggtca ggtgggcagg gagaggctga tgcttggagt cagtcacctg 
3401 caggaatgtt gtcattagga cgggggaagg actggacgag gatgtcacag 
3451 tggcgacagc ccccactcca tggcaggagg agaacgcttt tgggaatagt 
3501 ggggtttagg taaaagggca cccaagggtg ggggccttca ctgaggctgg 
Bl Int2(3580) > 
3551 cctacagacg gacatctggg agggagtcag gacccaggaa ggcaagtcca 
.. .. . .. . 
3601 gaaggctggg tgcacataac ggaaggaagg ggagcgcacc tgtatgtgtg 
3651 tgtgtcttgc atctgtgcac atctgtgtgt ttctctgtac ctgcatttgc 
3701 acgtgttgtg tgtgcancgt gtgtgcacgt gtctgtgtgc atgtatgtgt 
3751 ggtgtgtgtg cacgagtgtc tctgtgtgtg catgtgcagg tgctggcatg 
3801 ggtgtagtgt ctgtgcactt gtgtacatgt gtctcttcac acatggtgtt 
3851 gaggtcttgc atgggcgcat gtgagcatgt gcatcttctg cctgccatca 
' ' 
Bl Int2(3890) > 
3901 ctgtcaacag ctcacagcca gctggacata aataaagctt tgagttttgc 
3951 aggaatgtgg ctgacagggg aaattcctcc ccaccattcc ctggggcatc 
4001 catggagccc ccacgcactc tggctgtagg tgaggatggc atgaagcaca 
4051 aagcttggtt tctgtcctgc agaagatgca gacacttcag tcctgctgcc 
4101 ccagaggcac tgtgcccagg gcagggaagg gcggggagga gagggcagcc 
4151 aggggctctc ccctcaggac actgtgtggg tgaggtgggc aaagcttgac 
4201 aacaggggtc agttcctttc ttgcagaaaa tccctccccc ctactacagg 
4251 gagggcccgc atgggtgagg tggtgccaga cttggggcgc caggtcccgg 
4301 gaatgacctc agttaccctg tcagcacctg tgggcagaag ctaccatctc 
4351 atccctgctt agacctgagt ggcctttgtc cagcacctgg aggcsstctg 
4401 agaaaaggct gcagctcgaa cacaaacagg cagcttctac cagggccccc 
Y6263 > 
4451 agtcagctcc ctgcaggccg attccccttg ggacaaggag gatgggatac 
' . ' ······ 
4501 gggtcagggc ctgtgtcttg ctggggcggc ctcacaagct ctgccctggc 
< N4020 
4551 ctctgtagGA ATGGGCCTGA ATGGCGCTTC AACCGATTGC GGCTGAATCC Ex3 
4601 AGAAGTGCTG TCGCCCAACG CTGTGCAGAG GTTCCTCCCG ATGGTGGATG 
4651 CAGTGGCCAG GGACTTCTCC CAGGCCCTGA AGAAGAAGGT GCTGCAGAAC 
4701 GCCCGGGGGA GCCTGACCCT GGACGTCCAG CCCAGCATCT TCCACTACAC 
249 
4751 CATAGAAGgt gtgggccaca tgggttgatc cagcctcaga gaccctggag 
4801 tggccaggga cggggatggg ggactgaagg gagtgtgggg aggcagccag 
B4250 > 
4851 gaggcccggt tcccttgtgc tcagcagtgc atcctccccg cagCCAGCAA Ex4 
4901 CTTGGCTCTT TTTGGAGAGC GGCTGGGCCT GGTTGGCCAC AGCCCCAGTT 
4951 CTGCCAGCCT GAACTTCCTC CATGCCCTGG AGGTCATGTT CAAATCCACC 
5001 GTCCAGCTCA TGTTCATGCC CAGGAGCCTG TCTCGCTGGA CCAGCCCCAA 
5051 GGTGTGGAAG GAGCACTTTG AGGCCTGGGA CTGCATCTTC CAGTACGgtg 
5101 aggccaggga cccgggcagt gctatgggga aggacaccat cgggccccca 
<B4251 
5151 atttctccct ctccaccacc cagtggggaa tggaggccac agggaggggt 
5201 cggggattcc tcaccgtcct gccagggaga ttggtgtgag gctggggctg 
5251 ggctgggctg atccggagaa tttgggatga gagcagggag acttggtgct 
M6642 > 
5301 gggctagctg gcaggaggag gacactgaag gatgtttccc agcaccaaag 
5351 tctgagggct gcctcccgct ccccggatag GCGACAACTG TATCCAGAAA Ex5 
5401 ATCTATCAGG AACTGGCCTT CAGCCGCCCT CAACAGTACA CCAGCATCGT 
5451 GGCGGAGCTC CTGTTGAATG CGGAACTGTC GCCAGATGCC ATCAAGGCCA 
5501 ACTCTATGGA ACTCACTGCA GGGAGCGTGG ACACGgtcag gccggcaacc 
5551 agccccaccc agagagggtg atgccaagcc tgcctcccag gcactgcctg 
<M6643 
5601 ccaatgtcac acggcgccca cgtgtcccat gcccaggcta tgggccccac 
5651 atttcttact tgggattgtg atgtgataaa cacgtttgca ggttgccatg 
5701 gttggaatgg ggggttcctt tccttctgtg gaggactcag ggaaacgggg 
5751 tttggatggg cattaggatt tgaagtcttg ggctctgtcg tgctcagggt 
5801 atgcatgtct gcacccctca cagggaggtt gtcctgggag gggtgtcccg 
F42117 > 
5851 ggggctgagt cctcctgtgc aaggtctgac cctgcagctg tgtctcctgc 
5901 agACGGTGTT TCCCTTGCTG ATGACGCTCT TTGAGCTGGC TCGGAACCCC Ex6 
5951 AACGTGCAGC AGGCCCTGCG CCAGGAGAGC CTGGCCGCCG CAGCCAGCAT 
6001 CAGTGAACAT CCCCAGAAGG CAACCACCGA GCTGCCCTTG CTGCGTGCGG 
< F42299 
6051 CCCTCAAGGA GACCTTGCGg tgggtgctgg ctgaggcctc cctgtggccc 
6101 tggccctgct ggagagtcag cccccactgg gtggttgcag acagaatctg 
6151 ggctataaac acctacccag cagccatcct gactgctctc tcgcgtcaag 
250 
6201 gacagggagc tcttcttcct ctggaatccc tcttcaacgc cctggggatt 
6251 aacgtggggg catgtccttc tgcgctcggg gctgcttaag ttaggggagg 
6301 tttggccggg ctcagcaggt gcaaggaagc acttcctaca cctgggcttc 
6351 ccatggatct gggacctctg cggggtcttc ggtaggaagg gtgcagagag 
Y6259 > 
6401 cacaggaacc ccatcccagc tgagaccctt tctatggatg cccccacctc 
6451 cagGCTCTAC CCTGTGGGTC TGTTTCTGGA GCGAGTGGCG AGCTCAGACT Ex7 
6501 TGGTGCTTCA GAACTACCAC ATCCCAGCTG GGgtgagtga gccccacacc 
<Y6260 
6551 ctcgagctga gaacctccct ccccagtcat tccctgatcc ccgctctgct 
6601 ccgtccgcag ACATTGGTGC GCGTGTTCCT CTACTCTCTG GGTCGCAACC Ex8 
6651 CCGCCTTGTT CCCGAGGCCT GAGCGCTATA ACCCCCAGCG CTGGCTAGAC 
6701 ATCAGGGGCT CCGGCAGGAA CTTCTACCAC GTGCCCTTTG GCTTTGGCAT 
6751 GCGCCAGTGC CTTGGGCGGC GCCTGGCAGA GGCAGAGATG CTGCTGCTGC 
6801 TGCACCATgt gagcaggccc gggctgggga ggggcctggg cggggtctgg 
6851 gcagcatggg cggggcttga gcaatgtggg actggcctcg gcagagtggg 
6901 agtggcctgc atgtttcctg gactgggcag agcgggtact gggagaacct 
6951 gggccaggtt gaggctgtgt aggtcctggg caggagttgg tatggtgagg 
7001 agcgtaccat ctgggtgagg ttgctgctaa accgggtcag gtgggaactg 
7051 ggggaagtcg ggtggagcct gtacaggata gtggggcttg ggcaatacct 
7101 gggctggatg aattctgggc ctgggctgta aggtggggct ggtcaggaat 
M6635 > 
7151 gaaacaggtt ggaggccagg ctgctgttcc cccttcagca taatctctgc 
7201 aactttgagg gtctgagaag gctgcaccac gtgcatgggc tgcggaccaa 
7251 gccagatgga aacccggctt ctgtcctagG TGCTGAAACA CCTCCAGGTG Ex9 
7301 GAGACACTAA CCCAAGAGGA CATAAAGATG GTCTACAGCT TCATATTGAG 
< B1Exon9(as) 
7351 GCCCAGCATG TGCCCCCTC9 TCACCTTCAG .. AGCCATCAAC TAAtcacgtc 
7401 tctgcaccca gggtcccagc ctggcaccag cctccctttc tgcctgaccc 
7451 caggccaccc ctcttctctc ccacatgcac agcttcctga gtcacccctc 
7501 tgtctaacca gccccagcac aaatggaact cccgagggcc tctaggacca 
7551 gggtttgcca ggctaagcag caatgccagg gcacagctgg ggaagatctt 
7601 gctgaccttg tccccagccc cacctggccc tttctccagc aagcactgtc 
251 
7651 ctctggcagt ttgcccccat ccctcccagt gctggctcca ggctcctcgt 
7701 gtggccatgc aagggtgctg tggttttgtc ccttgccttc ctgcctctag 
7751 tctcacatgt ccctgttcct cttcccctgc cagggcccct gcgcagactg 
7801 tcagagtcat taagcgggat cccagcatct agagtccagt caagttccct 
7851 cctgcagcct gccccctagg cagctcgagc atgccctgag ctctctgaaa 
< Bl3'UTR+500 
7901 gttgfcgccc i:ggaataggg tcctgcaggg tagaataaaa aggcccctgt 
' ,- " .,~ '' " 
7951 ggtcacttgt cctgacatcc ccattttcaa gtgatacaac tgagtctcga 
8001 gggacgtgtg ttccccagct gatcgtgtca gcctcatgcc cctggcctca 
8051 tctttcatgg accaggcctt gttccaggag tgggcgttgg gtcctctgct 
8101 tcctgtgctg tcccctgggg aaggtcccaa ggatgctgtc aggagatgga 
8151 agagtcatgt ggggtgggaa cctggggtgt ggttccagaa atgtttttgg 
8201 caacaggaga gacaggattg ggccaacaag gactcagacg agttttattg 
8251 actattctct gaca 
CYPJJB2 
T8303D > 
1 Gaai:tctgca tcctgtgaaa ttatccttca aaagtgaaca taaatatttt 
51 ctcaggtaaa taaaaattga ggggattcgc tgccaataga actgacttgc 
101 cagaaatgtt ttttaaaagt tctgcagaga gaaagaaaat gatacaggtc 
151 agcaaccctg agctacataa agaaaggaag agcatttcag aaggaatcag 
201 taaagagaaa atgaagtctt ttattttttc ttaatcttaa ttgatctaag 
251 agtttgctaa aacaaaacaa caacaataaa aataggccgg gcgcggtgac 
301 tcaccacacc tgtaatccca gcactttggg aggccgaggt gggcagatca 
351 cctgaggtca ggagttcgag actagcctgg ccaacacggt gaaaccccgt 
401 ctctactaaa aatacaaaaa ttagctgggc gtggtggtgg cacatgcctg 
451 taatcccagc tacttgggag gctgaggcgg gagaattgct tgaacccggg 
501 agacagaggt cgcagtgagc cgagatcaca ccattgcact ctagcctggg 
551 cgacagagtg agactctgtc tcaaaaataa ataaataaat aaataaataa 
601 ataataaaaa taaataaata aaagccagaa agtgtatttg atgatcatag 
252 
651 ttatgtatat gtgaaatgaa ggacagcaat gatgcaaggg atgggtgagt 
701 ggaattaaaa atatcttatt atttatttat tttgagatgg agtcttgctt 
751 tgctgcccag gttggagtgc agtgggatga tctcaactca ctgcaacctc 
801 cgcctccttg attcaagcat tcatcttgac tcagcctgct gagaagccga 
851 gattacaggc atgcgccacc acacctggct aattttgtat ttttagtaga 
901 gacagggttt tgccatgttg gccaggctgg tctcgaactc ctgacctcag 
951 gtgatccacc tgcatcagcc tcccaaagtg ctgggatgac agacatgagc 
1001 cactatgccc agcctaagaa tatctgatga ttataaagtg cttgcattac 
1051 ctctgaagct gtatagtgtt atatgaaggt ggagttggag agatgagttt 
1101 taagcgtata ttgcaaactc tagggcaacc actaaagaag tgagacccag 
1151 cctctagaaa aaaaaaaaaa aaaggaaatt agctatcaag ccacgaaaag 
1201 aaatggagga accttaaacg catattacta actgagatac gtcactttga 
1251 aaaggctaca aacggtgtca ttccaactat acaacatttt ggaaaaggcc 
1301 aaagcatggt gatgataaaa aagatcggag atgtcaggga ctggggcagg 
1351 agggatgagc aggcagagca caggttttct tttcctcttt ttaagacagt 
1401 gaaaatactc ctaggatcct gcaaggaggg atacaaatta catacatttg 
1451 tcaaaaccca cagcatgttg accaccagga ggagacccca tgtgactcca 
1501 ggaccctggt tgataacaac gtatcgagat tcctcacatg gaaccagtgc 
1551 gctcctgtgg tggagggtgt acctgtgtca gggcaggggg tacgtggaca 
1601 ttttctgcag tttttgatca attttgcaat gaactaaatc tgtggtataa 
1651 aaataaagtc tattaaaaga atccaaggct ccctctcatc tcacgataag 
1701 ataaagtccc catccatttt actcctctca gccctggaga aaggagaggc 
1751 caggtcccac caccttccac cagcatggac ccccagtcca gaccccacgc 
1801 cttttctcag catcctcaga ccagcaggac ttgcagcaat ggggaattag 
1851 gcacctgact tctccttcat ctacctttgg ctgggggcct ccagccttga 
1901 ccttcgctct gagagtctca ggcaggtcca gagccagttc tcccatgacg 
1951 tgatatgttt ccagagcagg ttcctgggtg agataaaagg atttgggctg 
2001 aacagggtgg agggagcatt ggaATGGCAC TCAGGGCAAA GGCAGAGGTG Exl 
2051 TGCGTGGCAG CGCCCTGGCT GTCCCTGCAA AGGGCACGGG CACTGGGCAC 
253 
2101 TAGAGCCGCT CGGGCCCCTA GGACGGTGCT GCCGTTTGAA GCCATGCCCC 
2151 AGCATCCAGG CAACAGGTGG CTGAGGCTGC TGCAGATCTG GAGGGAGCAG 
2201 GGTTATGAGC ACCTGCACCT GGAGATGCAC CAGACCTTCC AGGAGCTGGG 
2251 GCCCATTTTC AGgtaaagcc ctccctggcc ctcgctggga acacccagat 
2301 ccctgcccct gctgcccagg accctgccag gcactcagca ctgccattcc 
2351 cagcaggtcc cggcactctg catcctttgg aggatgggga aggagtgcag 
2401 cacatgctgg tctgtggtgc tgccagggca ggggatagtg cagagaaaac 
2451 cccagctcac tgcagagagg gcaggactca gaagcactaa agttgaaagg 
2501 ttccagggag ccagcaggag ggctttagct gtgaagccgc taatccagga 
2551 gcagggaggg tggacaggag acactttgga ttgggactgc agggtggggc 
2601 cacgagggac atgaccccgt ccagcagggc ctcctgcttg gccccacagG 
2651 TACAACTTGG GAGGACCACG CATGGTGTGT GTGATGCTGC CGGAGGATGT Ex2 
2701 GGAGAAGCTG CAACAGGTGG ACAGCCTGCA TCCCTGCAGG ATGATCCTGG 
2751 AGCCCTGGGT GGCCTACAGA CAACATCGTG GGCACAAATG TGGCGTGTTC 
2801 TTGTTgtaag cggcgagttg ggagctgaga gctgggagca gggtgggcag 
2851 cctgggtgta ggggggaggc gagagaggta ggacccaaaa gcacatctgc 
2901 cctgggcccc tgtggtgggc agtgagggtg agcacccggc ccagaggacg 
2951 gccatcctgt ggggtcgcgt ctgcactgtg ggttggggaa gcagggcggt 
3001 ggtggagaaa tgggcacggg cacctctgca gagaagacgc agagcaatga 
3051 gcccttctgt gtagtgagaa cccgctctgc accaacctcg gcggctgctt 
3101 tctcttgcgg tctggggact gtccttccca taggtcagaa aactgaggcc 
3151 ctgagaaggg gacttccact ggcccaggtc acaggctgag tgctgagcct 
3201 ggtgttcgcc ggggccgcag cctccctcag ggcgctcagg gtccctgcag 
3251 tcctggcaaa ccttcctgat ggggacagtc cggggcagga ggcaggtggg 
3301 gacgcaggtg gctggtggtt ccgttgttct cagaagcaag gcacaaggtg 
3351 gggcggttga tggcactggg gaggatgttt cctggcccgt ggagagggtg 
3401 gcgcctggtc aggtgggcag ggagaggctg atgcttggag tcggtcacct 
3451 gcagggatgt tgtcattagg acgggggaag gactggatga ggatgtcaca 
3501 gtggtgacag cccccactcc atggtaggaa gggaacgcta ttgggaatag 
254 
3551 tggggtttag gtaaaagggc acccgtgggt cggggccttc actgaggctg 
3601 gcctatagat gacatctggg agagagtcag gacccaggaa ggcaggtcca 
3651 ggaggctggg tgcgcataat ggaaggaagg ggagcgctcc tgtctgtgtg 
3701 tgtgtcttgc atctgtgcac atgctgtgtg tttctctgta cctgcattgc 
3751 acatgtgtag tgtgtgcacg tgtcgtgtgt gaatgtatgt gtggtgtgtg 
3801 tgcacaagtg tctgtgtgtg tgcatgtgca ggtgccggca tgggtgtagt 
3851 gtttgtgcac acatgcacat gcgtctcttc acacatggtg ttgaggtctt 
3901 gcatgggcgc acgtgtgcat gtgcatcttc tgcctgtcat cactgtcaac 
3951 agctcacagc agccagctgg acataaataa aggagttttg caggaatgtg 
4001 gctgacaggg gaaattcctc cccaccattc cctgggggca tccatggagc 
4051 ccccacgcac tctggctgtg ggtaggatgg catgaagcac aaagcttggt 
4101 ttctgtcctg cagaagatat agatgcttca cagagacagc agagcagatg 
4151 ccccagaggc actgtgccca gggcggggaa gggtggggag gagagggcag 
4201 ccaggggctc tcccctcagg acactgtgtg ggtgaggtgg gcaaagcttg 
4251 acaacagggg tcacctcctt tcttggagaa aagccctacc ctgttactac 
4301 agggagggcc cgcatgggtg aggtggtgcc agacttgggt cgccaggtcc 
4351 cgggaatgac ctcagttacc ctgtcagcac ctgtgggcag aagctaccat 
4401 ctcatccctg cttagacctg agtggccttt gcccagcacc tggaggccgc 
4451 tctgagaaaa ggctgcagct cgaacacaaa caggcagctt ctaccagggc 
4501 ccccagtcag ctccctgcag gccgattccc cttggggaca aggaggatgg 
4551 gatacgggtc agggcctgtg tcttgctggg gcggcctcac aagctctgcc 
4601 ctggcctctg tagGAATGGG CCTGAATGGC GCTTCAACCG ATTGCGGCTG Ex3 
4651 AACCCAGATG TGCTGTCGCC CAAGGCCGTG CAGAGGTTCC TCCCGATGGT 
4701 GGATGCAGTG GCCAGGGACT TCTCCCAGGC CCTGAAGAAG AAGGTGCTGC 
4751 AGAACGCCCG GGGGAGCCTG ACCCTGGACG TCCAGCCCAG CATCTTCCAC 
4801 TACACCATAG AAGgtgtggg ccatgcggga aggtccagcc ccagagaccc 
4851 tggagtggcc agggatgggg atggaggact gaagggagtg tggggaggca 
4901 gccaggaggc ctggggctgc cttgtgctca gcagtgcatc ctccccgcag 
4951 CCAGCAACTT AGCTCTTTTT GGAGAGCGGC TGGGCCTGGT TGGCCACAGC Ex4 
255 
5001 CCCAGTTCTG CCAGCCTGAA CTTCCTCCAT GCCCTGGAGG TCATGTTCAA 
5051 ATCCACCGTC CAGCTCATGT TCATGCCCAG GAGCCTGTCT CGCTGGATCA 
5101 GCCCCAAGGT GTGGAAGGAG CACTTTGAGG CCTGGGACTG CATCTTCCAG 
5151 TACGgtgagg ccagggaccc gggcagtgct atggggaagg gacaccatgg 
< F33915 
5201 gggcccaatt tctccttctc caccacccag tggggaatgg aggccacagg 
5251 gaggggtcgg ggattcctca ccttcctgcc ggggagattg gtgcgaggct 
5301 ggggctgggc tgggctgatc cggagaattt gggatgagag cagggagatt 
T2138 > 
5351 tgggtgtcgg ggcagtctgg gcaggaggag gacactgaag gatgcttccc 
5401 agcaccaaga tctgagggct gtcccctgct ccctggacag GTGACAACTG ExS 
5451 TATCCAGAAA ATCTACCAGG AACTGGCCTT CAACCGCCCT CAACACTACA 
5501 CAGGCATCGT GGCGGAGCTC CTGTTGAAGG CGGAACTGTC ACTAGAAGCC 
5551 ATCAAGGCCA ACTCTATGGA ACTCACTGCA GGGAGCGTGG ACACGgtcag 
5601 gccagcaacc agccccaccc agagagggtg atgccaagcc tgcctcccag 
5651 gcactgcctg ccaatgccac acggcaccca cgttccccat ccccaggcta 
5701 caggccccac atttctgttg ccctcagcct tccccctcct ttgttaaggg 
5751 atgagatttg caggggaggg gaaatgtgag ctccccctca catgagactg 
5801 agtttgcagt tacctgtgtg gggatccatg ctccaggctg gaagaaagtt 
5851 ggatgaggcc ctggacacac agcagctctg tccccactgg aaagctctgg 
5901 gtgtacaagg agaaggaggg ttgagaggca gctggaggac tccactgggc 
5951 acccttccca gtgtgcccgg tcaccttggg ccagaaatgt agatgcatgg 
6001 gagggcaggg ttgtggggaa gacagcagca caggctccag ccagtgcaga 
6051 ggggcctgtg ggtgcacagt ggggagaact caatggaagc agagggagct 
6101 ggggctccag aactccctgg atgatgctga ggtgtggccc cctgccctaa 
6151 tggtggctgt gagaacccgc cctgaagagg ctgcagggga cctgggcctt 
6201 ggtggagatg ggggtcacct ttccctgaag aagtcaggga atctggccca 
6251 agtggtcatc aaggtttcag atccggggtc ccagggctct gtttttgctc 
6301 agggcatgga tgtctccacc cctcagaggg aggttgtcct gggaggggtg 
6351 tcccgggggc tgagtcctcc tgtgcaaggt ctgaccctgc agacatggct 
6401 tctgtagACA GCGTTTCCCT TGCTGATGAC GCTCTTTGAG CTGGCTCGGA Ex6 
256 
6451 ACCCCGACGT GCAGCAGATC CTGCGCCAGG AGAGCCTGGC CGCCGCAGCC 
6501 AGCATCAGTG AACATCCCCA GAAGGCAACC ACCGAGCTGC CCTTGCTGCG 
6551 GGCGGCCCTC AAGGAGACCT TGAGgtgggt gctggctgag gcctccctgt 
6601 ggccctggcc ccctgctgga gagcagcccc cactgggtgg tggcagacag 
6651 aatctggggc tgataaacag cgtcacccag cagcccattc ccctgcacct 
6701 gctcttcctc cccctcaagg acagggagct cttcttcctc tggaatccct 
6751 cttcaacgcc ctggggatta acgtggggca tgtccttctg cgctcggggc 
6801 tgcttaagtt aggggaggtt tggctgggct cagcaggtgc aaggaagcac 
6851 ttcctacgac ctgggcttcc catggatctg ggacctctgc ggggtcttcg 
6901 gtaggaaggg tgctgagagc acagggagcc ccatccagct gaggaccctt 
6951 tctgtggatg cccccacctc cagGCTCTAC CCTGTGGGTC TGTTTTTGGA Ex7 
7001 GCGAGTGGTG AGCTCAGACT TGGTGCTTCA GAACTACCAC ATCCCAGCTG 
7051 GGgtgagtga gccccacacc cctcgagctg agaacctccc tccccagtca 
7101 ttccctgatc cctgctctgc accgtccgca gACATTGGTA CAGGTTTTCC Ex8 
7151 TCTACTCGCT GGGTCGCAAT GCCGCCTTGT TCCCGAGGCC TGAGCGGTAT 
7201 AATCCCCAGC GCTGGCTAGA CATCAGGGGC TCCGGCAGGA ACTTCCACCA 
7251 CGTGCCCTTT GGCTTTGGCA TGCGCCAGTG CCTCGGGCGG CGCCTGGCAG 
7301 AGGCAGAGAT GCTGCTGCTG CTGCACCACG TAAGCAGGCC TGGGGGCGGG 
7351 GGCGGGACCT GGGCAGCAGA GGCGGGACCT GCACACTGGG GGCGGGGCTT 
7401 GCATGGTGTg attgacacct gggaacagtg gatggggcct tggttggttg 
7451 aggtcggcgt gaccagggag gatctgtgct gagcaagaca gggtaggatc 
7501 tgggtgaggt tgcttctaaa cattgaaatg gggactaggg gagtggggtg 
7551 gagcctgtac agaataatgg ggcttgggca agacctgggc aggattcagt 
7601 ctgggcctgg tccgcaaggt ggggctggtc agaaatggga taggttgggg 
7651 cccaggctgc tgctccccct tcagcataat tgttgcacct gggacgatgg 
7701 gaggaagctg ccccaggtcc atgggctact gaccaggcca gatggaaacc 
7751 cagcctctgt cctagGTGCT GAAGCACTTC CTGGTGGAGA CACTAACTCA Ex9 
B2 3'UTR > 
7801 AGAGGACATA AAGATGGTCT ACAGCTTCAT ATTGAGGCCT GGCACGTCCC 
7851 CCCTCCTCAC TTTCAGAGCG ATTAACTAGt cttgcatctg cacccagggt 
257 
7901 cccagcctgg ccaccagctt ccctctgcct gaccccaggc cacctgtctt 
< M6641 
7951 ct.ctcccacg tgcacagctt cctgagtcac ccctctgtcc agccagctcc 
8001 tgcacaaatg gaactcccca gggcctccag gactggggct tgccaggctt 
8051 gtcaaatagc aaggccaggg cacagctgga gacgatcttg ctggcagggc 
8101 ctggccttgt ccccagcccc acctggcccc ttctccagca agcagtgccc 
8151 tctggacagc ttgactctac tcctcccagc gctggctcca ggctcctcat 
8201 gaggccatgc aagggtgctg tgattttgtc ccttgccttc ctgcctagtc 
8251 tcacatgtcc ctgtccctct cgccctggcc agggcctctg tgcagacagt 
8301 gtcagagtca ttaagcggga tcccagcatc tcagagtcca gtcaagttcc 
8351 ctcctgcagc ctgaccccag gcagctcgag catgccctga gctctctgaa 
8401 agttgtcacc cagaaatacg atcctgcagg gtagactaaa aaggcccctg 
8451 tggtcactta tactgacaca ttttaagtga tacaactgag tctcgagggg 
8501 cgtgtgttcc ccagctgatc atgtcagcct catgccccag gcctcgtctt 
8551 tcatggacca ggtcttgttc aagcagcgag tgttgggtcc tctgcttcct 
8601 gagctgtccc ctggaaaagg tcccgaggat gctgtcagga gatggaagag 
8651 tcatgtgggg tgggaacctg gggtgtggtt ccagaaatgt ttttggcaac 
8701 aggagagaca ggattgggcc aacaaggact cagatgagtt tattgactca 
< B2 3'UTR 
8751 ttcctctgga agatacgcag c ........................ ctcccct 
9251 agtcagcaca tc 
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Appendix 2: Sequences of oligonucleotide primers 
In each case (s) indicated the sense primer and (as) indicated the antisense primer 
Ex on SSCP Primer Sequence Amp Rest. Fragment 
Size Enzyme Sizes (bp) 
(bp) 
s 5'-AATGAGTCCCTGCCTCCAGC-3' 
1 473 Xho11 49,260,164 AS 5'-GAATGGCAGTGCTGAGTGCC-3' 
s 5'-TTTGGATTGGGACTGCAGGG-3' 
2 260 Hha1 77,183 AS 5'-CCCACCCTGCTCCCAGCTTC-3' 
s 5'-TGGCCACTCCAGGGTCTCTG-3' 
3 349 Hha1 115' 234 AS 5'-CTGCAGGCCGATTCCCCTTG-3' 
s 5'-CCTTGTGCTCAGCAGTGCAT-3' 
4 306 Stu1 210,96 AS 5'-GTGGTGGAGAGGGAGAAATT-3' 
s 5'-AGGAGGACACTGAAGGATGTT-3' 
5 312 Rsa1 183,189 AS 5'-GACACGTGGGCGCCGTGTGAC-3' 
s 5'-TCTGACCCTGCAGCTGTGTCT-3' 
6 224 N/A 224 AS 5'-AGGGCCACAGGGAGGCCTCA-3' 
s 5'-AATGACTGGGGAGGGAGGTT-3' 
7 147 N/A 147 AS 5'-TGGATGCCCCCACCTCCAGG-3' 
s 5'-CCCTCGAGCTGAGAACCTCC-3' 
8 262 Hae111 119,143 AS 5'-CCAGTCCCACATTGCTCAAG-3' 
s 5'-CTGTTCCCCCTTCAGCATAAT-3' 
9 5'-GAGACGTGATTAGTTGATGGC-3' 224 N/A 224 AS 
Table 1. SSCP sense (S) and antisense (AS) primer sequences, amplicon sizes 
(Amp size) and restriction digests 
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CYP11B1 MUTATIONS 
Amino Sequence Ex on acid 
Change 
1 R43Q Sense 5'-GAA. GCC ATG CCC CAG CGT CCA GGC AA.C-3' 
Antisense 5'-GTT GCC TGG ACG CTG GGG CAT GGC TTC-3' 
2 L83S Sense 5'-CAG GTA CGA TTC GGG AGG AGC AGG CAT G-3' 
Antisense 5'-CAT GCC TGC TCC TCC CGA ATC GTA CCT G-3' 
2 H125R Sense 5'-GAC ACC ATC GTG GGC GCA AA.T GTG GCG TGC-3' 
Antisense 5'-GCA CGC CAC ATT TGC GCC CAC GAT GTT GTC-3' 
3 P135S Sense 5'-CTT GTT GAA. TGG GTC TGA ATG GCG CTT C-3' 
Antisense 5'-GAA. GCG CCA TTC AGA CCC ATT CAA. CAA. G-3' 
3 Fl39L Sense 5'-GGC CTG AA.T GGC GCC TCA ACC GAT TGC G-3' 
Antisense 5'-CGC AA.T CGG TTG AGG CGC CAT TCA GGC C-3' 
3 L158P Sense 5'-GTG CAG AGG TTC CCC CCG ATG GTG GAT G-3' 
Antisense 5'-CAT CCA CCA TCG GGG GGA ACC TCT GCA C-3' 
3 L186V Sense 5'-GGG GAG CCT GAC CGT GGA CGT CCA GCC-3' 
Antisense 5'-GGC TGG ACG TCC ACG GTC AGG CTC CCC-3' 
3 T196A Sense 5'-CAG CAT CTT CCA CTA CGC CAT AGA AGC CAG C-3' 
Antisense 5'-GCT GGC TTC TAT GGC GTA GTG GAA. GAT GCT G-3' 
Table 2. Primers for site-directed mutagenesis 
SEQUENCING PRIMERS 
Name Ex on Sequence 
V6776 pCMV4 (s)* 5'TAG TGA ACC GTC AGA ATT G 3' 
V6777 pCMV4 (as)* 5'TAG AGG ACA CTA GTC AGA C 3' 
N4019 Exon 2 (s) 5'AGA CAA. CAT CGT GGG CAC AAA. TG 3' 
* pnmers flankmg either side of the pCMV 4 clomng site 
Table 3. Sequencing primers for pCMV4-Bl wildtype and mutant constructs 
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Oligonucleotide Seq (5' -3') 
HBl sense TGC GCG TGT TCC TCT ACT CT 
HB 1 antisense GTG CAG AGA CGT GAT TAG TTG ATG 
HUMBIFL TAC AGC TTC ATA TTG AGG CCC AGC A-FL 
HUMBILC LC-TTC CCC CTC CTC ACC TTC AGA GC 
FL, Fluorescein; LC, LightCycler Red705 dye. 
Table 4: Lightcycler primers and probes for QRT -PCR 
Primer Sequence PCR 
B15'UTR (s) 5 ~ -TCC TTC GCA TCC CTT GTA GTA AGT T- 3~ Bl 5' 
B1Exon9 (as) 5 ~-TAG TTG ATG GCT CTG AAG GTG A- 3~ to Ex9 
M6635 (s) 5~-CTG TTC CCC CTT CAG CAT AAT- 3~ Bl 
B13'UTR+500 (as) 5~-CTA TTC CAG GGC GAC AAC TTT- 3~ 3'UTR 
T8303D (s) 5~-GAA TTC TGC ATC CTG TGA AAT TAT c- 3~ B2 5' 
F33915 (as) 5 ~ -GTG GTG GAG AGG GAG AAA TT- 3~ to Int4 
T2138 (s) 5 ~ -ATT TGG GTG TCG GGG CAG TCT-3~ B2 Ex5 
M6641 (as) 5~-CTG TGC ACG TGG GAG AGA AGA-3~ to Ex9 
B2 3'UTR (s) 5 ~-ATA TTG AGG CCT GGC ACG TC- 3~ 82 
B2 3'UTR (as) 5~-GAT GTG CTG ACT AGG GGA G- 3~ 3'UTR 
Table 5. Primer pairs for PCR amplification of the entire CYPJJBJ and 
CYPJJB2 genes 
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CYPJJBJ SEQUENCING PRIMERS 
Primer Ex on Sequence 5' - 3' 
B 1Prom-1750(as) 5' AAG TCA AAT TGT CTC TGT TTG 
F81092 (s) 5' CAC AGG GAA TGC TTC CAG TTT TTG 
F81093 (s) 5' CCA AGG GAT GAA GCC CAC TTG AT 
F81094 (s) 5' AAT GGT ACC AGT TCC TCC TTG TAC 
F81095 (s) 5' CTC TGA TGG TAG TTT GTA TTT CTG T 
F81097 (s) 5' TAA TCC TGA GTT CTA GTT TGA TTG C 
B9865 (as) 5' CTG CCT TTG CCC TGA GTG cc 
F31463 (s) 1 AAT GAG TCC CTG CCT CCA GC 
Y6266 (as) 1 CCC ACC CTG CTC CCA GCT CT 
Y6265 (s) 2 TTT GGA TTG GGA CTG CAG GG 
Bllnt2 (3280) (s) Int2 AGA AGC AAG GCA CGA GGT GG 
Bllnt2 (3580) (s) Int2 GGA CCC AGG AAG GCA AGT CCA 
B1Int2 (3690) (s) Int2 GGC TGC CAT CAC TGT CAA CA 
N4020 (as) Int2 TTC AGC CGC AAT CGG TTG AAG 
Y6263 (s) 3 CTG CAG GCC GAT TCC CCT TG 
B4251 (as) 3 GTG GTG GAG AGG GAG AAA TT 
B4250 (s) 4 CCT TGT GCT CAG CAG TGC AT 
M6643 (as) 4 GAC ACG TGG GCG CCG TGT GAC 
M6642 (s) 5 AGG AGG ACA CTG AAG GAT GTT 
F42299 (as) 5 AGG GCC ACA GGG AGG CCT CA 
F42117 (s) 6 TCT GAC CCT GCA GCT GTG TCT 
Y6260 (as) 6 AAT GAC TGG GGA GGG AGG TT 
Y6259 (s) 7/8 TGG ATG CCC CCA CCT CCA GG 
M6635 (s) 9 CTG TTC CCC CTT CAG CAT AAT 
B1Ex9as (as) 9 TAG TTG ATG GCT CTG AAG 
Bl3'UTR+500 (as) 3' CTA TTC CAG GGC GAC AAC TTT 
Table 6. Primers for the Sequencing of the entire CYPJJBJ gene 
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Primer Sequence 
Sense (B15'UTR) 5'-TCC TTC GCA TCC CTT GTA AGT T-3' 
PCR 1 Antisense (B 1 prom-260) 5'-CTT GGA TTA TTC ATC TCC TTG CAA GG-3' 
Sense (B15'7-32) 5'-GCA TCC CTT GTA AGT TGG ATT CCT AA-3' 
PCR2 Antisense (B 15'3 93-369) 5'-AAG CAT TCC CTT TGA AAA CTG GTA C-3' 
Table 7. Nested PCR primers for amplifying the region surrounding the -1889 
G/T and -1859 A/G polymorphisms 
The polymorphisms were then genotyped by sequencing using the primer B15'258-
238 (see table 5). 
Base 
Change SequencePrimeSequence 
SNP 
-1889 (S) 5'-CTC TGT TTG TCT GTT AAG TGT GTA TAA GAA TGC 
Gto T (AS) 5'-CAC AAG CAT TCT TAT ACA CAC TTA ACA GAC 
-1859 (S) 5'-GCT TGT GAT TTT TGT ACG TTG ATT TTG TAT 
A toG (AS) 5'-GTC TCA GGA TAC AAA ATC AAC GTA CAA AAA 
Table 8. Site-directed mutagenesis primers for CYPJJBJ 5'UTR 
polymorphisms 
AAA 
CCT 
TCA 
TTG TG-3' 
CAG AG-3' 
GAG AC-3' 
CAA GC-3' 
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Appendix 3: Reagents 
Unless otherwise stated all standard chemicals and reagents were purchased from 
Sigma (Sigma-Aldrich Chemical Co. Ltd, Poole, Dorset, UK). 
Bacterial media and plates 
LB medium lOg tryptone, 5g yeast extract, lOg NaCl to a final litre with 
deionised water, adjust to pH 7.0 with NaOH. Autoclave 
LB agar 1 Og NaCl, 1 Og Tryptone, 5g yeast extract, 20g of agar, adjust 
to pH 7.0 with NaOH. Autoclave 
LB-amp plates 1 litre of LB agar, add 400 Ill of filter-sterilized ampicillin 
Buffers 
lOmM Tris-HCl, lmM EDTA, pH 7.5 
40mM Tris-acetate, lmM EDTA, pH 8.0 
TE buffer 
TAE buffer 
Loading dye 1.5g Ficoll, 25mg Bromophenol Blue, 25mg Xylene Cyanol 
Site directed mutagenesis 
Quick change site-directed mutagenesis kit (Stratagene) 
Pfu DNA polymerase (2.5U/!ll) 
1 OX reaction buffer 
Dpn I restriction enzyme (1 OU/Ill) 
Reagents not supplied in the kit: 
Primers (see table 2 and 8, appendix 2) 
NZY+broth 16g ofNZM broth, 5g of yeast extract, 12.5ml 
of 1M MgC12, 12.5ml of 1M MgS04, lOml of 
2M filter-sterilized glucose solution per litre. 
LB-amp agar plates (see above). 
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